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ABSTRACT

Metabolic inflexibility is an emerging physiological marker indicative of metabolic dysfunction
and associated with type 2 diabetes (T2D) and obesity. Exercise is a potent stimulus to improve
metabolic health, however, not much is known about the acute effects of exercise on metabolic flexibility
(METFLEX). The purpose of this dissertation was study the time-course of diet and exercise and its
effects on METFLEX. Three studies were conducted to investigate molecular and clinical aspects of diet
and exercise and how these stimuli may alter the metabolic response to fuel.
The first study was conducted on obesity-prone, Osborne-Mendel (OM) and obesity-resistant
S5B/Pl (S5B) rats. This experiment investigated inherent differences in EE, metabolic rate, METFLEX
and skeletal muscle markers of metabolism, lipid storage and lipid oxidation between OM and S5B, as
well as HFD-induced strain differences in these parameters. The consumption of a HFD in S5B rats
increased metabolic rate and EE and decreased metabolic rate and EE in OM rats. These strain differences
were not due to the differences in activity or food intake. These results suggest that HFD-induced
differences in metabolic rate and EE may be mediated by HFD-induced differences in pAMPK and
PPARγ expression and lipid accumulation in the gastrocnemius muscle of OM and S5B rats.
The second study was designed to investigate the effect of acute aerobic exercise at an intensity
that maximizes the rate of fat oxidation (FATMAX) on glucose tolerance, insulin action, and METFLEX
compared to acute aerobic exercise at lactate threshold (OBLA) resulting in greater carbohydrate (CHO)
oxidation. OBLA exercise appears to have deleterious effects on oral glucose tolerance and metabolic
flexibility acutely, however, FM exercise does not confer improved METFLEX. These results suggest
that predominate substrate utilization does not promote improved glucose tolerance and metabolic
flexibility in young overweight men. The third and final study of this dissertation was designed to

v

investigate the immediate and extended of a single bout of high intensity interval exercise (HIIE) on
METFLEX and mitochondrial function. Participants were recruited with a family history (FmHx) of T2D
(n=8) and without a family history of T2D (n=8). The extended effects (48 hours) work via the reduction
fat oxidation by increasing resting fat oxidation rate and improving the suppression of fat oxidation in
response to a mixed meal.

vi

CHAPTER 1. INTRODUCTION

Metabolic flexibility (METFLEX) and metabolic inflexibility (MI) are biomarkers for metabolic
health and dysfunction respectively. Kelley and colleagues (1999) first noted a profound lack of plasticity
in obese skeletal muscle to reduce fat oxidation and increase carbohydrate oxidation in the presence of
insulin 1. In this seminal work, the authors define METFLEX as “a high capacity to modulate rates of
energy production, blood flow, and substrate utilization”. Since that time, METFLEX is more often
described as the body’s ability to match fuel oxidation to fuel availability. Interestingly, MI is not only a
characteristic of T2D and obese patients, but also those with a family history (FmHx) of T2D and is
linked to mitochondrial dysfunction 2-6.
Exercise interventions (6-12 weeks) have been shown to improve insulin sensitivity and
metabolic flexibility in obese and type 2 diabetic patients, with greater improvements demonstrated with
higher intensities 7,8. Recent research suggests that 2-6 weeks of high intensity interval training (HIIT)
improves insulin sensitivity and skeletal muscle oxidative capacity 9,10. Interestingly, the time course of
glucose tolerance and insulin action in response to a single bout of exercise reveals periods of increased
insulin sensitivity (immediately post exercise to 3 days) and resistance (5 to 7 days’ post exercise) 11,12.
Moreover, improvements found in insulin sensitivity due to exercise training often do not coincide with
improvements in METFLEX, suggesting MI does not simply occur secondarily to insulin resistance or
obesity 13,14.
The purpose of this dissertation was study the time-course of diet and exercise and its effects on
METFLEX. Three studies were conducted to investigate molecular and clinical aspects of diet and
exercise and how these stimuli may alter the metabolic response to fuel. These include work using both
animal models and human participants. The first study was conducted on obesity-prone, Osborne-Mendel
(OM) and obesity-resistant S5B/Pl (S5B) rats. This experiment investigated inherent differences in energy
expenditure (EE),
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metabolic rate, METFLEX and skeletal muscle markers of metabolism, lipid storage and lipid oxidation
between OM and S5B, as well as HFD-induced strain differences in these parameters. The consumption
of a HFD in S5B rats increased metabolic rate and EE and decreased metabolic rate and EE in OM rats.
These strain differences were not due to the differences in activity or food intake. These results suggest
that HFD-induced differences in metabolic rate and EE may be mediated by HFD-induced differences in
pAMPK and PPARγ expression and lipid accumulation in the gastrocnemius muscle of OM and S5B rats.
The second study was designed to investigate the effect of acute aerobic exercise at an intensity
that maximizes the rate of fat oxidation (FM) on glucose tolerance, insulin action, and metabolic
flexibility (METFLEX) compared to acute aerobic exercise at lactate threshold (OBLA) resulting in
greater carbohydrate (CHO) oxidation. OBLA exercise appears to have deleterious effects on oral glucose
tolerance and metabolic flexibility acutely, however, FM exercise does not confer improved METFLEX.
These results suggest that predominate substrate utilization does not promote improved glucose tolerance
and metabolic flexibility in young overweight men.
The third and final study of this dissertation was designed to investigate the immediate and
extended of a single bout of high intensity interval exercise (HIIE) on METFLEX and mitochondrial
function. In study 3, participants were recruited with a family history (FmHx) of T2D (n=8) and without a
family history of T2D (n=8). Participants completed baseline (no previous exercise) mixed tolerance tests
(MMTT) to assess METFLEX. On a separate week participants completed a single bout of HIIE follow
by an immediate (1 hour later) MMTT and follow-up MMTT (48 hours later) MMTT. The immediate
effects (1 hour) of HIIE on METFLEX are primarily directed on the increase in carbohydrate oxidation
and blood flow in response to a mixed meal. The extended effects (48 hours) work via the reduction fat
oxidation by increasing resting fat oxidation rate and improving the suppression of fat oxidation in
response to a mixed meal.
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CHAPTER 2. HIGH FAT DIET DIFFERENTIALLY REGULATES METABOLIC
PARAMETERS IN OBESITY-RESISTANT S5B/Pl RATS AND OBESITY-PRONE
OSBORNE-MENDEL RATS

2.1 Introduction
The current prevalence of obesity has been linked to a number of health consequences.
1,2

. Differences in the susceptibility to becoming obese exists and a subset of individuals gain

weight and become obese on high-fat/energy dense diets, while others resist weight gain on the
same diet 3-7. Studies indicate that the susceptibility to develop obesity is due to several central
and peripheral factors. These factors may include an inability to adapt to the consumption of an
energy dense diet by the obesity-prone individuals 8-10. Inherent differences in metabolic
parameters and a differential response to the consumption of an energy dense diet on energy
expenditure (EE) may influence the susceptibility to develop obesity.
Energy expenditure and carbohydrate and fat metabolism is regulated by skeletal muscle
and alterations in the regulation of EE, metabolic rate and skeletal markers of glucose and fatty
acid metabolism may affect the susceptibility to developing obesity 11-18. Studies have
demonstrated that respiratory exchange ratios (RER) measured in isolated muscle tissue during
fasting in obese people and those with type 2 diabetes are elevated and do not respond to insulin
stimulation 19-21. An increased susceptibility to obesity has been linked to metabolic inflexibility,
which may be due to alterations in the transport and oxidation of fatty acids and glucose in
skeletal muscle 18,20,22. The fatty acid receptor, CD36, and the glucose transporter, GLUT4, are
important regulators of fatty acid and glucose uptake in skeletal muscle and are regulated by the
phosphorylated state of AMP-activated protein kinase (AMPK) 23. Defects in peroxisome
proliferator-activated receptor-gamma (PPARγ), a regulator of fatty acid storage and glucose
metabolism, are also associated with increased susceptibility to developing obesity 24. Obesity5

prone and obesity-resistant rodent models and obese and lean humans demonstrate differential
expression of skeletal muscle proteins induced by a high fat diet (HFD) 14 suggesting that
dysregulation of one or more of these skeletal muscle markers may affect the susceptibility to
becoming obese.
Obesity-prone, Osborne-Mendel (OM) and obesity-resistant S5B/Pl (S5B) rats are
animal models used to assess the mechanisms underlying HFD intake and obesity 3-5,8,25-31. OM
rats are susceptible to diet-induced obesity and gain more weight and adiposity when eating a
HFD, than S5B rats, which are resistant to obesity, when consuming the same diet. The current
experiment tested the hypothesis that consumption of a HFD would differentially affect
metabolic parameters and skeletal muscle markers of metabolism in obesity-prone, OM and
obesity-resistant, S5B rats. This experiment investigated inherent differences in EE, metabolic
rate and skeletal muscle markers of metabolism, lipid storage and lipid oxidation between OM
and S5B, as well as HFD-induced strain differences in these parameters. Assessment of
metabolic rate, EE, glucose and carbohydrate metabolism, and lipid oxidation and storage in
skeletal muscle will provide insight into mechanisms which alter the susceptibility to developing
obesity.
2.2 Methods
2.2.1 Animals:
Male obesity-prone Osborne-Mendel (OM; n=8/diet) and obesity-resistant S5B/Pl (S5B;
n=8/diet) rats (8-9 weeks old) used in these studies were bred in the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC)-approved Pennington Biomedical
Research Center vivarium. Rats were individually housed on a 12/12 h light/dark cycle (lights on
at 0700) with food and water available ad libitum. Animals were given access to a pelleted high
fat diet (HFD, 60% kcal from fat, Research Diets, New Brunwick, NJ) or a pelleted low fat diet
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(LFD, 10% from fat, Research Diets). All procedures were approved by the Pennington
Biomedical Research Center Institutional Animal care and Use Committee.
2.2.2 Fasting Glucose:
Following 2 weeks access to HFD and LFD, OM and S5B rats underwent an overnight
fast (16 hours) and glucose levels were measured. For the determination of circulating glucose
level, blood was taken from the tail and glucose was measured using a glucometer (Contour
blood glucose monitoring system, Bayer Health Care, Mishawaka, IN).
2.2.3 Body Composition:
OM and S5B rat were fed the HFD or the LFD for 2 weeks prior to assessment of
metabolic parameters. Immediately prior to placement in the metabolic chambers, rats were
weighed and body composition was determined using nuclear magnetic resonance imaging
(NMR, MiniSpec Plus, Bruker Corp.). Percent body fat was determined for each rat ((fat mass
(g)/body weight (g))*100) and percent lean mass for each rat was calculated ((lean mass
(LBM)(g)/body weight (g))*100).
2.2.4 Effect of HFD consumption on metabolic parameters in OM and S5B:
For metabolic testing, OM-LFD (n=6), OM-HFD (n=6), S5B-LFD (n=6) and S5B-HFD
(n=6) rats were individually housed in metabolic chambers (PhenoMaster System,TSE Lab
Master System, Homburg, Germany), which performed continuous metabolic measurements for
5 days (1 day of habituation and 4 days of data collection). The PhenoMaster System at PBRC
contains 24 metabolic cages. All rats were placed in the metabolic chambers at the same time
and measurements for all rats were collected concurrently. Rats were weighed immediately prior
to being placed in the metabolic chambers. Throughout metabolic assessment, rats continued to
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receive ad libitum access to HFD or LFD. Data from the metabolic chambers were
assessed, calculated and analyzed using the TSE Systems LabMaster software (v.1.5).
Respiratory exchange ratio (RER), EE (kcal/h/LBM), metabolic rate (VO2/kg LBM), food intake
(g), and activity (beam breaks) were assessed every 40 min throughout the experiment by the
TSE system. EE and VO2 were calculated based on lean body mass (kg) as determined by
NMR. Food intake was converted to kilocalories. For each day, the data point for an individual
rat was averaged across the light and the dark cycle. Total daily food intake and activity values
were obtained by combining the average data from the light cycle and the dark cycle for each rat.
The values for each day were combined and used to provide an average value for the light cycle,
the dark cycle, and the total daily value. To determine the shift in substrate utilization (RER)
between the light and dark phase, the RER value during the light phase was subtracted from the
RER value from the dark phase.
2.2.5 Protein Expression in Skeletal Muscle:
OM and S5B rats fed HFD or LFD diet (n=6/strain/diet) were used to assess protein
expression of skeletal muscle markers of glucose and lipid metabolism. At the time of sacrifice
(0900-1100), the gastrocnemius muscle was dissected and a 100mg sample was collected, frozen
in liquid nitrogen and stored at -80°C until further processing. Rats were not fasted prior to
sacrifice. Protein was isolated and Western Blot analyses were conducted as previously
described 8. For protein isolation, samples were incubated on ice in RIPA buffer (Sigma-Aldrich,
St. Louis, MO) containing 1:100 protease inhibitor (Sigma-Aldrich), and 1:100 phosphatase
inhibitor (Sigma-Aldrich) and then homogenized for 30 seconds or until a smooth suspension
resulted. Homogenized samples were centrifuged for 10min at 16,874 x g at 4⁰ C. Supernatant
was collected and measured for protein concentrations using a BCA protein assay kit
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(Pierce/Thermo Fisher Scientific, Rockford, IL). For Western Blot, equal amounts of protein (30
µg) were separated on a 10% Tris-Hepes-SDS premade gel (Pierce/Thermo Fisher Scientific)
and transferred to a PVDF membrane (Amersham, Amersham, UK) as indicated by the
manufacturer. The membrane was then blocked in TBS (20 mM Tris-Base, 150 mM NaCl, pH
7.6) containing 5% nonfat dry milk overnight at 4⁰ C. On Day 2, the membrane was incubated
for 1h with primary antibody for CD36 (1:500; Novus Biologicals, Littleton, CO), GLUT4
(1:1000; Abcam, Cambridge, MA), PPARγ (1:1000; Abcam), pAMPK (1:2000; Cell Signaling,
Danvers, MA), total AMPK (AMPK-α; 1:1000; Cell Signaling) or alpha-tubulin (1:500; Abcam)
against rabbit in TBS containing 5% nonfat dry milk. Following several washes the membrane
was incubated for 45min with horseradish peroxidase-conjugated anti-rabbit antiserum
(1:10,000, Abcam). Immunoreactivity was visualized using ECL Western blotting detection
reagents (Amersham). Images were obtained using exposure to chemiluminescence film
(Amersham). Bands were quantified using ImageJ for densitometry and values were normalized
to alpha-tubulin. pAMPK was also normalized to total AMPK. For quantification in Image J,
films were scanned and saved as jpeg files. Images were cropped to contain the appropriately
sized band. Using Image J, a box was drawn around the band for each sample. This same box
was used for each sample on each image. Image J provided graphical information on the relative
density of each band, which reflected the portion of the drawn box that contained the band. This
allowed for a more precise measurement of densitometry of the actual band and not the
surrounding image.
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2.2.6 Histological Analysis of gastrocnemius muscle in OM and S5B (Succinate
Dehydrogenase and Oil Red O):
Fat and connective tissue were dissected from gastrocnemius muscle, frozen in
isopentane, and stored at -80°C until histological processing. At the time of processing, sections
(10µm) were cut using a cryostat (Shandon Cryotome, Thermo Scientific) at -20°C and mounted
on slides. Slides with cross sections of the gastrocnemius muscle were incubated with succinate
dehydrogenase (SDH) to evaluate the presence of oxidative enzymes or Oil Red O to detect the
presence of intramuscular lipids. Images were captured via light microscope (Nikon Eclipse 80i)
with a connected digital camera under a 10x objective. Within the cross section, quantitative
image analysis was conducted using the Image J Software on a minimum of 75 fibers. Image J
provided a numerical value for the density of staining for each fiber. The oxidative capacity of
the muscle was determined by the intensity of SDH staining according to validated methods 32.
With this method, there is a positive linear correlation between color and oxidative potential.
Type I fibers (slow twitch, oxidative) stain darkest and Type II fibers (fast twitch, glycolytic)
stain lighter. Oil Red O staining was quantified according to the area occupied by the lipid
staining within individual muscle fibers 33.
2.2.7 Statistical Analysis:
Data is presented as mean + SEM. Two way ANOVAs were used to determine if
significant differences between groups (strain vs. diet). If an overall ANOVA demonstrated
significant differences, post hoc comparisons were performed using a Bonferroni t-test.
Differences were considered significant if p < 0.05. Statistical analyses were performed using
SPSS.
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2.3 Results
2.3.1 Fasting Glucose:
Fasting glucose levels were significantly affected by diet and strain (F=6.03, p<0.05;
Figure 2.1A). Consumption of HFD increased fasting glucose levels in the OM, but not the S5B
rats.
2.3.2 Body Composition:
OM rats weighed more than S5B rats fed either the HFD or the LFD (F=10.6, p<.01;
Figure 2.1B). Body weight was increased by the consumption of a HFD in OM and S5B rats,
with a greater increase in body weight in the obesity-prone OM rats, compared to the obesityresistant S5B rats (58.3 g vs. 15.3 g, respectively). Body composition was assessed by NMR and
a higher percentage of body fat was detected in OM rats, compared to S5B rats (F=5.9, p<.05;
Figure 2.1C). HFD intake increased the percentage of body fat in OM rats only. The percentage
of LBM was not altered by strain or diet (Figure 2.1D).
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Figure 2. 1: A. Fasting glucose levels were elevated in OM rats consuming the HFD.
B. OM rats weighed more than S5B rats. HFD intake increased body weight in both strains. OM
rats consuming a HFD weighed more than S5B rats consuming a HFD. C. Consumption of a
HFD increased the percentage of body fat in OM rats. D. The percentage of LBM was not altered
by HFD consumption. Data is shown as mean + SEM, p<.05, # diet differences, *strain
differences.
2.3.3 Effect of HFD consumption on metabolic parameters in OM and S5B:
Rats were placed in the metabolic chambers for 5 days (1d habituation, 4d data collection),
during which food intake, RER, activity, metabolic rate (VO2) and EE were measured. Data
collected during the dark phase and the light phase was analyzed, as well as over the total 24h
period (for food intake and activity). Rats consuming the HFD exhibited a significantly lower
RER value than rats consuming the LFD during the light phase (F=4552.8, p<.001; Figure 2A,
2B) and an interaction between strain and diet was detected during the dark phase (F=22.0,
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p<.001). During the light phase, S5B rats fed the LFD were able to shift their substrate utilization
toward fat oxidation, compared to the OM rats (difference in light to dark: OM-LFD 0.020 +
.007 vs. S5B-LFD 0.074 + .008, p<.001).
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Figure 2.2: A. RER time course over 4 days of measurements in metabolic chambers. B. RER
was lower in rats consuming HFD, reflecting the predominance of fat utilization. During the dark
cycle, OM rats consuming LFD exhibited a higher RER than S5B rats consuming a LFD. C. OM
rats consumed more LFD and HFD during the light cycle. During the dark cycle, OM rats
reduced their consumption of LFD. OM rats consumed more HFD over the 24h period than S5B
rats. Black bars indicate dark period. Data is shown as mean + SEM, p<.05, # diet differences,
*strain differences.
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Differences in HFD and LFD intake were seen across the light and dark cycles. During
the light cycle, OM rats consumed more HFD and LFD than S5B rats and more LFD, than HFD
(F=15.2, p<.001; See Figure 2C). During the dark cycle, OM rats consumed less LFD than the
S5B rats and similar amounts of HFD (F=15.7, p<.001). Total daily HFD intake was higher in
the OM rats (F=7.9, p<.001). OM rats were more active in the metabolic cages than S5B rats
during the light cycle (F=6.9, p<.01; Figure 2D) and HFD fed OM rats were more active than
S5B rats during the dark cycle (F=27.5, p<.001). Total daily activity was highest in OM rats
consuming the HFD (F=4.2, p<.05).
Metabolic rate (VO2 based on kg LBM) was differentially affected by diet in the OM and
S5B rats during the light (F=20.6, p<.001) and dark phase (F=27.8, p<.001; Figures 2.3A, 2.3B).
In both the light and the dark phase, HFD consumption increased metabolic rate in the obesityresistant S5B rats and decreased metabolic rate in the obesity-prone OM rats. Estimated hourly
EE was calculated by the TSE software and based on kg LBM. Estimated EE was differentially
affected by diet in the OM and S5B rats during the light (F=20.5, p<001) and dark (F=27.1,
p<.001) cycles (Figures 2.3C, 2.3D). Estimated hourly EE was increased by HFD consumption
in the S5B rats and decreased by HFD intake in the OM rats.
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Figure 2.3: A. Time course of metabolic rate (VO2 (kg LBM). B. HFD intake differentially
affected VO2 level in OM and S5B rats. HFD intake increased metabolic rate in obesity-resistant
S5B rats and decreased metabolic rate in obesity-prone OM rats. C. Time course of estimated EE
over 4 days of measurements in the metabolic chambers. D. HFD consumption increased EE in
S5B rats and decreased EE in OM rats. Black bars indicate dark period. Data is shown as mean +
SEM, p<.05, # diet differences, *strain differences.
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2.3.4 Skeletal Muscle CD36, GLUT4, pAMPK and PPARγ protein expression:
Protein expression of skeletal muscle markers of fat and carbohydrate metabolism were
assessed by Western blot. There were no inherent strain differences or HFD-induced alterations
in the expression of CD36 (Figure 2.4A). GLUT 4 expression was elevated in OM rats (F=5.6,
p<.05; Figure 2.4B). A differential response to HFD consumption was detected for pAMPK/total
AMPK (F=12.2, p<.01, Figure 2.4C) and PPARγ (F=4.8, p<.05; Figure 2.4D) between OM and
S5B rats. Consumption of HFD decreased pAMPK and PPARγ in the obesity-prone OM rats. In
LFD fed rats, PPARγ expression was higher in OM rats, compared to S5B rats.
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Figure 2.4: Western Blots were used to assess protein expression of skeletal muscle markers of
metabolism in OM and S5B rats fed LFD or HFD. A. CD36 protein levels were not altered by
strain or diet. B. GLUT4 protein expression in the gastrocnemius muscle was increased in
OMrats OM rats. C. pAMPK levels in the gastrocnemius muscle were decreased by HFD in OM
rats. D. PPARɣ protein expression was decreased in OM rats consuming a HFD. Data is shown
as mean + SEM, p<.05, # diet differences, *strain differences.
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2.3.5 Histological Analysis of gastrocnemius muscle in OM and S5B (Succinate
Dehydrogenase (SDH) and Oil Red O:
Assessment of inherent and HFD-induced differences in oxidative activity of the
gastrocnemius muscle, as measured by SDH activity, indicated that HFD consumption increased
the oxidative capacity of the skeletal muscle in both strains (F=172.9, p<.01, Figure 2.5). SDH
activity indicates a greater number of Type I, slow twitch fibers following HFD consumption.
HFD consumption increased intra-muscular lipid droplets, as measured by Oil Red O, in both
OM and S5B rats (F=178.4, p<.001, Figure 2.6). The intensity of Oil Red O staining was higher
in the OM rats fed the HFD, than the S5B rats fed the HFD.
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Figure 2.5: SDH assay was used to determine oxidative capacity of the gastrocnemius muscle in
OM and S5B rats fed LFD or HFD. The consumption of a HFD increased SDH staining in OM
and S5B rats, suggesting an enhanced oxidative capacity. OM rats fed LFD had greater SDH
staining than S5B rats fed LFD.
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Figure 2.6: Oil Red O was used to determine lipid deposition in the gastrocnemius muscle S5B
and OM rats fed LFD or HFD. An increase in density of Oil Red O stain is reflective of an
increase in lipid deposition. The consumption of a HFD increased Oil Red O staining in OM and
S5B rats. Lipid deposition in HFD fed was markedly enhanced in OM rats, compare to S5B rats.
Data is shown as mean + SEM, p<.05, # diet differences, *strain differences.
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2.4 Discussion
OM rats are susceptible to diet-induced obesity and gain more weight and body fat when
eating a HFD, than obesity-resistant S5B rats. The current experiment investigated inherent
strain differences and HFD-induced differences in metabolic parameters (e.g. metabolic rate) and
skeletal muscle markers of metabolism, lipid storage, lipid oxidation and muscle fiber type in
these animal models. It was hypothesized that the consumption of HFD would differentially
affect metabolic parameters and skeletal muscle markers of metabolism in the obesity-prone,
OM and the obesity-resistant, S5B rats. The results from this experiment elucidate HFD-induced
changes in the metabolic phenotype of these two strains, which may contribute to the
susceptibility to develop diet-induced obesity.
The animals models used in the current study have been studied for a number of years to
assess physiological and pharmacological differences that would alter the susceptibility to
developing diet-induced obesity. Multiple studies have demonstrated innate strain differences as
well as strain differences in response to HFD consumption 3-5,8,25-31. However, metabolic
parameters have not been assessed in these models and these strains may differ from other
models of diet-induced obesity on these parameters. Previous studies using other models of
obesity have examined differences in metabolism and activity as potential mechanisms to
account for the susceptibility to obesity. A recent study by Azzout-Marniche and colleagues 34
failed to demonstrate differences in EE, or substrate utilization in fat-resistant and fat-sensitive
Wistar rats fed a HFD, though fat-sensitive rats were more active. Jackman and colleagues 9
reported a sex difference in the response to dietary fat in obesity-prone and obesity-resistant rats,
indicating that their male rats demonstrated minor increases in EE, compared to female rats.
Their study concentrated on the switch from a LFD to a HFD, and reported a lack of difference
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in activity levels. Reported differences in activity have also been suggested as a method by
which obesity-resistant rats are able to resist obesity. Specifically, high levels of spontaneous
physical activity (SPA, very low-intensity physical activity) were associated with obesity
resistance in selectively-bred obesity resistant Sprague-Dawley rats. 6,35-37. In these studies,
obesity-resistant rats spent more time being ambulatory than Sprague-Dawley rats, and exhibited
decreased body weight, fat mass and food intake, suggesting that EE generated from SPA
accounts for the difference between obesity resistance and propensity in this model.
In the current experiment, HFD consumption increased fasting glucose levels in the
obesity-prone OM rats, but not the obesity-resistant, S5B rats. These data are in congruence with
previous reports suggesting that OM rats have higher circulating insulin and leptin levels 26,28, in
response to a HFD. OM and S5B rats gained weight on the HFD and OM rats consuming the
HFD weighed considerably more than the OM rats consuming the LFD (approximately 58g). A
HFD-induced increase in the percentage of body fat was only seen in the OM rats and there were
no differences in percentage of LBM between the strains, regardless of diet. Similar percentages
of LBM in these strains suggest that differences in metabolic parameters and skeletal muscle
markers are not due to HFD-induced muscle degradation. As expected, daily food intake was
highest in the OM rats consuming the HFD. This increase in total HFD intake by the OM rats
appears to be driven by an increase in HFD consumption during the light phase. An increase in
activity levels during the light phase was also seen in the OM rats, suggesting that these rats were
awake, active and eating. This increase in LFD consumption and increase in activity, compared
to the S5B rats, may account for the lack of “flexibility” in RER of the OM rats during the light
phase. Multiple studies have suggested that obese individuals are metabolically inflexible,
suggesting that these individuals are not able to adequately shift from carbohydrate to fat
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oxidation during times of fasting (e.g. sleep) 18,20,22. In the current study, the rats fed the HFD
exhibited a RER that reflected fat oxidation. Since this diet contains 60% of its kilocalories from
fat (20% from carbohydrates), this was expected. Metabolic inflexibility was not able to be
assessed in the HFD groups, since the RER did not fluctuate between the light and dark cycle.
Energy expenditure and metabolic rate were assessed in the OM and S5B rats fed the
HFD and LFD. The consumption of the HFD increased metabolic rate (VO2) and estimated EE
in the obesity-resistant S5B rats during the light cycle and the dark cycle. This was not due to an
increase in activity level, since S5B rats fed the HFD were not more active than those fed the
LFD. This was also not due to an increase in HFD intake, since the S5B consumed the same
number of kilocalories regardless of diet. Conversely, consumption of HFD decreased metabolic
rate and estimated hourly EE in the obesity-prone OM rats. These decreases were not due to a
decrease in HFD intake, since OM rats consumed more HFD than LFD and they were not due to
a decrease in activity level, since OM rats consuming the HFD were more active than those
consuming the LFD. These data suggest that there is an alternate mechanism regulating the
HFD-induced alterations in metabolic rate and EE in the OM and S5B rats. Previous studies have
investigated altered sympathetic output, as measured by peripheral norepinephrine, in these
strains and have shown higher concentration of norepinephrine in brown adipose tissue following
HFD intake in S5B, compared to OM rats, supporting decreased EE in OM rats consuming HFD
38

.
Skeletal muscle is a major component of glucose utilization and metabolic rate, and is

predicted to be a major factor in the resistance to developing obesity. Therefore, the current
study assessed skeletal muscle markers of carbohydrate and lipid metabolism, as well as lipid
oxidation and storage. Expression of the fatty acid receptor, CD36, did not differ between OM
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and S5B rats and was not affected by HFD consumption. GLUT 4 expression was higher in OM
rats. Inherent strain differences in pAMPK and PPARγ expression were not detected, however,
HFD consumption decreased pAMPK (pAMPK/total AMPK) and PPARγ expression in obesityprone OM rats, but not in obesity-resistant S5B rats. AMPK serves as a key protein kinase that
integrates nutrient and hormonal signals to regulate whole-body metabolism by stimulating
glucose uptake and partitioning fatty acids toward oxidation 23,39-42. Investigations linking obesity
with impaired skeletal muscle AMPK have provided largely inconsistent findings. In several
genetic models of obesity, AMPK levels in skeletal muscle were altered 16,43,44, however, other
studies assessing AMPK levels in obese and insulin resistant models did not indicate differences
45-50

. In the current experiment, pAMPK expression was decreased by HFD consumption in OM

rats. Due to the role of AMPK as an energy sensor and a regulator of fat oxidation, these data
suggest that HFD-induced decreases in AMPK phosphorylation in the skeletal muscle of OM
rats may be a mechanism by which OM rats decrease their metabolic rate and EE in response to a
HFD. Previous research has implicated defects in PPARγ , a regulator of fatty acid storage and
glucose metabolism, as a mediator of the susceptibility to developing obesity 24, which supports
data from the current study.
Inherent and HFD-induced alterations in lipid accumulation in the skeletal muscle of
OM and S5B rats were measured by Oil Red O. HFD intake increased lipid accumulation in both
strains, but to a greater extent in the OM rats. Oxidative capacity of the skeletal muscle was
assessed by an SDH assay and these data suggest that the gastrocnemius muscle of OM rats have
a greater oxidative capacity (more Type I fibers). HFD consumption increased the oxidative
capacity of the muscle in both strains. Lipid accumulation in skeletal muscle, in most cases, is
indicative of the cellular energy status, which favors storage rather than oxidation, and is
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associated with obesity and type 2 diabetes 51. Previous studies have demonstrated excessive fat
transport and β-oxidation in skeletal muscle following HFD intake 52, which rendered rats
incapable of switching to carbohydrate oxidation in the postprandial state, and therefore inhibited
metabolic flexibility. The accumulation of intramuscular triglycerides and the intermediaries of
incomplete fat oxidation (DAG, ceramides) have been shown to alter the insertion of GLUT4 in
the plasma membrane 53-55. Excessive, but incomplete fat oxidation leading to an accumulation
of lipids in skeletal muscle has been seen in rats fed a HFD 52 and is similar to the pattern seen in
the current study, in which HFD intake increased fat oxidation and lipid accumulation in OM
rats. Incomplete fat oxidation and excessive lipid accumulation may explain, in part, the
increased susceptibility to developing obesity in the OM rats.
The current experiment tested the hypothesis that there were inherent differences and
HFD-induced alterations in metabolic parameters, skeletal muscle markers of carbohydrate and
fat metabolism, and oxidation and lipid accumulation in skeletal muscle of obesity-prone and
obesity-resistant rats. Obesity-prone OM rats gained more weight and body fat on a HFD and
consume more HFD, than obesity-resistant S5B rats. HFD consumption also increased fasting
glucose levels in the OM rats, suggesting glucose intolerance. No inherent strain differences
were detected in metabolic rate and estimated EE. However, the consumption of a HFD in S5B
rats increased metabolic rate and EE and decreased metabolic rate and EE in OM rats. These
strain differences were not due to the differences in activity or food intake. HFD-induced
differences in metabolic rate and EE may be mediated by HFD-induced differences in pAMPK
and PPARγ expression and lipid accumulation in the gastrocnemius muscle of OM and S5B rats.
HFD intake decreases in pAMPK and PPARγ expression in OM rats predict a decrease in EE
and an increase in lipid accumulation. Taken together these data suggest that the susceptibility to

23

developing HFD-induced obesity, in these two strains, may be mediated by differential rates of
EE, which are mediated by AMPK and PPARγ and by lipid accumulation in skeletal muscle.
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CHAPTER 3. DIFFERENTIAL EFFECTS OF FATMAX VS. HIGH CARBOHDRATE
OXIDATION (OBLA) EXERCISE ON ORAL GLUCOSE TOLERANCE AND
METABOLIC FLEXIBILITY
3.1 Introduction
Exercise is an important lifestyle intervention used to prevent, delay, or treat the
development of metabolic disorders such as obesity and type 2 diabetes 1. However, there is a
need to develop more effective exercise strategies to account for the large variability in the
response to exercise in people with metabolic disorders 2. For example, an acute bout of exercise
has been shown to improve insulin sensitivity for up to 24 hours, in some, 3-5,but not all studies
6,7

. This discrepancy is due to numerous factors including exercise intensity 8-10 , glycemic status

of subjects 11, dietary behavior 12,13, or timing of the post-exercise measurement of insulin
sensitivity 14. The total dose of exercise at differing intensity is also a consideration that might
explain the variability in post exercise insulin sensitivity.
The improvements in glucose tolerance with aerobic exercise may be the result of 1)
increased glucose uptake to support glycogen synthesis 3 or 2) more complete oxidation of
intramuscular triglycerides (IMTG), and lipid species 15. Previous research suggests that a single
bout of aerobic exercise at a higher intensity (as a percentage of maximal cardiorespiratory
fitness; VO2max) improves glucose tolerance to a greater extent 16. However, this result may be
partially due to a lower variability in individual responses regarding fuel utilization as high rates
of carbohydrate oxidation are common at higher exercise intensities. At lower exercise
intensities, physiologic, nutritional, and genetic factors lead to an increase in the variability in
fuel selection potentially obscuring the benefits of increased fat oxidation during acute exercise
17,18

. Aerobic exercise can also be prescribed at an intensity (FATMAX) eliciting a maximal fat

oxidation rate (MFO; g/min). The FATMAX varies between individuals, but is easily
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determined by a standard graded exercise test to exhaustion (VO2max) 19. To our knowledge, only
one study has examined the effect of aerobic training at FATMAX 20. In this study, insulin
sensitivity improved after only 4 weeks of aerobic training at FATMAX compared to 4 weeks of
aerobic interval training of equal caloric dose. The effect of acute exercise at FATMAX on
glucose tolerance is unknown. Additionally, no research exists comparing a single bout of
aerobic exercise at FATMAX to a higher intensity exercise in which the primary fuel source is
carbohydrate (i.e onset of blood lactate accumulation). Determining the intensity of aerobic
exercise that has the greatest impact on glucose tolerance has practical applications and could
potentially offer options for individuals looking to start exercise programs, especially sedentary
individuals at risk for diabetes. Likewise, a lower intensity exercise may also promote greater
adherence through improved affective (feeling and arousal) responses during exercise.
The purpose of this study is to investigate the effect of acute aerobic exercise at an
intensity that maximizes the rate of fat oxidation (FATMAX) on glucose tolerance compared to
acute aerobic exercise at a higher intensity resulting in greater carbohydrate oxidation (OBLA).
We hypothesize that glucose tolerance will improve acutely post FATMAX and OBLA exercise.
Additionally, we expect that affective responses will be stable and more positive during the
FATMAX trial compared with the OBLA trial.
3.2 Methods
3.2.1 Participants
Eight apparently healthy, sedentary, overweight/obese college-aged men gave written
informed consent to participate in this study. Individuals who presented with any known
cardiovascular disease, type 2 diabetes, resting blood pressure ³140/90mmHg, and/or body mass
index ³35kg/m2 were excluded. Baseline participant characteristics are provided in table 1. The
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participants enrolled were all college aged, sedendtary, and overweight. All participants had
fasting plasma glucose levels below the threshold criteria (³126 mg/dl) and 120-minute threshold
of ³200 mg/dl. All participants were physically inactive, nonsmokers, presently not taking any
medications, and had physician approval to participate. This study was approved by the
Institutional Review Board at Louisiana State University.
Table 3.1. Baseline Characteristics
Age (y)

20.5 ± 1.5

Height (m)

1.81 ± 0.04

Weight (kg)

95.9 ± 13.8

BMI (kg/m2)

29.5 ± 4.7

VO2peak (ml•kg-1•min-1)

33.2 ± 6.8

Fasting plasma glucose (mg/dl)

93.9 ± 10.6

120 min plasma glucose (mg/dl)

93.2 ± 12.2

Fasting RER

0.80 ±0.05

VO2peak maximal aerobic capacity; BMI body mass index;
Respirator Exchange Ratio (VCO2/VO2) ±SD
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3.2.2. Experimental Protocol
Screening
Visit

OGTT,
Randomization*

Acute
Exercise 1

24-hour Diet
0

6

OGTT, Resting
Metabolism

Acute
Exercise 2

24-hour Diet
7

14

OGTT, Resting
Metabolism

24-hour Diet
15

21

22

Visit Schedule (days)
Figure 1. Visit Schedule. *After confirmation of non-diabetic status, participants undergo 2 acute aerobic
exercise sessions in random order. The intensity of the acute exercise sessions will be 1) FatMax or 2) high
carbohydrate oxidation. 24-hour diet records will be kept prior to the baseline OGTT and replicated between
the acute exercise sessions and the OGTTs.

Participants underwent a maximal cardiorespiratory fitness test (VO2max) with
electrocardiogram (ECG) on a cycle ergometer (Velotron, Racermate, Inc., Seattle, WA).
Participants started at an initial workload of 25 Watts for 4 minutes. The workload was
increased by 25 Watts every 4 minutes until respiratory exchange ratio reached 1.05 after which
the workload increased by 25 Watts every 2 minutes until volitional exhaustion. Throughout the
test, respiratory gases were analyzed using a metabolic cart (ParvoMedics Inc., Sandy, UT) and
fat oxidation rates were determined using stoichiometric equations21. FATMAX was determined
using a 3-parameter logistic line of best fit calculated from the fat oxidation vs. exercise intensity
(%VO2max) graph (figure 3.2) 19. During the VO2max test, we also obtained finger stick blood
lactate concentrations (Lactate Plus,Waltham,MA), at the end of each interval for the
determination of onset of blood lactate accumulation (OBLA; 4 mM lactate). The exercise ECG
was reviewed by a cardiologist for final study approval.
The baseline OGTTs occurred ~1 week after the screening visit and VO2max test. Prior to
the baseline visit participants recorded all food and beverages ingested for the 24-hour period
prior to the baseline OGTT. Participants were required to abstain from exercise 48 hours prior to
the visit. Participants then completed, in random order separated by ~1 week, two bouts of
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isocaloric (400 kcal) exercise at either FATMAX or OBLA. Additional OGTTs were conducted
24 hours after the 2 acute exercise sessions separated by ~1 week. Prior to the post-exercise
OGTTs, participants replicated the 24-hour food and beverage diary recorded prior to the
baseline OGTT. All OGTTs and exercise sessions were conducted in the morning hours after a
10-hour fast.
The acute aerobic exercise sessions occurred ~1 week after the screening visit and
VO2max test and were performed on a cycle ergometer at intensities eliciting 1) FATMAX and 2)
high carbohydrate oxidation (lactate threshold). All participants underwent the acute aerobic
exercise sessions in a random, counter-balanced order. The targeted total dose of exercise was
400 kcal for both exercise sessions. Caloric expenditure rates were monitored periodically
throughout exercise. The time to finish the 400 kcal exercise dose was accurately determined by
extrapolating the kcal expenditure rate (from the metabolic cart) at each time point to the final
caloric dose. We estimated that a 100 kg male (VO2peak=35 ml×kg-1×min-1) will finish the
FATMAX session in ~50 minutes and the OBLA session in ~30 minutes 22.
3.2.3 Experimental Measures
3.2.3.1 Exercise Prescription
FATMAX was determined using a 3-parameter logistic line of best fit calculated from the
fat oxidation vs. exercise intensity (%VO2max) graph 23 (figure 3.2). According to this method, we
required >3 valid fat oxidation points with 2 valid inflection points. Once MFO was identified
FATMAX intensity could be determined by using the corresponding power generation (watts)
performed during the GXT (Figure 2). FATMAX calculated for each individual participant.
Lactate was measured at the end of each stage during the GXT. OBLA was considered the onset
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of blood lactate (4mM). The corresponding intensity was determined by the inspection method
24

.

Figure 3.2 Example of FATMAX analysis. FatMax and MFO calculated by MatLab (.exe) from
VO2max test. Fat oxidation (FAOx) by Jeukendrup and Walis equation (2005). Required 3 PL
regression with ≥ 3 valid FAOx points with 2 valid inflection points. Lower Bound = 0%; forced
equation through origin (0,0). Upper Bound (UB) ≤ 100% and LB < FatMax < UB.

3.2.3.2 Exercise Sessions
During both exercise sessions, respiratory gases were measured at 5-min intervals prior to
25%, 50%, 75% and 100% of the exercise bout, equivalent to 100, 200, 300, and 400kcal,
respectively, and the time to complete the exercise bout was adjusted accordingly. Any excessive
energy expenditure achieved during the first of the randomized sessions was accounted for in the
subsequent session to match energy expenditure.
Affective responses were measured from the perspective of the circumflex model of
affect. Affect is defined by the orthogonal and bipolar dimensions of affective valence (pleasuredispleasure) and perceived activation (low-high). To capture these dimensions, two single-item
measures were used. The Feeling Scale is an 11-point measure of affective valence. The scale
ranges from -5 to +5. Anchors are provided at zero (“Neutral”) and at all odd integers, ranging
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from “Very Bad” (-5) to “Very Good” (+5). The Felt Arousal Scale 25 is a 6-point measure of
perceived activation. The scale ranges from 1 to 6, with anchors at 1 (“Low Arousal”) and 6
(“High Arousal”). Affective responses were measured pre- and post-exercise in all 3 trials as
well as at each minute during the initial VO2max test and at regular intervals (e.g., ~25%, 50%,
75%, and 100% of the 400 kcal exercise dose) during the experimental conditions. Additionally,
rating of perceived exertion (RPE) was recorded at the same intervals as other affective
responses.
3.3.3.3 Oral Glucose Tolerance Test (OGTT)
The baseline OGTT occurred ~1 week after the screening visit and VO2max test. . The
baseline OGTT completed the exclusion criteria for high fasting glucose (> 125 mg/dL) and
abnormal 2-hour glucose (> 200 mg/dL). Additional OGTTs was conducted 24 hours after the 2
acute exercise sessions and was separated by ~1 week. Prior to the post-exercise OGTTs,
participants were asked to replicate the 24-hour food and beverage diary recorded prior to the
baseline OGTT. Glucose area under the curve was measured by the trapezoidal method 26.
Indirect calorimetry was performed prior to and during each OGTT. Resting energy
expenditure and substrate utilization were assessed using the ParvoMedics, TruOne 2400
metabolic cart (Sandy, UT) calibrated with standard gas mixtures . A transparent plastic hood
connected to the metabolic cart was placed over the participant’s head and calculations of energy
expenditure and carbohydrate and fat oxidation rates were made from expiratory gases diluted in
a constant air flow (~40 L/min). Resting metabolic measurements were assessed before the
OGTT (0 min) and at 60 and 120 minutes after ingestion of the glucose drink. The average of
the last 20 minutes of the 30 minute measurement was used to calculate resting metabolic rate
and substrate oxidation using the equations of Jequier et al 27. Participants remained motionless
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and awake during these periods. Metabolic flexibility was measured at 60 minutes (RER 60-0
min) and at 120 minutes (120-0 minutes).
3.2.4 Statistical Analysis
All statistics were performed using JMP statistical software (SAS Institute Inc., Cary,
NC). Data analysis generally followed CONSORT recommendations using General Linear
Models and repeated measures analysis of variance (RM-ANOVA) co-varied as needed
depending on normality distributions at baseline and order of intervention trials. In addition,
two-way RM-ANOVA (exercise session x time point) were used to determine differences in
responses in both the primary and secondary outcome variables. Primary outcomes included
AUC plasma glucose and change in metabolic flexibility (shift in RER pre to post oral glucose).
Baseline (non-exercise) and exercise (FATMAX and OBLA combined) comparisons were
evaluated using contrast statements with the one-way RM-ANOVAs. Significant effects were
further evaluated using student’s t-test post-hoc analyses were appropriate. Data will be reported
as mean±SD and differences declared at P<0.05.
3.3 Results
3.3.1 Substrate Oxidation During Fat Max and OBLA Exercise
The percent VO2max at FATMAX (41±12%) and OBLA (68±10%) differed significantly
(p<0.001). Substrate oxidation for fat (figure 3.3A) and carbohydrate (figure 3.3B) was measured
during FATMAX and OBLA exercise. Total energy expenditure was 416.1 ± 11.4kcal for
FATMAX and 422.1 ± 10.4kcal for OBLA exercise. FATMAX exercise elicited greater average
fat utilization (18.6 ± 12.1g) than OBLA (10.1 ± 20.3g; p=0.03) exercise (figure 3.4).
Accordingly, OBLA (82.8 ± 12.1g) exercise elicited greater carbohydrate utilization than
FATMAX (62.4 ± 20.3g; p<0.05) exercise. As expected, the average time to complete the OBLA
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exercise was less (40.0± 10.9 min) compared to the FATMAX exercise trial (62.9± 21.9 min;
p=0.01).

FATMAX

0.2
0.1

10

75

0

0.0

50

A)

OBLA

0.3

25

Fat Oxidation (g/min)

0.4

% of total time

B)

OBLA

2.5
2.0
1.5
1.0
0.5

0
10

75

50

0.0

25

CHO Oxidation (g/min)

FATMAX

% of total time

Figure 3.3 A) Fat oxidation and B) CHO oxidation during acute bout of exercise for
the FATMAX and OBLA trials. + SEM
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Figure 3.4. Average fat oxidation (A) and total carbohydrate (CHO) oxidation (B)
for the FM and OBLA exercise exercise trials. * FM significantly greater fat
oxidation (P<0.05) during FM trial and carbohydrate oxidation was significantly
greater during the OBLA trial. Group means + SEM
3.3.2 Affective Response
Participants completing the FATMAX exercise session reported lower RPE (Figure 7a) at all time
points (25%, 50%, 75%,100%) compared to OBLA (average RPE FATMAX 10.1±2.1vs. OBLA
13.9±2.4; pvalue). Participants completing the FATMAX trial also reported significantly lower Felt
Arousal (FA)(Figure 7b) (p<0.05) and Feeling Score (FS) (Figure 7c) (p<0.05) at the 25 (FATMX
1.6±1.7 vs. OBLA 2.5±1.5) and 50% (FATMAX 1.7±1.1 vs. OBLA 3.0±1.2) time points and 75
(FATMAX 2.5±2.7 vs. OBLA 0.05 ±3.0) and 100% (FATMAX 2.1±3.1 vs. OBLA -0.05±3.3)
respectively.
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Figure 3.5. A) RPE, B) Feeling Score (FS), and C) Felt Arousal (FA) during FM
and LT exercise. *P<0.05 , #P<0.001. + SEM

3.3.4 Oral Glucose Tolerance
No significant differences were detected for fasting glucose at baseline or before the
FATMAX or OBLA exercise conditions (84.2 ±17.0 and 90.0 ± 19.9 mg/dl respectively). Total
AUC for glucose (figure 3.6) was higher for OBLA (15126.2±1351.1) exercise than baseline
condition (13143.9±909.5; p<0.05). There were no significant differences between AUC for
glucose after FATMAX (13411±1721) compared to baseline conditions (p=.58). Additionally,
peak plasma glucose did not differ between trials (Baseline=128.8±15.4, FATMAX=
142.2±24.4, and OBLA=148.8±17.1)).
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Figure 3.6 Glucose area under the curve (120-0 AUC) for all visits.
*p<0.01 OBLA vs. baseline.

3.3.5 Metabolic Flexibility
No significant differences were detected between the FATMAX (0.089 ± 0.032) and baseline
measurements (0.11± 0.04; p<0.005) for the metabolic flexibility (DRER 120-0) (figure 3.7). There was
however, a lower DRER (0.051 ± 0.032) 24-hr post OBLA exercise at the 60-minute time point compared
to baseline (values; p<0.05). There were no significant differences between any condition at 120 minutes.
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Figure 3.7 Metabolic flexibility measured during the OGTT at baseline and 24hrs
after FATMAX and OBLA exercise sessions. *p<0.05 OBLA vs. baseline. + SEM
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3.4 Discussion
The purpose of this study was to investigate the effect of acute isocaloric aerobic exercise
at FATMAX and OBLA on the glucose tolerance and metabolic flexibility of young overweight
males. Previous work suggests that acute exercise increases insulin sensitivity for up to 24 hrs.
post-exercise 7,10,28,29. However, within these studies there appears to be differential effects of
exercise due to intensity, type, meal timing, measurement timing, and diabetic status. Energy
expenditure (total kcal) is a modifiable facet of exercise that is a potential source variability that
may explain the response to exercise. In the current study, we found that OBLA exercise acutely
lowers glucose tolerance and metabolic flexibility under well-controlled exercise conditions.
This suggests that the acute period (24 hours) is characterized by delayed glucose disposal and
oxidation.
Substrate utilization during exercise is dictated primarily by the intensity of exercise 23,30.
Duration of exercise also affects carbohydrate and fat oxidation especially when comparing
trained versus untrained individuals. Klein et al (1990), demonstrated that fat oxidation was
higher in trained volunteers (vs. untrained) during 4 hours of treadmill running at a low intensity
(~20 ml/kg-1/min-1), despite similar rates of lipolysis and fatty acid uptakes 31. Fat oxidation is
also impacted by carbohydrate availability and the production of lactate 30,32,33. However, these
factors have been demonstrated under long duration (2.5-4 hours) exercise, which may not be
clinically applicable.
Fat oxidation can be challenging to measure, in part, to the different sources (adipose and
IMTG) of FFA available to the skeletal muscle during exercise. Evidence suggests that IMTG
are a major source of FFA during exercise at low to moderate intensity 34,35. Experimental
inhibition of adipose lipolysis does appear to increase IMTG oxidation in healthy and T2D
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patients, which suggests IMTG does account for some percentage, albeit varying, amount of fat
oxidation 36,37. As exercise intensity exceeds ~55% of VO2max there appears to be a decrease in
fat oxidation rate, especially IMTG oxidation 23,35. In our study, FATMAX exercise trials were
completed at individually calculated FATMAX thresholds (41.1 ± 12% VO2max). During
FATMAX exercise (Fig. 1A and 1B) we demonstrated a consistent level of fat oxidation without
significant increases in carbohydrate oxidation. This suggest that the dosage of exercise (400
kcal) may be ideal to observe such effects.
As expected, as exercise duration increased during the OBLA trial there was an increase
in fat oxidation and the contribution of FA to overall energy expenditure. However, average
carbohydrate oxidation (20.8±3.4 g/min) was greater during OBLA exercise suggesting the
higher exercise intensity promoted preferential utilization of carbohydrates (78.9±5.3% of total
energy expenditure). The increased fat oxidation during OBLA exercise can be explained by
numerous factors. As exercise duration increases, the availability of FA increases as does the
transport of FA into the contracting skeletal muscle 35,38. The isocaloric (400 kcal) study design
was successful in executing exercise trials that promoted preferential substrate oxidation without
exceeding the physiological threshold that would promote greater carbohydrate oxidation in the
FATMAX trial and greater fat oxidation in the OBLA trial.
The accretion of IMTG is thought to be a factor in the development of insulin resistance
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. However, this hypothesis is more specifically focused on the lipid intermediaries (ceramides,

DAG, Faty acyl-CoA) 40. The accumulation of these by-products of incomplete FA oxidation
have been shown to interfere with the insulin signaling cascade of the skeletal muscle. The
oxidation of IMTG and potentially lipid intermediaries could promote increased insulin
sensitivity 41-43. In the current study, we were not able to label and track specific sources of FA
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being oxidized. Therefore, we cannot be certain as to the contribution of IMTG being utilized
during the FATMAX trial. Nonetheless, we did not observe a lower glucose AUC 24 hrs post
FATMAX exercise, which suggests there was no improvement in insulin sensitivity due to acute
FATMAX exercise. Conversely, there was a significant increase in glucose AUC post OBLA
exercise. The sympathoadrenal system is stimulated to a greater degree with higher intensity and
longer duration exercise. The counter regulator hormones that are responsible for fuel
mobilization (glucagon, epinephrine, norepinephrine, growth hormone, etc.) are activated, which
increases glycogenolysis and gluconeogenesis 44,45. A similar study comparing a single bout of
exercise at 50% and 70% VO2max did not detect significant difference in endogenous glucose
production 30-minutes post exercise, which would suggest that effect does not extend to 24 hrs
after exercise 7. However, the sedentary and overweight status of our participants, could explain
the effects of the acute higher intensity OBLA exercise and the duration its metabolic effects.
Peak metabolic flexibility (∆RER 0.09±0.04) occurred at 120 minutes post oral glucose,
but was not significantly improved by FATMAX exercise (0.08±0.04) or OBLA exercise
(0.07±0.04). The shift in RER was significantly (p<0.05) lower at the 60-minute time point for
OBLA exercise when compared to baseline (0.01±0.05) (Figure 3.7). Metabolic inflexibility is a
common feature of obesity, impaired glucose tolerance, and T2D 46-48. Metabolic inflexibility is
also a characteristic of the offspring of type 2 diabetics 39,49, who are at a significantly greater
risk for future develop of T2D 50. The current study cohort did not have a positive family history
of T2D and did not demonstrate metabolic inflexibility at baseline. The negative effect of OBLA
exercise on metabolic flexibility does appear to be related to impairments in glucose tolerance 60
minutes post oral glucose (Figure 3.6). Higher resolution techniques (i.e hyperinsulinemic clamp
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and radioactive labeled glucose) would be helpful in elucidating the mechanism behind this
phenomenon.
A primary metabolic stimulus for triggering muscle glucose uptake is glycogen depletion
51

. The post exercise period of glycogen resynthesis is characterized by the rapid resynthesis

immediately post exercise and the slower insulin mediated resynthesis. Kelley et al (1988)
reported that skeletal muscle takes up ~26% of the glucose load after an OGTT and of that 50%
is oxidized, 35% is stored as muscle glycogen, and the remaining 15% is released as
gluconeogenic precursors (lactate, pyruvate, alanine)
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. However, after glycogen depleting

exercise, muscle glycogen storage can account for up to 40% of total oral glucose uptake 53,54.
These studies were conducted to maximize glycogen breakdown (2 hours of cycling at ~75%
VO2max). The amount of time, 40.0±10.9 min for OBLA compared to the FATMAX exercise
trial 62.9± 21.9 min, and average intensity 41% vs 68% VO2max likely did not reach the same
level of glycogen depletion. Additionally, our sample was sedentary overweight young men, a
group, that compared to well-trained individuals, has reduced glycogen storage capacity 53.
Nonetheless, exercise has been shown to increase the partitioning of oral glucose to glycogen
storage even in the untrained.
OBLA exercise utilized a greater total amount of CHO (82.8 g) vs. FATMAX exercise
(62.4 g), suggesting a greater potential level of glycogen depletion. The higher glucose AUC
during the 24-hour post OBLA exercise OGTT, in combination with reduced oxidation of CHO
(lower RER), suggests that non-oxidative glucose disposal may be impaired in this cohort. In
fact, the post-exercise period in which the OGTT was performed (24 hours post FATMAX or
OBLA exercise) is considered primarily insulin-mediated. Therefore, it is reasonable to assume
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the effect exercise at OBLA in this group does not promote insulin sensitivity in the time frame
we studied.
Participants reported feeling significantly less stressed and/or feeling better during the
FATMAX trial compared to OBLA exercise. Considering the significantly lower intensity level
(FATMAX 41±12% and OBLA 68±10%) experience during FATMAX exercise this is not
surprising. However, this does suggest that this FATMAX intensity exercise provides some
positive feedback to participants and does not acutely negatively affect glucose metabolism.
These finding may be particularly relevant for certain populations, such as the population in this
study (overweight sedentary young men) that are at increased risk for the development of
cardiovascular disease.
In conclusion, there appears to be differential effects on glucose tolerance and metabolic
flexibility in response to a single bout of FATMAX and OBLA exercise. The potential benefits
of exercise may not manifest until sufficient adaptations have occurred. Another potential
explanation for the differential response to exercise at FATMAX and OBLA intensity is the time
course for measurement of oral glucose tolerance and metabolic flexibility. The period after
exercise (immediately post to 24 hours) is characterized by metabolic responses that make the
interpretation of health-related outcomes troublesome, therefore the measurements of these
outcome may require a fuller understanding of the impact and lasting effects of a single bouts of
exercise.
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CHAPTER 4: THE IMMEDIATE AND EXTENDED EFFECTS OF INTENSE INTERVAL
EXERCISE ON METABOLIC FLEXIBILITY AND MITOCHONDRIAL FUNCTION

4.1 Introduction
Metabolic flexibility (METFLEX) is defined as the ability to switch from predominantly lipid
oxidation and fatty acid uptake in the fasted state to insulin-stimulated suppression of lipid oxidation and
high rates of muscle glucose uptake and glycogen synthesis that occurs in the postprandial state 1. The
inability to “shift” (Δ respiratory exchange ratio (RER)) metabolism from lipid to glucose oxidation,
termed metabolic inflexibility, is a characteristic of obesity and T2D 2-4 and is implicated in the
development of insulin resistance 1,5,6. However, metabolic inflexibility is present prior to the
development of insulin resistance and fasting hyperglycemia in the offspring of T2D individuals 6-8 and
remains in previously obese individuals after weight loss 4.
Metabolic inflexibility is associated with impaired fasting lipid oxidation 3,5,9, which suggests that
metabolic inflexibility is a reflection of the inability of the mitochondria to switch between fuels.2 Since
lipid oxidation occurs in the mitochondria, it is logical to deduce that impairments in mitochondrial
function could alter whole-body lipid oxidation. Adding clarification to this issue, Ukropcova (2007) and
van de Weijr (2013) have demonstrated that skeletal muscle mitochondrial function is reduced in
metabolically inflexible individuals 8,10. Recent evidence also suggests that the offspring of type 2
diabetics have impaired METFLEX without the presence of other metabolic risk factors 7. Moreover,
individuals with a biological mother that has T2D are at greater risk of developing T2D, when compared
with a father with a positive history 11,12.
Continuous moderate to high intensity exercise training (6-12 weeks) has been shown to improve
insulin sensitivity and metabolic flexibility in obese and type 2 diabetic patients, with greater
improvements demonstrated with higher intensities 13,14. Interestingly, the time course of glucose
tolerance and insulin action in response to a single bout of exercise reveals periods of increased insulin
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sensitivity (immediately post exercise to 3 days) and potential resistance or no improvement (5 to 7 days
post exercise) 15,16. However, the data regarding improvements due to a single bout of exercise or exercise
training is more difficult to interpret in the light of the change in body weight (reduction in whole body
adiposity)2,17-19. Favorable changes in body composition have significant impact on insulin action and
METFLEX 2,20,21, thereby complicating the interpretation of the benefits of exercise in the absence of
weight loss.
Recent research suggests that 2-6 weeks of high intensity interval training (HIIT) improves
insulin sensitivity and skeletal muscle oxidative capacity 22,23. However, data regarding changes in
METFLEX in response to a single bout of high intensity interval exercise (HIIE) are lacking. Arad et al
(2015) did not find any differences in fasted or insulin stimulated change in RER after 14-weeks in
sedentary, premenopausal, African American women when compared to a non-exercising control group
24

. Careful measures were taken to keep body weight stable during this intervention. The design of the

study was focused on measuring the chronic adaptations to HIIT and therefore, reassessment of insulin
sensitivity and METLFEX utilizing the hyperinsulinemic-euglycemic clamp method was completed 72
hours after the final training session. This study, and others, suggest that the timing and methodology of
measuring METFLEX and insulin sensitivity should be carefully considered. While the clamp technique
is considered the “gold standard” for measuring insulin sensitivity the insulin infusion level likely does
not reflect the ability of endogenously produced insulin to suppress whole body fat oxidation in the
postprandial state.
To date there are no studies investigating the time-course of METLFEX in response to a single
bout of HIIE. Characterizing the immediate and extended response of a single bout of HIIE could provide
insight into the therapeutic applications of this exercise approach. The purpose of this study was to
determine the immediate and extended (48-hr) effects of a bout of high intensity interval exercise prior to
a mixed meal on METFLEX in men and women. We sought to test the hypothesis that acute HIIE would
improve METFLEX in men and women. Additionally, we were interested in whether young men and
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women with a FmHx of T2D, were metabolically inflexible as has been reported in older adults 8,12,25. We
also sought to measure in vivo mitochondrial function (OXPHOS) by completing a near-infrared
spectrophotometry (NIRS) protocol. Several studies demonstrate that the adult children of mothers with
T2D are more likely to develop metabolic inflexibility and that, in part, may be due to the inherited
mitochondrial dysfunction passed on through the mother’s mitochondrial DNA 8,25-27. Finally, we aimed
to determine the effect of a single bout HIIE on METFLEX in FmHx participants.
4.2 METHODS
4.2.1 Participants
Sixteen apparently healthy, active, normal weight (BMI = 18 to 25 kg/m2) young (age 19 to 25 y)
men and women with (n=8) and without (n=8) a positive family history of T2D participated in this study.
A positive family history (FHx) was defined as having a biological mother with T2D. The control
participants were considered to have no FHx if both parents and grandparents were free of T2D. All
participants reporting being no more than moderately physically active (3 days week of 30 minutes of
moderate intensity physical activity) and no participant reported engaging in regular HIIE. Individuals
with known cardiovascular, T2D, and/or metabolic disorder were excluded from the study. This study
was approved by Louisiana State University’s Institutional Review Board. All participants provided
written informed consent.
4.2.2 Experimental Design
After an initial screening and confirmation of positive or negative FHx eligible participants were
scheduled to complete a baseline maximal graded exercise test, near-infrared spectrophotometry (NIRS)
OXPHOS, and mixed meal tolerance test (MMTT) (Figure 4.1). Results from the maximal graded
exercise test were used to prescribe a single bout of HIIE performed during a separate week and followed
by a MMTT 1 hour post HIIE (1hrPE). Finally, a follow-up MMTT was performed 48 hours after the
HIIE day (48hrPE).
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4.2.3 Experimental Protocol and Measurements
4.2.3.1 Maximal Graded Exercise Testing (VO2max)
If participants meet all inclusion/exclusion criteria during the screening visit, a maximal
cardiorespiratory test (VO2max) on a cycle ergometer (Velotron, Racermate, Inc., Seattle, WA) was
completed during the baseline visit. Participants rode at an initial workload of 25 Watts for 4 minutes.
The workload increased by 25 Watts every 4 minutes until respiratory exchange ratio reached 1.05 after
which, the workload increased by 25 Watts every 2 minutes until volitional exhaustion. Throughout the
test, respiratory gases were analyzed using a metabolic cart (ParvoMedics Inc., Sandy, UT) and fat
oxidation rates will be determined using stoichiometric equations28. The watts achieved at the time of
volitional exhausting was consider 100% watt max.
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4.2.3.2 NIRS Protocols to Measure Muscle Metabolism (e.g., NIRS mVO2, blood
flow, and OXPHOS)
Study participant arrived at laboratory having refrained from exercise 24 hours prior to the study
visit and having fated overnight. Measurements of subcutaneous adipose tissue and muscle depth were
collected for the vastus lateralis and vastus medials via use of B-mode ultrasound (LOGIQ e, GE
Healthcare, Little Chalfont, UK) Participants were positioned on a table rested in the supine position with
knees slightly flexed. The NIRS optodes (Oxymon MKIII, Artinis Medical Sytsems) were placed
longitudinally on the non-dominant vastus lateralis and vastus medialis just anterior to the iliotibial band
and ~1/3 the distance between the top of the patella and the greater trochanter of the test leg (Figure 4.2).
The optodes were secured in place with adhesive tape and Velcro strap. A blood pressure cuff
(Hokanson, Bellevue WA) was placed proximal to the optode, and connect the cuff to a rapid cuff
inflation system (Hokanson E20, Bellevue WA) that was controlled using an external controller and
Labview Software. NIRS signals for oxygenated (O2Hb) deoxygenated (HHb), and total hemoglobin
(tHb) were continuously monitored by NIRS.
Resting muscle blood flow was measured in triplicate using venous occlusions by inflating the
blood pressure cuff to (50-60 mmHg) for 20 seconds with at least 120 seconds between each
measurement. Blood flow was measured by calculating the slope of the linear increase total hemoglobin
(tHb): BF= (((DtHb x 60)/ ((([Hb] x1000)/4))x1000/10 in ml-1•min•100ml-1. Measurements of resting
muscle oxygen consumption (mVO2) were made in triplicate using arterial occlusions by inflating the
blood pressure cuff to (250-300 mmHg) for 20 seconds with at least 120 seconds between each
measurement and were calculated by measuring the linear decrease in O2Hb by the following formula:
mVO2=Abs(((DO2Hb x 60)/(10 x 1.04)) x 4) x 22.4/1000) in mlO2•min-1100g-1.
For measurement of muscle oxidative capacity (NIRS-OXPHOS), participants completed a 7second isometric contraction of the vastus lateralis (by knee extension) immediately followed by a series
of 15-20 arterial occlusions (250-300 mmHg) to measure the rate of recovery of mVO2. The occlusions
started with a series of 9 occlusions at 5 seconds on and 5 seconds off followed by a series of 11
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occlusions 10 seconds on 10 seconds off. This NIRS-OXPHOS protocol was repeat twice with ~5-10
min between each trial. Recovery mVO2 was calculated for each occlusion and fit to a monoexponential
function as follows according to Ryan et al (2014): y=(end – delta) x e-kt where y is the relative mVO2
during the arterial occlusion, end is the mVO22 immediately following the isometric knee extension, delta
is the change in mVO2 from rest to knee extension, k is the fitting rate constant and t is time29. Finally,
we performed an ischemic calibration procedure and calculate mVO2 corrected for blood volume as
previously described 30, which includes a 15-20 second isometric contraction of the vastus lateralis (by
knee extension) immediately followed by ~8-10-minute arterial occlusion (250-300 mmHg). According to
the methods of Ryan et al (2013) Time constants (Tc) functioned as an index of mitochondrial function 31.
NIRS data was analyzed via a custom written program in MATLAB (Mathworks, Natick, MA). Muscle
blood flow and mVO2 were measured 30 minutes prior to and 30 minutes, 60 minutes, and 120 minutes
after ingestion of the mixed meal.

VM

VL

Figure 4.2 A.) Longitudinal placement of NIRS optodes on vastus lateralis (VL) and
vastus medialis (VM).
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4.2.3.3 Mixed Meal Tolerance Test (MMTT)
Prior to the baseline MMTT visits, participants were asked to refrain from exercise, alcohol, and
caffeine, for 48 hours and were ask to provide a record of food intake the day preceding the test. The
morning of the test, participants arrived fasted and provided the food record. Upon arrival participants
started a 30-minute rest period. During this time, the participants were provided with a heart rate monitor
and NIRS probes were attached, as described previously, for measurements of blood flow -30, +30, +60,
and +120 post mixed meal ingestion.
After the 30-minute rest period the -30 minute metabolic rate measurement was taken by placing
a vented canopy system to measure expired O2 and CO2 (ParvoMedics Inc., Sandy, UT) to measure
resting energy expenditure (REE; Kcal/day) and calculate carbohydrate and fat oxidation rates using
stoichiometric equation 32. Exhaled air was continuously measured for 30 minutes pre-mixed meal (-30 to
0 minutes,) and post meal (+40 to +70 minutes and 110-140 minutes) while the participate remained still
and refrained from sleeping. The last ten minutes of each collection period was averaged and used to
report REE, RER, and substrate oxidation rates.
After completion of the fasted pre-mixed meal metabolic rate measurement, the mixed meal drink
(Ensure, Abbott laboratories, Lake Forest, Illinois) was prepared by calculating the average REE
(kcal/day) of the final 10 minutes of the measurement period and dividing by 3. A member of the study
staff then prepared the meal by measuring the grams of powder and mixing into ~150-200 ml of water.
Additionally, blood was drawn through an IV catheter immediately before the ingestion of the mixed
meal and 5, 10, 15, 20, 30, 60, 90, 120, 150, 180 minutes post meal. All procedures for the MMTT,
including the energy content (kcal) of the mixed meal, were replicated for the immediate and 48-hour post
exercise visits.
4.2.3.4 High Intensity Interval Exercise (HIIE) and 48 hr follow-up visit
On a separate week from the baseline measurements, participants arrived fasted overnight having
replicated the diet 24 hours prior to the baseline MMTT. Participants were also asked to refrain from
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alcohol, caffeine, and vigorous exercise 48 hours prior to the visit. Upon arrival participants completed
30 minutes of rest followed by the baseline REE measurement. Participants then completed a 5-minute
warm-up on the cycle ergometer (Velotron, Racermate, Inc., Seattle, WA) at 50 watts. Immediately after
the warm-up participants then completed alternating intervals of watts corresponding to 90% of the watts
achieved at peak oxygen consumption during the VO2max test for 60 seconds followed by 60 seconds at
30% of the max watts for a total of 20 minutes.
After completion of the HIIE intervention (1hrPE) participants returned to the resting laboratory
to rest for 60 minutes, after which fasted blood samples were drawn, the mixed meal was provided and
sampling proceeded as detailed previously. Forty-eight hours after the HIIE visit (48hrPE) participants
returned to the laboratory to complete the final MMTT of the study. Participants were asked to replicate
their baseline study diet and refrain from alcohol, caffeine and additional exercise between the HIIE visit
and 48-hour follow up.
4.2.3.4 Measurement of Metabolic Flexibility and Calculation of Substrate Oxidation
Metabolic flexibility (METFLEX) was defined primarily as the difference (D) in RER 60 minutes
post mixed meal ingestion compared the RER at 0 minutes prior to the mixed meal. Additionally, we will
define flexibility at the change in rise rate of carbohydrate oxidation and the decrease in rate of fat
oxidation (Figure 4.3). REE, carbohydrate (CHO) and fat oxidation rates were calculated utilizing the
following equations 32.

1.) REE= ((3.58 x VO2) + (1.448 x VCO2)-0.002)) x 1440
2.) CHO Ox= (4.55 x VCO2) – (3.21 x VO2)
3.) Fat Ox=(1.67 x VO2) – (1.67 x VCO2)
Additionally, we will classify the different phases of METFLEX as the early or “1st phase” which
was be measured by subtracting the rate of CHO and fat oxidation (mg/kg/min) at the 60-minute time
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point by the 0 minute time points. 2nd and 3rd phase will represent the latter phases of METFLEX that
correspond to (60-120 minute) and (120-0 minute) calculations respectively.
During the 1st phase of a healthy METFLEX response, insulin should mediate the rapid increase
in CHO oxidation and suppression of fat oxidation (Figure 4.3). The 2nd is likely to correspond to a
lower, but still elevated levels of CHO oxidation, whereas fat oxidation should start to approach near
fasted levels. The 3rd will represent either the residual CHO oxidation and fasted or higher levels of fat
oxidation.
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Figure 4.3. Conceptual model of metabolic flexibility based on the rise in carbohydrate oxidation rate and decrease in fat
oxidation rate. Outward pointing arrows indicate greater metabolic flexibility. Inward pointing arrows reflect decreased
metabolic flexibility.

4.2.3.5 Plasma and Serum Assays
Blood samples were collected in Sodium fluoride/Oxalate EDTA tube and immediately placed on
ice. An additional set of tubes without anticoagulant was used for the collection for serum. The tubes
were centrifuged at 2000 rpm for 10 minutes thereafter plasma and/or serum were transferred to a plastic
microtube and frozen at -80 degrees Celsius. The glucose oxidase technique was used during the MMTT
via a bedside glucose measurement system (GL5, Analox Instruments LTD. Lunenburg, MA). The
measurement of plasma insulin was completed with the use of an enzyme linked immunoabsorbance
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assay (ELISA) kit (Sigma Aldrich, St. Louis, MO). Serum non-esterified fatty acids (NEFA) were
quantified by an in vitro enzymatic colormetric assay (Wako chemical, Richmond, VA).
4.2.4 Statistical Analysis
All statistics were performed using JMP statistical software (SAS Institute Inc., Cary, NC). Data
analysis will generally follow CONSORT recommendations using General Linear Models and repeated
measures analysis of variance (RM-ANOVA), co-varied as needed depending on normality distributions
at baseline. An unpaired t-test will be used to compare between group baseline characteristics. In addition,
two way RM-ANOVA (exercise session x time point) were used to determine differences in responses in
both the primary and secondary outcome variables. Significant effects will be further evaluated using
student’s t-test post-hoc analyses when appropriate. Data will be reported as mean±SD and differences
declared at P<0.05.
4.3 Results
4.3.1 Participants
A list of participant characteristics is presented in table 4.1. Participants were (n=16, 6 males, 10
females) young (21.2±1.2 y) with normal body weight (22.6±2.6 m/kg2) and physically active (³30
minutes of moderate intensity exercise). All participants had normal fasting plasma glucose levels
(5.4±0.5 mmol/l).
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4.3.2 Baseline Measurements
4.3.2.1 Maximal Graded Exercise Test
Table 4.2 provides the data acquired from the maximal graded exercise test completed on the cycle
ergometer. There were significant differences between males and females for VO2max, maximum watts
achieved during the test (Max Watts), however, when watts were expressed as watts/kg there were no
significant differences between Max Watts. The prescribed exercise intensity for HIIE was 90% of the Max
Watts during the work interval and 30% of Max Watts during the recovery interval. There were significant
differences according to gender at 90% (men= 187.5 ± 30.7 W vs. women 135 ± 21 W; p=.006 ) and at 30%
(men= 62.5 ± 10.2 vs. women 45 ± 7.0 W; p=.0063). These differences were not significant in terms of
watts/kg for the 90% and 30% intervals (p=.674 and p=.1759 respectively).
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4.3.3.2 NIRS OXPHOS
Mitochondrial function (OXPHOS) was significantly (p=0.03) lower in FmHx participants
(46.5±25.6 %/s) compared to control participants (28.4±10.3 %/s) (figure 4.4). There were no significant
associations between OXPHOS and VO2max.

Time Constants (%/s)

150

Mitochondrial Function

*

100

50

0
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FmHX

Figure 4.4 Mitochondrial Function measured in control and FmHx participants during baseline
assessments. *p<0.05. Data are expressed as mean + SEM
4.3.3.3 Resting Energy Expenditure and Mixed Meal Composition
Individual baseline REE was used to determine the content of the mixed meal (table 4.3). There
were no significant differences in REE and therefore no differences in meal composition. The mean
baseline REE was not significantly different between males (1337±234.9 kcal/d) and females
(1118.2±198.6 kcal/d). CHO, Pro, and Fat intake were similar across all groups.
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Table 4.3 Mixed Meal
Total (n=16)
REE (kcal/d)
1241.2 ± 219.2
Meal (kcal)
412.2 ± 71.5
Kcal/kg
6.5 ±
0.8
CHO (g)
54.4 ±
9.4
Fat (g)
14.4 ±
2.5
Pro (g)
14.4 ±
2.5
CHO(g/kg)
0.9 ±
0.1
Fat(g/kg)
0.2 ±
0.0
Protein(g/kg)
0.2 ±
0.0
CHO, carbohydrate; Pro, protein.
Mean±SD

Males (n=8)
1337.7 ± 234.9
445.9 ± 78.3
6.3 ±
1.0
58.9 ± 10.3
15.6 ±
2.7
15.6 ±
2.7
0.8 ±
0.1
0.8 ±
0.1
0.2 ±
0.0

Females (n=8)
1183.2 ± 198.6
392.0 ± 62.5
6.7 ±
0.8
51.8 ±
8.3
13.7 ±
2.2
13.7 ±
2.2
0.9 ±
0.1
0.2 ±
0.0
0.2 ±
0.0

4.3.2 Metabolic Response to Mixed Meal and HIIE
Resting energy expenditure (Figure 4.5) was not different between visits. REE increased (23.3%)
between the 0 and 60 minute time points. Baseline REE (1241.1±219.1 kcal/d) increased to 1531.1±327.9
kcal/d (p<0.0001), but returned to a non-significant (p=0.72) rate at 120 minutes (1488.8±338.6 kcal/d).
During the 1hrPE REE increased (p<0.0001) in a similar manner from 1305.8±224.9 to 1647.7 kcal/d as
was the case with the 48hrPE visit as well (1330.9±265.3 to 1539.7±373.0 kcal/d; p<0.001). No
significant interaction between visit and time point were detected.
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Figure 4.5 REE across time points (0, 60, 120 min) and visits. *<0.001 (0 min vs. 60
minute). REE, resting energy expenditure. Data are presented as mean ± SD
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Analysis of the 1st phase ΔRER (ΔRER60-0min) (Figure 4.6) METFLEX response did not reveal
any statistical differences between baseline and 1hrPE (p=0.65) and 48hrPE (p=0.31). There was no
significant relationship between any visits and the 2nd or 3rd phase shift in RER. There were no significant
differences detected between groups for the 1st, 2nd, or 3rd phase shift in CHO oxidation during the mixed
meal tolerance (baseline vs. 1hrPE p=0.09; baseline vs. 48hrPE, p=0.65; 1hrPE vs. 48hrPE, p=0.88) or fat
oxidation (baseline vs. 1hrPE p=0.91; baseline vs. 48hrPE, p=0.28; 1hrPE vs. 48hrPE, p=0.40).
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Figure 4.6 Baseline METFLEX measured as the difference between RER at 60 subtracted
from RER at 0 min. RER, respiratory exchange ration (VCO2/VO2). Data are presented as
mean ± SD
Fasted CHO oxidation (1.17 ±0.77 mg/kg/min) was not significantly different between any visits
(1hrPE 0.97±0.69 and 48hrPE 0.87±0.56) CHO oxidation (mg/kg/min) was increased (p<.0001) within
the baseline trial when transitioning from fasted CHO oxidation to the measured peak at 60 minutes
(2.23±0.67) and remained elevated (p=0.04) in the 2nd phase and at 120 minutes (p<0.0001) post mixed
meal ingestion. Similar differences (p<0.0001) were detected within the 1hrPE and 48hrPE visits to the
60 minute time point (2.24±0.92 mg/kg/min and 2.11±0.80 mg/kg/min). CHO oxidation rate was not
different 1hrPE when comparing the 120 minute time point to the 0 minute (fasted) CHO
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oxidation,(1.23±0.58 mg/kg/min), indicating that CHO oxidation levels returned to fasted level more
quickly than baseline and for the 48hrPE trial (1.39±0.62 mg/kg/min; p<0.0001).
Fasted fat oxidation rate (figure 4.7) at baseline (0.95±0.32 mg/kg/min) was not significantly
different when compared to the fasted “0 min” measurement during the 1hrPE (1.1±0.32 mg/kg/min) visit
prior to the HIIE intervention. Fasted fat oxidation rate was elevated (p=0.049) at the 48hrPE visit
suggesting a residual increase in fat oxidation due to the HIIE intervention.
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Figure 4.7 Fasted oxidation rate prior to mixed meal and or exercise for all
visits. *p<0.05 baseline vs. 48hrPE. Data are presented as mean ± SD

There were no differences (figure 4.8) detected when measuring the transition from fasted to 60
min for the reduction in fat oxidation during this time period. Fat oxidation decreased from fasted rates to
0.83±.032 and 0.98±0.35 mg/kg/min for the baseline and 1hrPE visit respectively. However, fat oxidation
rate decreased significantly (p=0.012) within the trial for 48hrPE falling to a rate of 0.94±0.38
mg/kg/min. The fat oxidation rate during the 48hrPE at 120 minutes (1.31±0.39) remained elevated above
fasted level (1.31±0.39), but not significantly (p=0.08). The overall METFLEX response for all visit and
comparisons to between visits is presented in figure 4.9.
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Figure 4.8 Decrease in fat oxidation (1st Phase) in response to the mixed meal. BL,
baseline, 1hrPE, 1 hour post exercise, 48hrPE, 48 hours post exercise. *p<0.05
within visit. Data are presented as mean ± SD

B a s e lin e v s . 4 8 h r s P o s t E x e r ic s e

B a s e lin e M E T F L E X
3

1 .0

0 .4
1
0 .2

B a s e lin e F a t O x

100
2

50

1

4 8 h rP E C H O O x

BL Fat O x
48 hr Post
E x e r c is e F a t O x

0 .0
0

3

2

m

1

in

0

1

2

6

0

0

0

m

m

in

in

0

B a s e lin e C H O O x

C H O O x ( m g /k g /m in )

0 .6

BL CHO Ox
3

F a t O x ( m g /k g /m in )

2

F a t O x ( m g /k g /m in )

C H O O x ( m g /k g /m in )

150

0 .8

B a s e lin e v s . 1 h r P o s t E x e r ic s e
1 h rP E v s . 4 8 h rP E
1 .0

3

1 .0

2

0 .4
1
0 .2

1 h rP E C H O O x
1 h rP E F a t O x

0 .6

0 .4
1

1 h rP E F a t O x
4 8 h rP E F a t O x
1 h rP E C H O O x
4 8 h rP E C H O O x

0 .2

0 .0
0 m in

6 0 m in

1 2 0 m in

in

in

m
0
2
1

6

0

m

m
0

0 .8
2

0

0 .0

in

0

BL Fat O x

C H O O x ( m g /k g /m in )

0 .6

BL CHO Ox

F a t O x ( m g /k g /m in )

0 .8

F a t O x ( m g /k g /m in )

C H O O x ( m g /k g /m in )

3

Figure 4.9 METFLEX response for CHO and Fat oxidation alteration at baseline, basline vs.
1hrPE, baseline vs. 48hrPE, and 1hrPE vs. 48hrPE. Data are presented as mean ± SD
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4.3.3 Plasma and Serum Analysis
Fasting plasma glucose was increased (p=0.043) in the 1hrPE (5.9±1.3 mmol/l) visit when
compared to the baseline visit (5.3±0.5 mmol/l), but not the 48hrPE visit (5.5±0.7 mmol/l; p=0.45).
Fasting plasma insulin was not different between baseline (10.7±4.3 uUI/ml) and 1hrPE (9.3±3.3 uUI/ml;
p=0.68) and the 48hrPE (7.9±3.1 uUI/ml; p=0.25) visits or between 1hrPE and the 48hrPE (p=0.73) visits.
Fasted serum NEFA levels were significantly greater (p=0.006) 1hrPE (1.2±0.2) when compared to
baseline (0.76 ±0.2 mmol/l). Fasted NEFA levels returned to near baseline fasted levels at 48hrPE (0.74
±0.3. The time course of plasma glucose (4.10), plasma insulin (4.11), and serum NEFA (4.12) did reveal
significanty differences for the calculated total area under the curve (4.13A) and insulin (4.13B) across all
visits. There was no significant difference between time points.

P la s m a s G lu c o s e (m m o l/l)

P la s m a G lu c o s e
10

8

B a s e lin e
1 h r P o s t E x e rc is e

*

4 8 h r P o s t E x e rc is e
6

4

2
0

20

40

60

80

100 120 140 160 180 200

M in u te s

Figure 4.10 Plasma glucose response across time points and visits. *p<0.05 baseline
vs. 1hr post-exercise. Data are presented as mean ± SD
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Figure 4.11 Plasma insulin response across time points and visits. Data are presented as mean ±
SD
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Figure 4.12 Serum NEFA response across time points and visits. Data are
presented as mean ± SD
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Figure 4.13 A.) Total glucose area under the curve and B.) total insulin area
under the curve. Data are presented as mean ± SD

4.3.4 Blood Flow Measurements
Blood flow measurements (Figure 4.14) were conducted prior to ingestion of the mixed meal 0
min, 30 minutes, 60 minutes, and 120 minutes after. Blood flow measurement are expressed in terms of
fold change. Blood flow did not increase to a significant degree during the baseline visit between 0 and 30
minutes (p=0.72) and at the 60 minute time point (p=0.20), but did increase at the 120 minute time point
(p=0.04). During 1hrPE visit blood flow increased (p=0.02) at 30 minutes, 60 minutes (p<0.0005), and
remained nearly significant (p=0.07) at 120 minute post mixed meal. No differences were detected within
the 48hrPE trial. Between group analysis revealed an increased fold change during the 1hrPE visit at the
60 minutes (1.83±0.8, p=0.03) and 120 minute time point (2.0±1.0; p=0.04)) above the corresponding
fold change during the baseline visit (1.4±1.01) and 48hrPE visit (1.18±0.5; p=0.004).
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Figure 4.14 Blood flow response reported as fold change from 0 min measurement across visits
and time points. *p<0.05 within visit increase in blood flow. α p<0.05 between visits, β p<0.005.
Data are presented as mean ± SD
4.3.5 Comparison of Positive Family History Versus No Family History of T2D
A comparison of the fold change (figure 4.15) in CHO oxidation and fat oxidation during the
baseline visit revealed differences in the suppression of fat oxidation (0.99±0.08 fold change) at the 60
minute time point between the control group (0.76±0.08) and FmHx (p=0.926). These differences did not
extend past to the 120 minute time point for the fold change in fat oxidation. The increase in CHO
oxidation at the 60 minute mark did not reach statistical significance (p=0.052) in the FmHx group,
whereas the control group had significantly (p=0.02) increased CHO oxidation at the 60 minutes.

74

Control vs. FmHx Baseline
BL Control Fat Ox
CHO & Fat Fold Change

5

BL FmHx Fat Ox
BL Control CHO Ox

4

BL FmHx CHO Ox

3
2
1
0

0 min

60 min

120 min

Figure 4.15 Comparison of the fold change in CHO oxidation and fat
oxidation between control participants those with FmHx. Data are presented
as mean ± SD

Differences were detected (p=0.043) in the ability to suppress fat oxidation in during the 1hrPE
visit at the 60 minute time point (figure 4.16). The ability to increase CHO oxidation was improved
(p<0.0001) at 60 minutes during the 1hr PE visit, with an approximate 4 fold increase in CHO oxidation
compared to a 2.5 increase at baseline. The improvement in CHO oxidation during the 1hrPE visit did
not extended to the ability to suppression fat oxidation during any of the time points for the FmHx group
during the 1hrPE visit. However, this effect also manifested itself in the control, whereby, the increase in
CHO oxidation significantly increased (p<0.0001) without a significant decrease in fat oxidation (60
minute, p=0.043; 120 minutes, p=0.09).
During the 48hrPE visit (figure 4.17)FmHx participants nearly significantly increased CHO
oxidation at 60 minutes (p=0.053) and to similar fold change measured during the BL visit (BL 2.25 vs.
48hrPE 2.31). The ability to suppress fat oxidation 48 hours post exercise improved from a fold change
0.99±0.08 to 0.81±0.07. Comparatively, the control group achieved a suppression fold change of
0.78±.08, which did not differ significantly between groups.
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Figure 4.16 The comparison between baseline and 1hrPE METFLEX response
within the FmHx group.* p<0.05. Data are presented as mean ± SD
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4.4 Discussion
The purpose of this study was to determine the effect of HIIE on METFLEX immediately after
exercise (1hrPE) and to measure any extended effects 48 hours after exercise (48hrPE) on METFLEX.
To establish baseline METFLEX, we implemented a MMTT that was specifically prescribed for the
individual participants based on one-third of their measured REE. We assessed METFLEX by measuring
the difference (1st phase) in RER, CHO oxidation, and fat oxidation from the fasted 0-minute time point
to 60 minutes. METFLEX was reassessed at the 1hrPE and 48hrPE visits to determine if HIIE
intervention promoted greater 1st phase METFLEX response. These measurements were conducted to test
the hypothesis that acute HIIE would increase the 1st phase response immediately post exercise.
We sought to understand some of the potential mechanisms and links to metabolic flexibility,
measuring plasma glucose, plasma insulin, and NEFA in response to the mixed meal to determine to what
degree glucose tolerance and insulin sensitivity was affected by HIIE. Additionally, we were interested in
whether young men and women with a FmHx of T2D were metabolically inflexible as has been reported
in older adults 8,12,25 and if HIIE improved metabolic flexibility. The primary findings of this study were
that METFLEX was differentially improved 1hrPE and 48hrPE via increased CHO oxidation and
increased suppression of fat oxidation respectively. Additionally, we detected significantly reduced
mitochondrial function in participants with a FmHx of T2D. We also established improved METFLEX in
FmHx participants in response to HIIE via similar mechanism demonstrated by control participants as
previously mentioned.
Metabolic inflexibility is characterized by the inability to increase RER in response to insulin
stimulation via either oral glucose administration or hyperinsulemic clamp method 2. However, recent
work has improved our understanding of METFLEX as the inability to partition fuel once it enters the cell
33-35

. It has been suggested that provision of a single macronutrient (glucose) or stimuli does not challenge

cells to partition fuel and cannot, therefore, assess METFLEX 33,36. Therefore, we chose to provide a
mixed meal (~412 kcal, 55g CHO, 14g fat, and 14g Pro) to adequately challenge postprandial metabolism
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with a mixture of macronutrients. The MMTT is also considered the gold standard test to measure the
insulin release, which plays an important role in the postprandial response to METFLEX 37,38.
The metabolic response (figure 4.5) to a mixed meal in our study was evident in the increase in
REE at the 60-minute time point. The 23% increase in REE is likely due to a couple of factors. The
thermic effect of digestion increases metabolic rate typically proportionally to the energy consumed 39,40.
There are also mechanisms involved in the hypothalamus-pituitary-adrendal axis that work to increase
gastric motility that influence REE 40. The response to the meal did not reveal any differences between
study visits (baseline 23% increase, 1hrPE 26% increase, and 48hrPE 15% increase) suggesting
differences in RER, CHO ox, and fat ox were likely not due to a simple increase REE.
We did not detect a difference in the 1st phase shift in RER between baseline METFLEX and
1hrPE and or 48hrPE visits. The 2nd phase shift in RER (60min-120min) measures the increase in RER
from the peak. This phase represents the balance of residual increases in CHO oxidation and or fat
oxidation suppression. Interestingly, the 2nd phase RER response was significantly elevated at the 1hrPE
visit. Parsimonious, analysis suggests that the increase in CHO oxidation is the factor that is driving the
increase in RER during the phase at the 1hrPE visit. There was an increase, albeit not statistically
significant (p=0.09), in the 2nd phase response at the 1hrPE visit compared to baseline.
Exercise at higher intensity (>75% VO2max), in particular intermittent or interval-based exercise,
alters the relationship of hepatic glucose output (HGO) and glucose uptake in the muscle 41,42. Typically,
during steady state exercise HGO meets the demands of the working skeletal muscle, however, during
very intense exercise HGO typically exceeds the rate of demand 42. As exercise ceases, glucagon,
epinerphrine, and norepiphrine remain elevated, which leads to the increase in HGO and resulting
hyperglycemia42-44. Elevated glucose levels in healthy people increase insulin levels in order return to
euglycemia. Insulin, in this scenario, will promote glucose uptake, oxidation, and storage to varying
degrees 45.
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In the current study, we identified a significant increase in plasma glucose 1 hour post HIIE when
compared to baseline and 48hrPE visits. The increase in plasma glucose concentration is a likely
mechanism to promote the oxidation of glucose in addition to the carbohydrate ingested as a part of the
mixed meal. The fact that fasted insulin levels were not increased significantly prior to the mixed meal,
during the 1hrPE visit, may be due to the fact that blood was not taken until immediately before the mixed
meal was given (60 minutes after HIEE). This point is supported by a study conducted by Marliss et al
(2002), whereby insulin levels had returned to fasted levels 60 minutes after a 40-minute bout of
moderate intensity exercise and return to baseline within 20 minutes after a 15-minute bout of exercise at
87% VO2max42.
Glucose AUC was not different between baseline, 1hrPE, and 48hrPE visits. Insulin AUC was
also not affected by the HIIE at 1hrPE or 48hrPE visits. In current, young healthy cohort, reports of a lack
of improvement in glucose tolerance not entirely surprising. Several studies have indicated with mixed
meal feeding a lack of effect in terms of glucose tolerance and insulin sensitivity in response to various
intensities of exercise 46-50. Potentially, the benefit of utilizing the mixed meal to measure metabolic
flexibility may not be optimal for testing glucose tolerance and therefore, may indicate the two are not as
closely related as previously thought 51.
An interesting finding of our study was the increase in resting-fasting fat oxidation rate
(mg/kg/min) at the 48hrPE visit. Important to note, REE was not elevated at 48hrPE visit. The lasting
effect of post-exercise oxygen consumption (EPOC) is due to many factors (fitness level, intensity and
duration of exercise) 52-55, however, in most cases the effect an exercise bout on has REE has diminished
within 24 hours. The specific increase in fat oxidation as a result of HIIE is of interest and coincides with
existing literature that demonstrates increased skeletal muscle mitochondrial enzyme levels after 2-6
weeks of HIIE training 23,56. While there is a paucity of data regarding the effects of a single bout of
HIIE, a study conducted by Little et al (2011) demonstrated that a single bout of HIIE (4x30s maximum
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effort or ~500% peak power) increased mitochondrial biogenesis via the increase in the nuclear
abundance of PGC1-a 57.
The HIIE protocol utilized in the aforementioned study by Little et al (2011) was a wingate-based
model. The demands (specialized equipment, hard to tolerate, unsafe for some individuals) of the
wingate-based model reduced its practicality and applicability. The HIIE protocol utilized in the current
study (60s at 90% Wmax followed by 60s at 30%Wmax x 10) was also developed in the lab of Martin
Gibala and Jonathan Little and is referred to as the “practical model”. Interestingly, similar mitochondrial
adaptations have been shown using this protocol in 2 weeks of training 22. The results of the current study
may potentially provide physiological evidence that some mitochondrial adaptations occur within 48
hours of a single bout practical model HIIE.
The increase in fasting fat oxidation rate at 48hrPE also corresponded to a significant suppression
in fat oxidation rate after ingesting the mixed meal during the 1st phase METFLEX response. An
important function of insulin is the suppression of lipolysis and fat oxidation in the postprandial period
36,51,58

. Fat oxidation rate decreased significantly at the 48hrPE visit (~26% reduction), whereas, similar

levels of suppression were not measured at baseline (10% reduction) or during 1hrPE visit (~12%
reduction). This phenomenon was not robust enough to significantly increase RER during 1st phase
METFLEX, however, it does emphasis an important component of METFLEX in altering the balance of
increasing CHO oxidation and decreasing fat oxidation in the postprandial period.
The levels of NEFA in the blood stream reflects the balance of lipolysis systemically. 1hrPE
fasted serum NEFA levels were significantly elevated when compared to baseline and 48hrPE. As was the
case with HGO, the hormones epinephrine, growth hormone, and hormone sensitive lipase are secreted in
an intensity-dependent manner 59-61. Therefore, it is expected that NEFA levels would be elevated after
one hour HIIE. Increasing NEFA levels has been experimentally shown to induce metabolic inflexibility
in lean sedentary individuals and lean endurance trained individuals by reducing CHO oxidation 62.
However, the lean endurance- trained participants increased non-oxidative glucose disposal (i.e. glycogen
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storage) in response to the lipid infusion. These results were linked to the superior mitochondrial
performance measured in the endurance-trained compared to the sedentary participants.
In the current study, the increased NEFA levels did not reveal any impairment in the ability to
increase CHO oxidation. Although we did not purposely maintain elevated NEFA levels, as did the
previous study, we simply demonstrated an intact mechanism for insulin to reduce lipolysis and lower fat
oxidation in the postprandial period. An intriguing mechanism that has emerged from these data involves
increased fasting fat oxidation as an integral component to improve the function of insulin to increase
CHO oxidation and suppress fat oxidation. This is not a trivial finding, as elevated NEFA have been
shown to inhibit insulin action and glucose transport in the skeletal muscle. 58 63
Impaired postprandial blood flow is considered a potential factor in the actions of insulin and
control of glucose levels 64,65. Additionally, metabolic syndrome is often associated with a reduced
sensitivity to beta-adernergic stimulation thereby reducing blood flow to the skeletal muscle and adipose
tissue 66. METFLEX is potentially affected by blood flow alterations in the postprandial period
considering that a large amount of glucose will be oxidized in the skeletal muscle. Utilizing NIRS (figure
4.14) we measured the change in blood flow during the MMTT at baseline, 1hrPE, and 48hrPE.
Significant increases were measured 120 minutes after ingestion of the mixed meal during the baseline
visit. Blood flow increased 1.3, 1.5, and 1.7-fold 30 minutes, 60 minutes, and 120 minutes post mixed
meal during the 1hrPE visit. The increases in blood flow were greater than the comparative changes at 60
minutes during baseline. The changes in blood flow were also evident at 120 minutes 1hrPE when
compared to 48hrPE. These finding demonstrate the HIIE is effective at increasing blood flow
postprandially.
A secondary aim of this study was to investigate whether young participants with a FmHx of T2D
were metabolically inflexible and had reduced mitochondrial function, as has been reported in older
adults 7,8, and if HIIE improved METFLEX. Baseline mitochondrial function (figure 4.4) was
significantly lower in FmHx participants when compared to controls. Reduced mitochondrial function is
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frequently demonstrated as a potential component of metabolic inflexibility and insulin resistance 25,67,68.
In our study control participants and FmHx particiapants were matched BMI, activity level, and fitness
(VO2max) all of which may have be closely related to mitochondrial function. These results indicate that
mitochondrial dysfunction may play a role in the early manifestation of metabolic inflexibility without the
presence of insulin resistance or increase adiposity.
There were no detected interactions between FmHx and the 1st phase RER, CHO oxidation, and
fat oxidation METFLEX response, however, there were differences within each visit that were not
detected in our control group. At baseline FmHx did not significantly reduce fat oxidation (fold change)
(Figure 4.15) in the 1st phase (60-0 min) and the capacity to increase CHO did not reach statistical
significance (p=0.052). 1hrPE (Figure 4.16) FmHx significantly increased CHO oxidation during the 1st
phase, however, fat oxidation suppression was unaltered. This phenomenon appears to be a uniform
response across groups. The robust increase in CHO oxidation during the 1hrPE visit suggests the effect
exercise persists at least 2 hours post-HIIE. Additionally, the reduced suppression in fat oxidation in the
1st phase during the 1hrPE visit may be due to the increased flux of fatty acids during that time point, and
under such circumstances would dictate great fat oxidation.
During the 48hrPE (Figure 4.17) visit there was a significant improvement in 1st phase fat
oxidation suppression which was not present during the baseline visit or 1hrPE visit. Importantly, this
degree of fat oxidation suppression was similar the control group. There was a difference in the resting
fat oxidation between controls (1.23±0.3 g/min) and FmHx group (1.8±g/min) at the 48hrPE visit. The
relationship may point to a relationship between the actions of insulin and rate of fat oxidation.
This study was limited in terms of the ability to determine the rate of HGO as a factor in glucose
tolerance and or the METFLEX response to exercise. Aside from its role in increasing CHO oxidation,
glycogen storage, and fat suppression insulin also works to reduce HGO. Understanding the role of the
liver in METFLEX is a potentially critical component that we were not able to elucidate. Another
limitation of this study was the inability to assess the level of glycogen depletion during HIIE and to
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determine if the METFLEX response was associated with the degree of depletion. The rate of glycogen
storage is a primary determinant for METFLEX 36,51,62 and insulin sensitivity 69,70. The determination of
factors involving the time frame of glycogen resynthesis after exercise and in the day after hold
considerable potential. The amount of calories and carbohydrate in the mixed meal may have been
another potential limitation. It is possible that a greater total amount may have produced a response that
could be evaluate under the influence of exercise.
In conclusion, the immediate effects (1 hour) of HIIE on METFLEX are primarily directed on the
increase in carbohydrate oxidation and blood flow in response to a mixed meal. The extended effects (48
hours) appear to work via fat oxidation or mitochondrial mechanisms by increasing resting fat oxidation
rate and improving the suppression of fat oxidation in response to a mixed meal. The lack of difference in
RER under these conditions demonstrates the need to assess the alteration in fuel oxidation, whereas RER
does reflect the balance of CHO and fat oxidation it does not identify the influencing factor. Finally,
HIIE improved METLFEX in participants with a FmHx of T2D, that demonstrated metabolic inflexibility
and reduced mitochondrial function, by improving the suppression of fat oxidation in the postprandial
period.
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CHAPTER 5. CONCLUSION

The purpose of this dissertation was study the time-course of diet and exercise and its effects on
METFLEX. Three studies were conducted to investigate molecular and clinical aspects of diet and
exercise and how these stimuli may alter the metabolic response to fuel. These include work using both
animal models and human participants. Additionally, we sought to understand the METFLEX response in
individuals with FmHx of T2D and to determine the effects of exercise in the group. The first study was
conducted on obesity-prone, Osborne-Mendel (OM) and obesity-resistant S5B/Pl (S5B) rats. This
experiment investigated inherent differences in energy expenditure (EE), metabolic rate, MF and skeletal
muscle markers of metabolism, lipid storage and lipid oxidation between OM and S5B, as well as HFDinduced strain differences in these parameters. The consumption of a HFD in S5B rats increased
metabolic rate and EE and decreased metabolic rate and EE in OM rats. These strain differences were not
due to the differences in activity or food intake. These results suggest that HFD-induced differences in
metabolic rate and EE may be mediated by HFD-induced differences in pAMPK and PPARγ expression
and lipid accumulation in the gastrocnemius muscle of OM and S5B rats.
The second study was designed to investigate the effect of acute aerobic exercise at an intensity
that maximizes the rate of fat oxidation (FATMAX) on glucose tolerance, insulin action, and METFLEX
compared to acute aerobic exercise at the onset of blood lactate accumulation (OBLA) resulting in greater
carbohydrate (CHO) oxidation. OBLA exercise appears to have deleterious effects on oral glucose
tolerance and metabolic flexibility acutely, however, FATMAX exercise does not confer improved MF.
These results suggest that predominate substrate utilization does not promote improved glucose tolerance
and metabolic flexibility in young overweight men.
The third and final study of this dissertation was designed to investigate the immediate and
extended of a single bout of high intensity interval exercise (HIIE) on METFLEX and mitochondrial
function. In study 3, participants were recruited with a family history (FmHx) of T2D (n=8) and without a
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family history of T2D (n=8). Participants completed baseline (no previous exercise) mixed tolerance tests
(MMTT) to assess MF. On a separate week participants completed a single bout of HIIE follow by an
immediate (1 hour later) MMTT and follow-up MMTT (48 hours later) MMTT. The immediate effects (1
hour) of HIIE on METFLEX are primarily directed on the increase in carbohydrate oxidation and blood
flow in response to a mixed meal. The extended effects (48 hours) work via the reduction fat oxidation
by increasing resting fat oxidation rate and improving the suppression of fat oxidation in response to a
mixed meal. Particiapants with a FmHx of T2D demonstrated reduced mitochondrial function and some
impairments in metabolic flexibility. HIIE improved METFLEX in a similar time course and mechanism
as mentioned previously.
In summary, the potential benefits of exercise may be contained within a certain time frame after
the completion of exercise. The degree to which exercise perturbs metabolism often dictates the length of
the response and therein the benefits of exercise on health. The susceptibility to develop metabolic
inflexibility appears to be linked to mitochondrial dysfunction. The early manifestation of this
phenomenon in our cohort demonstrates the important role that mitochondrial metabolism plays in the
pathogenesis of metabolic inflexibility. The extend and duration to which exercise improves
mitochondrial function will be of considerable importance in the future study of metabolic health.
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Introduction

Inflammation is a fundamental component of a living organism’s response to noxious or
infectious stimuli. The immune system is comprised of specialized organs (thymus, bone marrow, lymph
nodes, etc.) and cells (T cells, B cells, macrophages) and responds to eliminate an invading parasite, virus,
or bacteria from the host. In some cases, the host’s initial innate barriers are overwhelmed and infection
can occur. In order to defend against these pathogens the host’s immune system works to increase
inflammation in order to isolate and kill the pathogen by recruiting specific immune cells. If inflammation
persists, the physiological function of the affected tissue can be destroyed 1 . Chronic inflammation is
linked to many costly chronic conditions such as obesity, type 2 diabetes (T2D), and cardiovascular
disease 2-4. In fact, some suggest that chronic inflammation plays a major role in the development of
obesity and insulin resistance 5,6.
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Obesity is a chronic disease characterized by impaired energy balance, which favors the
accumulation and expansion of adipose tissue during periods sustained energy excess. The global
prevalence of obesity has doubled from 1980 to 2008. According to the world health organization (WHO)
205 million men and 297 million women over the age of 20 are obese (BMI >30 kg/m2) 7. Obesity is not
only strongly correlated with T2D, this disease is considered to be a primary driver in the development
T2D. T2D is a chronic disease that occurs due to lack of insulin production by the pancreas or the
inability to utilize the insulin produced in the periphery. The global prevalence in 2000 was estimated to
be 2.8% for all age groups 8. The 2030 models predict that 4.4% of global population will have T2D.
These reports suggest that the T2D epidemic will continue even if obesity levels remain consistent 8-10.

Decreasing amounts of physical activity and exercise have coincided with the increasing
rates of obesity and T2D 11. Currently, 50% of US adults do not meet the recommended
guidelines for weekly physical activity and 25% report no regular physical activity
(cdc.gov/nccdphop/dnpa/physical). The relationship of physical inactivity and increased
morbidity and mortality rates is indisputable and physical inactivity is a major risk factor for the
development of a cluster of metabolic disorders (obesity, insulin resistance, dyslipidemia, and
hypertension) called metabolic syndrome 12-15. Moreover, structured exercise programs can
significantly slow the development and progression of these diseases 16-18. In this review, I will
explore the mechanism of chronic inflammation initiated by metabolic dysfunction and how
skeletal muscle can mediate the anti-inflammatory effects of exercise.

Obesity and Type 2 Diabetes
The expansion of adipose tissue is the defining characteristic of obesity. For many years,
adipose tissue was thought to be an inert tissue that simply served as storage site for triglycerides
19

. The discovery of leptin, a fat derived hormone, demonstrates that adipose tissue plays a role
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in systemic metabolism by producing hormones that have downstream effects on the liver and
skeletal muscle. Serum leptin levels positively correlate with increases in body fat 20 and in vitro
research demonstrated that leptin plays a direct role in skeletal muscle fatty acid metabolism 9.
The obesity related reductions in leptin production, are thought to contribute to the development
of skeletal muscle insulin resistance 10.
Skeletal muscle insulin resistance is argued to be the primary defect in T2D 21. In
humans, under euglycemic hyperinsulinemic conditions approximately 80% of glucose uptake
occurs in the skeletal muscle 22. In the skeletal muscle of healthy individuals, glucose that enters
the cell is rapidly converted to glycogen or oxidized into carbon dioxide and water. The natural
progression from insulin resistance to frank T2D is characterized by inability to convert glucose
to glycogen. Like obesity, there are many contributing factors to the development of insulin
resistance. Obesity itself significantly increases the risk of becoming insulin resistant. However,
there is a cohort of individuals that are not classified as obese or overweight that demonstrate
insulin resistance. These lean individuals demonstrate impaired insulin mediated glucose
disposal in skeletal muscle and are likely to develop T2D if the condition persists23.
Histological analysis of obese adipose tissue demonstrates an increase in the presence of
inflammatory cytokine producing macrophages 2,24. In the skeletal muscle of type 2 diabetics,
there is increased concentration of inflammatory cytokines, particularly tumor necrosis factor
alpha (TNF-α). Elevated systemic markers of inflammation, such as C-reactive protein (CRP),
accompany the local inflammation present in adipose and skeletal muscle during metabolic
dysfunction 1,25-27. This evidence demonstrates that the metabolic and immune systems are
closely linked in disease progression.
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Exercise and Chronic Inflammation
Regular exercise reduces levels of chronic inflammatory markers (1) and also promotes
both pro and anti-inflammatory responses within the skeletal muscle (8). The type and intensity
of exercise appears to modulate the balance between the two responses. Exercise has been
shown to be an effective treatment for obesity and T2D 18. In addition exercise also has antiinflammatory qualities that promote metabolic health 28-30
The mechanism responsible for anti-inflammatory effects of exercise remains
controversial. On a gross level, exercise induces hormonal fluctuations that have effects on
immune function (23, 9). Exercise reduces chronic inflammation, in part, by the production of
muscular derived IL-6, which then stimulates the release of anti-inflammatory cytokines (IL-1rα
and IL-10) and a beneficial reduction CRP 31. Additionally, exercise is efficacious at reducing
chronic inflammation, even without the loss in body fat 32. However, the mechanisms associated
with this positive effect are unclear. In this portion of the review, I will provide a more in depth
examination of chronic inflammation.

Acute vs. Chronic inflammation:
Inflammation is the response mounted by the immune system characterized by the
recruitment of leukocytes to areas of the body that have been damaged or infected by foreign
pathogens 33. Initially, recognition of infection is modulated by tissue resident macrophages and
mast cells. These immune cells secrete inflammatory cytokines, chemokines, and lipid molecules
that dictate the inflammatory response. Inflammatory cytokines act in countless ways
throughout the body. For example, during an acute infection, the inflammatory cytokines TNF-α
and interleukin-1 (IL-1) work to increase the vascular permeability of the affected tissue and to
increase the activation of vascular adhesion molecules, such as vascular cell adhesion molecule-1
99

(VCAM-1). Circulating neutrophils and monocytes gain access to the inflamed tissue via
interaction with their cell surface receptors for VCAM-1. Once inside the inflamed tissue these
innate immune cells attempt to eliminate the foreign pathogen by their own effector function and
in conjunction with the activation of the adaptive immune system 33 .
If the source of the inflammation (exogenous) is eliminated by an effective immune
response then levels of inflammation will subside. A classical inflammatory response is
necessary for host defense. Physical injury of a tissue is also a potent activator of the
inflammatory response and is necessary to initiate tissue repair. Prolonged periods of tissue
dysfunction or stress also represent an inflammatory trigger. This inflammatory response is the
host’s response to restore the organ to balance 34. However, in chronic conditions such as obesity
and T2D, the prolonged inflammation can eventually destroy normal physiological function of
metabolically active tissues 1.
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Pro- and Anti-inflammatory cytokines
Cytokines are soluble glycoproteins that aid in communication between both immune and
non-immune cells and act to mediate inflammation 35. The benefits of regular exercise are
believed to be modulated via the reduced production of inflammatory cytokines and or lowered
expression of toll-like receptors (TLR) on monocytes and macrophages 36. The pro- or antiinflammatory effects of a cytokine depend on the environment in which it is activated, the cell
type from which secreted, and the specific cell-signaling cascade utilized 33,37,38.
Tumor Necrosis Factor-Alpha (TNF-α)
Tumor necrosis factor-alpha TNF-α is a 212 amino acid cytokine produced as a
transmembrane (mTNFα) and soluble (sTNF-α) factor mainly by monocytes and macrophages.
TNF- α is considered a pro-inflammatory cytokine because it is released in response to
lipopolysaccharide, which is the product of gram-negative bacteria in order to induce the acute
phase response. TNF-α acts throughout the body in many different ways. During an
inflammatory response the increased concentration of TNF-α acts to recruit additional monocytes
and neutrophils to the affected area. TNF-α is associated with a number of acute and chronic
conditions. Septic shock is an acute life-threatening condition whereby mass amounts of TNF-α
are released into the blood stream causing systemic vasodilation resulting in death. Chronically
elevated levels of TNF-α is also associated with muscle wasting conditions 39.
Hotamasligil and colleges 6 were the first to report the metabolic link between obesityinduced insulin resistance and TNF-α. This initial observation was followed by a series of
experiments that demonstrated that adipose tissue of obese diabetic mice had increased
expression of TNF- α 40,41. The specific function of TNF-α was then studied by generating a
TNF-α knockout mouse model (TNF-α-/-) that was fed a high fat diet (HFD) to induce obesity
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and glucose intolerance 42,43. These high fat fed TNF-α-/- mice did not demonstrate the same
degree of glucose intolerance when compared to obese wild type mice (with the intact TNF-α
gene). The TNF-α-/- animals were not protected from developing obesity and still demonstrated
some glucose intolerance, albeit greater than wild type mice, suggesting that TNF-α is not solely
responsible for the development of obesity-related insulin resistance.
In humans, serum concentrations of TNF-α and sTNF-α receptors levels have been
shown to be elevated in obesity 44,45. These effects have also been observed within the adipose
tissue itself. For example, TNF-α mRNA content was measured in the adipose tissue of obese
premenopausal women before and after weight loss 25. When compared to lean controls, obese
women had significantly increased TNF-α mRNA and protein from adipose and secretion from
adipose. Adipose tissue TNF-α mRNA was also significantly correlated with plasma insulin
(r=0.82, P<0.001), glucose (r=0.031, P=0.06), and triglycerides (r=0.40, P=0.02). After diet
induced weight loss both adipose tissue TNF-α mRNA and plasma insulin concentrations were
reduced. However, the weight loss period failed to induce a significant reduction in the
circulating levels of TNF-α 25. Consequently, some have suggested that TNF-α may act in a
paracrine-autocrine manner, as opposed to an endocrine manner, on nearby by tissues.
In vitro and in vivo data suggest that TNF-α can induce insulin resistance by reducing the
expression of key molecules involved in the insulin-signaling cascade 46,47. Specifically, obese
mice with intact TNF-α signaling have decreased muscle glucose transporter type-4 (GLUT4),
insulin receptor substrate-1 (IRS-1), and insulin receptor phosphorylation. Insulin receptor
phosphorylation is restored to significant degree when TNF-α function is ablated 42. However,
Stephens et al (1997) studied the effects of prolonged TNF-α exposure (96 hrs) on 3T3-L1
adipocytes and demonstrated no impairment in GLUT4 translocation to the plasma membrane.
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Rather, the transcriptional activity of GLUT4 and IRS-1 were inhibited which reduced the total
available protein 47 . Given these findings, it is apparent that TNF-α can induce insulin
resistance by inhibiting the transcription factors responsible for the synthesis of insulin signaling
intermediaries.
Although glucose transport into adipose is an important physiological phenomenon, it
pales in comparison to the role that skeletal muscle plays in glucose disposal. In fact, there is a
50% reduction in skeletal muscle glucose uptake during the last hour of insulin clamp studies in
diabetic subjects 48. Saghizadeh et al (1990) demonstrated that expression of TNF-α, in skeletal
muscle, was increased by four fold in insulin resistant and diabetic subjects compared with
insulin sensitive subjects 45. Using a hyperinsulinemic euglycemic clamp technique these
researchers were able to show that, in insulin sensitive subjects, there was a significant inverse
linear relationship between glucose disposal rate and muscle TNF-α 45.
The key substrates involved in the skeletal muscle insulin-signaling pathway appear to be
altered by elevated TNF-α. In healthy humans, TNF-α infusion induces insulin resistance in
skeletal muscle by increasing the phosphorylation of p70 S6 kinase, extracellular signal-related
kines-1/2, and c-Jun NH2-terminal kinase in addition to increased serine and reduced tyrosine
phosphorylation of IRS-1 46. TNF-α also promotes insulin resistance by altering skeletal muscle
fatty acid oxidation by suppression of activated AMP-kinease (AMPK) activity through TNFR1
signaling 49. Suppression of fatty acid oxidation in skeletal muscle causes the accumulation of
fatty acid intermediaries (DAG, acyl co-A, ceramides) 50,51. These bioactive molecules can
activate the serine/threonine kinase cascade and lead to disruption of proper insulin signaling5154

.
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Interleukin-6 (IL-6)
IL-6 is a pleiotropic cytokine, primarily synthesized by monocytes/macrophages,
endothelial cells, and fibroblasts that serves both pro-and anti-inflammatory functions throughout
the body and plays a significant role during infection or illness 55. IL-6 is pivotal in the synthesis
of acute phase proteins that are released in an effort to restore homeostasis to the infected/injured
tissue/organ 56. IL-6 also promotes inflammation through the proliferation and activation of T
cells and the differentiation of B cells 33 .
IL-6 signals through the IL-6 receptor complex consisting of IL-6R (80 kDa) and 130
kDa glycoprotein gp130 which acts as a signal transducer 57. Once binding occurs between IL-6
and gp130 a Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT)
signaling cascade is initiated 38,58. Additionally, IL-6 possesses a soluble receptor that binds to
IL-6 in circulation to form an IL-6/sIL-6R complex extending the half-life of IL-6 59. This
complex can activate the JAK/STAT pathway through membrane bound gp130. The improved
stability and intact functional capability allows IL-6 to interact with many different cell types 59.
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Elevated IL-6 concentrations are commonly associated with increased risk of T2D,
obesity, atherosclerosis, hyperinsulinemia, and low HDL-Cholesterol 60-62. When dietary
measures are taken to reduce body fat there is a reduction in circulating IL-6 63. Until recently,
the mechanisms related to IL-6 production and the progression of obesity induced insulin
resistance has been speculative and dependent on the tissue of study. In vitro studies
demonstrate that adipocytes 64,65 and hepatocytes 66become insulin resistance when cultured with
IL-6. Additionally, Klover et al (2003) demonstrated that chronic infusion of IL-6 similar to
levels observed during obesity induced hepatic insulin resistance in mice67.
Priceman et al (2013) recently determined that IL-6 signaling through STAT3 in the T
helper 1 (TH1) and regulatory T cells (T regs) cells that reside within visceral adipose depots was
essential in diet-induced obesity (DIO) induced insulin resistance. The results of this study
demonstrated that STAT3 was elevated in obese visceral adipose tissue (VAT) and in VAT T
cells. Ablation of STAT3 in T cells reduced VAT inflammation, DIO and improved insulin
sensitive and glucose tolerance. Interestingly, loss of STAT3 signaling shifted the VAT resident
macrophage population from M1 classically activated to M2 alternatively activated 68.
Circulating concentrations of IL-6 are directly related to increased concentrations of
CRP, which suggest its involvement in the acute phase response. During an infection IL-6, is
released primarily from monocytes and macrophages to target hepatocytes to release CRP 56,69.
CRP is one of the strongest predictors of cardiovascular events and is thought to play a direct
role in the development of atherosclerotic lesions 70,71. The relationship of IL-6 and CRP and the
overwhelming evidence that increased adiposity contributes to elevated serum IL-6 demonstrate
that metabolic dysregulation can perturb the immune system to cause chronic systemic
inflammation.
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Anti-inflammatory Cytokines:
During an inflammatory response, pro-inflammatory cytokines increase the circulating
number of lymphocytes, monocytes, and granulocytes. Once the inflammatory cascade is set into
motion the compensatory anti-inflammatory response is initiated via the production of antiinflammatory cytokines 37. IL-10 is an anti-inflammatory cytokine produced by cells of both the
innate and adaptive immune system 72. The primary producers of IL-10 are T helper 2 cells (TH2)
cells and M2 macrophages. IL-10 acts to regulate and, in many cases, diminish the inflammatory
response initiated by myeloid and lymphoid cells. Genetic deficiencies in IL-10 are commonly
associated inflammatory disease such as systemic lupus erythromatosis, inflammatory bowel
disease and bechet’s disease73-75. Additionally, IL-10 knockout mice reportedly demonstrate
chronic enterocolitis 76. These data clearly demonstrate that IL-10 is necessary to promote
tolerance meditated through an appropriate TH2 cell response 73-75,77.
Low circulating levels of IL-10 are associated with obesity and metabolic syndrome in
humans 78. The mechanism of IL-10 release from T cells and M2 macrophages works to
downregulate the chronic inflammatory response that is potentiated by the adaptive immune
system 77. IL-10 reduces the secretion of IL-12 and TNF-α from macrophages and dendritic cells
in order to reduce inflammation. Reductions in IL-12 cause the downregulation of MHC IIpeptide presentation on antigen presenting cells (APCs) and the reduction of the co-stimulatory
molecules CD80 and CD86 79.
In murine models muscle specific overexpression of IL-10 prevents lipid induced insulin
resistance [80]. Increased IL-10 expression in skeletal muscle increases circulating systemic
levels, but was not associated with decreased weight gain compared to wild type mice fed a
HFD[81]. The overexpression of IL-10 significantly increases glucose infusion rate, whole-body
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glucose turnover, and skeletal muscle glucose uptake in both chow and HFD fed animals
compared to wild type. Immunohistochemical analysis demonstrates that greater expression of
IL-10 decreases the infiltration of CD68, F4/80, and total macrophage infiltration in skeletal
muscle. Muscle IL-10 transgenic mice prevented macrophage infiltration by reducing the
expression of macrophage recruiters CCR2 and MCP-1. It is apparent that IL-10 regulates the
inflammatory response by modulating the intracellular signaling molecules of macrophages and
resident tissues.
The nuclear factor kappa-B (NF-κB) pathway is an essential pathway that mediates
inflammatory responses 80. IL-10 binding with its receptor (IL-10r) inhibits the NF-κB pathway
in macrophages and that prevents release of interferon-Υ, (INF-γ), IL-2, interleukin-3 (IL-3),
TNF-α and granulocyte macrophage colony stimulating factor (GM-CSF) 81,82. The transcription
regulation of IL-10 is controlled by the gene regulators GATA3, E4BP4, and to a lesser degree
MAF 81. In a similar fashion to IL-6, IL-10 binds its receptor and initiating the JAK/STAT
signaling pathway by phosphorylating the tyroinse kinases JAK2 and Tyk2, which then
phosphorylate and activates STAT1, STAT2, STAT3, and STAT5 82.
Interleukin-1 receptor antagonist (IL-1ra) is anti-inflammatory cytokine that binds IL-1
and IL-1β receptors 83. As a result the activity of IL-1 and IL-1β are significantly reduced. In
terms of systemic chronic inflammation, IL-1ra appears to play a role in blocking IL-1β which
plays a primary role in the inflammatory macrophage-adipocyte cross talk 84. IL-1ra is often
referred to as a soluble factor and not an active cytokine per se. IL-1ra was originally called IL-1
inhibitor because it blocks the ability of IL-1 to stimulate synovial PGE2 inflammatory response
85

. In vitro, IL-1ra binds to T cells and fibroblast at the same infinity as IL-1. Remarkably, this

binding does not induce any of the agonist activity of IL-186.
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Many of the negative metabolic consequences that arise from systemic chronic
inflammation are associated with elevated levels of TNF-α. TNF-α binding with its receptors
TNF receptor I and II (TNFRI) works to increase the inflammatory response 41. Under certain
circumstances the ectodomain of the 55-kda transmembrane TNFRI can be proteolytically
cleaved or remain intact packed into exosomes to be released as a functioning soluble receptor
(sTNFRI) 87. Cells of the immune system will shed their TNF receptor to neutralize the function
of TNF-α without provoking an inflammatory response 88.

Sources of inflammation:
Adipose Tissue:
Adipose tissue is a complex tissue composed mainly of adipocytes. However, other cells,
such as pre-adipocytes, fibroblast, and endothelial cells comprise the stromal vascular fraction
(SVF) are usually present. Immune system cells also occupy the SVF of adipose primarily in the
form of macrophages called adipose tissue macrophages (ATMs). Adipose acts a major
endocrine organ that regulates energy expenditure and food intake and secretes regulatory
hormones like leptin, estrogen, and resistin. Adipose tissue increases the expression and
secretion of inflammatory cytokines, primarily IL-6, during the development of obesity. These
cytokines are primarily produced by ATMs, which comprise approximately 40% of the adipose
tissue of obese individuals 2,89.
Adipose tissue, as a whole, can be subdivided into subcutaneous adipose tissue (SAT)
and visceral adipose tissue (VAT). VAT, also referred to as abdominal fat, resides between
abdominal organs. VAT significantly increases during obesity and is positively associated with
insulin resistance and T2D 62,90. As is the case with all tissue, adipose contains a resident
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population of immune system cells that provide surveillance against foreign microbes. Resident
tissue macrophages in SAT and VAT are essential for the removal of apoptotic cells without
increasing inflammation 91. However, if the stress is extreme or prolonged, as is the case in obese
adipocytes, ATM may recruit addition immune system cells that promote inflammation. Kanada
et al (2006) demonstrated that obese mice with malfunctioning adipocytes secrete monocyte
chemoattractant protein-1 (MCP-1) to recruit additional macrophages into the adipose tissue 92.
The physiological mechanism for this signal appears to be linked to tissue stress induced by
hypoxic environment 93.
Several animal and human studies demonstrate that as adipose tissue mass expands, there
is decreased partial pressure of oxygen (PO2) to white adipocytes 94-97. In fact, in lean
individuals, blood flow to the adipose is increased postprandially while there is no change in
obese individuals 98,99. As adipocytes expand from energy imbalance, the diffusion of oxygen
into the adipose becomes impaired, thereby lowering the O2 saturation of the tissue. This
represents a fundamental physiological stress on adipose tissue. The hypoxic environment of the
adipocyte can trigger the regulator of cellular O2 homeostasis hypoxia inducible factor-1 (HIF-1).
HIF-1 regulates the cells response to hypoxia by increasing chemoattractants (MCP-1 and
CXCL12) to the stressed tissue 93. Immunohistochemistry of the adipocytes of high fat fed
C57/BL6 mice confirms that hypoxic areas had the greatest accumulation of macrophage and
cytotoxic T cells 100.
Excessive energy intake for prolonged periods of time without increases in energy
expenditure tips the scale in favor of fat storage into adipocytes. As adipocytes reach their
maximal storage capacity the cellular environment becomes stressed, which leads to the
increased secretion of chemokines (MCP-1 and CCL5) and the cell surface expression of
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adhesion molecules (α4β7) to recruit and navigate monocytes to the area. Adipocytes that have
been stressed in this manner can undergo apoptosis and their cellular contents (glycerol) spill
into the interstitial space attracting more macrophages. This cycle of tissue expansion, hypoxia,
and metabolic stress work to overwhelm the resident tissue macrophage and activate the innate
immune system in an attempt to restore homeostasis 34,93,96.
Inflammatory Macrophages:
Dendritic cells, granulocytes (neutrophils, basophils, eosinophils, mast cells), and
macrophages comprise the three phagocytic cell classes of the innate immune system. Dendritic
cells function primarily to ingest antigens and migrate to peripheral lymphoid tissues where they
can present peptide to the cells of the adaptive immune system. Granulocytes are highly
phagocytic cells that confer immediate short-live response to pathogens. Macrophages serve a
primary role in immune surveillance and orchestrating the inflammatory response 33,101.
Macrophages are long-lived cells that mature from circulating monocytes and populate
tissues. Macrophages that encounter a pathogen or microbe are stimulated to release proinflammatory cytokines. During a classical, pathogen initiated immune response these cytokines
promote increased blood flow, cell-adhesion molecules expression, and vascular permeability.
The purpose of the inflammatory cascade is to increase the number of effector cells to the
initiating site and to promote the destruction of the pathogen. The cytokine, macrophage colonystimulating factor (M-CSF) promotes the maturation of monocytes into macrophages that will
continue to promote the inflammatory response or become tissue resident macrophages2.
Tissue resident macrophages serve a central role in immune surveillance and the
clearance of cellular debris from apoptotic cells. An important aspect of immune surveillance is
the “silent” removal of cellular debris that does not stimulate the release of inflammatory
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cytokines or noxious substances. ATMs in lean mice (F4/80+) are considered to be “alternatively
activated” (M2). This differs from classically activated macrophages (M1), which are induced by
T helper 1 cell (TH1) cytokines INF-γ and TNF-α to initiate a classical inflammatory response.
M2 macrophages, on the other hand, can be induced by TH2 cytokines IL-4 to secrete antiinflammatory cytokines.
In mice, the development of obesity stimulates the recruitment and conversion of the
ATM population to switch from M2 “anti-inflammatory” to M1 “pro-inflammatory”
macrophages 102. These M1 macrophages expressed the surface protein CD11c and have been
shown to represent 90% of the ATM population in obese adipose tissue in mice 103. Humans do
not demonstrate the same polarization in macrophage differentiation. Human ATMs during
obesity presents a mixed profile exhibiting variable qualities of both anti-and pro-inflammatory
macrophages 24,104. An analysis of ATMs from lean and obese individuals, utilizing flow
cytometry, revealed that ATMs from obese humans produced pro-inflammatory cytokines (IL-6,
TNF-α, IL-23, MCP-1, IL-8, and cyclooxygenase-2) and anti-inflammatory cytokines (IL-10,
TGF-β, and cyclooxygenase-1)24.
Human ATMs are considered to be positive for CD45, CD14, HLA-DR, CD31, and
CD206 when analyzing cell surface markers 104. Within the population of ATMs there are
markers for differentiation. For example, CD206, the manose receptor, is highly expressed on the
surface of differentiated macrophages and, along with other scavenger receptors, promote a prophagocytic phenotype. Additionally, the ATMs increase expression of matrix metalloproteinase9 (MMP-9), which is key protease involved in the breakdown of the extracellular matrix
promoting angiogenesis 24,105. These studies demonstrate that human ATMs exhibit distinct
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macrophage subpopulations that cannot be solely categorized on cell surface makers, but rather
cellular behavior 24,104,105.
Macrophages in vivo demonstrate high degrees of plasticity in their differing states of
activation. This makes segregation of human ATMs into distinct classes and subsets unrealistic.
In murine models of DIO adipose tissue there is a marked increase in the M1 macrophage that is
temporally associated with insulin resistance. There is substantial evidence in favor of obese
adipocytes undergoing apoptosis and recruiting monocytes from the circulation to be classically
activated macrophages. MCP1-/- mice exhibit significantly less adipose tissue macrophage
infiltration and subsequently have improved insulin sensitivity and hepatic steatosis when
compared to wild type mice on HFD 106.
Obesity can lead to the activation of the cytostolic multiprotein complex NLRP (NODLLR-and pyrin domain containing), adaptor molecule ASC, and caspase-1 effector molecule
termed the inflammasome 91. The inflammasome can be activated in macrophages, and other
cells of myeloid lineage, by pattern associated molecular patterns (PAMPs), reactive oxygen
species (ROS), and endogenous ligands such bioactive lipid molecules (i.e. ceramides) 91,107.
The result of activation of the inflammasome leads to the cleavage of pro-caspase-1 into caspase1, which then leads to processing and release IL-1β. IL-β is considered a master inflammatory
cytokine and a potential candidate for macrophage induced insulin resistance. Elevated levels of
IL-1β and IL-6 are positively associated with increased risk of T2D. Gao et al (2014) found that
IL-1β is a critical cytokine facilitating macrophage-adipocyte cross-talk, which detrimentally
effects insulin signaling (i.e. significant reductions in GLUT4, IRS-1, IRS-2) 108. This study also
demonstrates that inhibition of IL-1β results in increased protein expression insulin signaling
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molecules GLUT4, IRS-1, PI3K p85α, and completely reverses the lipolysis initiated by the
macrophage cytokine treated media.
To summarize, ATMs represent a diverse subset of macrophages that may or may not
represent a distinct lineage of circulating monocytes attracted to areas undergoing metabolic
stress. The difference between human and murine ATM behavior may be representative of the
models as a whole. The murine immune system has more distinct roles and relationships to
certain cytokines, whereas the human immune system is clearly more pliable. Human ATMs are
more hybrid macrophages that possess qualities of both pro-and anti-inflammatory (M1 and M2)
macrophages. Murine models of DIO elicits a clear transition in macrophage activation from
“M2” alternatively activated macrophages that promote a toleragenic environment capable to
quietly clearing cellular debris to a “M1” classically activated macrophage that secretes proinflammatory cytokines. Considering these observations it is clear that macrophage infiltration
into obese adipocytes promotes chronic inflammatory state 2,91,104.
Human ATMs do not provide the same “smoking-gun” in their relationship to obesity
related insulin resistance and chronic inflammation. There is currently no consensus on all the
cell surface markers to distinguish the activation state of human ATMs. However, in obese
adipocytes, ATMs produce cytokines that promote insulin resistance, proteases that remodel the
extracellular matrix, and induce adipocyte differentiation. The ATMs in obese humans appear to
promote inflammation in order to rebuild the adipocyte structure in order to store more lipids.
Insulin resistance, due to the pro-inflammatory cytokines IL-6, TNF-α, and IL-1β, is potentially a
adaptive response to limit the uptake of glucose into adipocytes that are overwhelmed 103,108 109.
There is now little doubt that adipose tissue is the source of increased pro-inflammatory
cytokines in circulation that defines obesity and chronic inflammation. Measurements of arterio-
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venous blood flow across subcutaneous adipose tissue beds demonstrate that approximately 30%
of circulating IL-6 is produced by the adipose 89. While TNF-α is typically not detected in the
serum of obese individuals, its protein expression is significantly increased in the adipose of the
obese 89,110,111. This pro-inflammatory environment works not only to increase the recruitment of
monocytes/macrophages, but also increases their phagocytic activity. Increased uptake of
necrotic adipocytes and lipids by macrophages increases the presentation of those molecules by
both major histocompatibility complex I and II (MHC I and MCH II) to cells of the adaptive
immune system 89,110.
Skeletal Muscle Inflammation:
Adipose tissue has been the primary focus of research in metabolically derived chronic
inflammation. However, in recent years skeletal muscle has been receiving more interest as an
affected tissue during chronic inflammation and as a potential contributor to inflammation.
Indeed, there are many conditions under which skeletal muscle becomes inflamed. Duchene’s
Muscle dystrophy and myasthenia graivs are characterized by an intense inflammatory response
and repair process that promote fibrosis 112,113.
Activating inflammatory pathways within the skeletal muscle interferes with insulin
signaling pathways and therefore insulin stimulated glucose uptake. Several in vitro studies
demonstrate impaired glucose uptake when skeletal muscle cells are exposed to inflammatory
cytokines 114-116. However, these data do not fully support the role of inflammatory cytokines in
the development of obesity. For example, attempts to reverse insulin resistance by administering
neutralizing antibodies against inflammatory cytokines has been largely unsuccessful 34.
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Skeletal Muscle Macrophages
The infiltration of inflammatory macrophages into expanding adipose tissue during
obesity has been repeatedly demonstrated in both animal and human models and is positively
associated with chronic inflammation 1,91. The primary disease states associated with obesity are
insulin resistance and frank T2D 21. T2D is largely considered a disease of the skeletal muscle
due to the fact that the majority dietary glucose is disposed within skeletal muscle 48. Therefore,
it is logical to speculate that inflammatory macrophages may be increased in the skeletal muscle
of obese individuals and type 2 diabetics.
To address this, Fink et al (2013) obtained biopsies from lean normal glucose tolerant
(NGT) individuals and overweight and obese individuals with and without T2D 117. The results
of this study demonstrate that CD11c+ macrophages are positively correlated with T2D in
addition to HbA1c and fasting plasma glucose. The genes for alternatively activated antiinflammatory macrophages (CLEC10A, MRC1, CD163) are inversely associated with the same
parameters for T2D. The investigators of this study stated that when corrected for age these
relationships did not reach significance 117. These results demonstrate that muscle-residing
macrophages might play a role in the preserving or impairing insulin sensitivity.
Limited methodological analysis of inflammatory macrophage infiltration in skeletal
muscle has created a discrepancy in the theory that inflammatory macrophages infiltrate skeletal
muscle and contribute to insulin resistance. Several of these studies cite low relative number of
macrophages in muscle when compared to adipose tissue 118-120. However, these studies failed to
determine the inflammatory activity and polarization of macrophages in muscle in obesity.
Studies by Varma et al (2009) and Fink et al (2014) utilize a multitude of techniques (flow
cytometry, qPRC, and immunohistochemistry) to analyze the population and behavior of
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macrophages in the muscle of mice fed a HFD and obese humans alike 26,121. These data
demonstrate a differential immune cell response in muscle in response to obesity. In response to
a HFD human and mouse muscle have proportionally fewer T cells than adipose tissue, but
showed increased neutrophils. Importantly, MCP-1 (CCL2) increases in response to a HFD, in
mice and humans, and is necessary to increase macrophage numbers within muscle 121.
The cytokines and chemokines released by skeletal muscle macrophages and by the
muscle fibers themselves appear to act synergistically to promote inflammation in response to
HFD feeding in mice 5,26. In obese and type 2 diabetic humans, there is a similar response that
up-regulates the expression of MCP-1 to recruit monocytes from circulation and populate the
stressed muscle. This state of chronic inflammation initiates the cross-talk between skeletal
muscle tissue and its resident immune cells that promotes insulin resistance and fibrosis 26,117,122.

Chronic Inflammation and the Adaptive Immune System:
Innate immune system responses are mounted against extracellular and intracellular
pathogens. As mentioned previously, monocytes are immature leukocytes that reside within the
vascular endothelium and in circulation. Monocytes, in the presence of inflammation due to
infection or tissue injury, mature to become macrophages. These phagocytic macrophages
consume and lyse pathogens so that their peptide components can be “presented” on their surface
by major histocompatibility complex class I and class II (MHC I and MHC II) 33.
Vital to the survival of an organism is the ability to differentiate “self” from “not self”.
Nearly all cells of the body display “self” peptides in conjunction of MHC I and II molecules.
When an antigen-presenting cell has consumed and killed a pathogen by phagocytosis it will then
present the pathogen to T cells and B cells that have specific receptors for that peptide-MHC
complex. Early in the development of human and mice there is an education of the immune
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system, whereby the T cells and B cells undergo both positive and negative selection. T cells are
a subset of lymphocyte that mature in the thymus. During that early maturation T cells that are
auto-reactive or bind to strongly to “self” are deleted from population 33,123.
The presentation of digested adipocytes and lipids through MHC I and MHC II molecules
on the surface of macrophages functionally builds a bridge between the innate and adaptive
immune system. A major aspect the chronic inflammatory response is the persistent presentation
of antigen via macrophages. The T cell’s role in host protection is primarily in cellular defense,
whereas, B cells contribute to humoral defense. Due to this fact T cells will be the primary focus
of this portion of the review 124.
T Cells
T cells are CD3+, but also demonstrate other markers of differentiation such as CD8 and
CD4. CD8+ T cells are called cytotoxic T cells that recognize antigen in the form of peptideMHC I and are major protectors against intracellular pathogens. CD4+ T cells recognize antigen
in the context of peptide-MHC II. Upon recognition of the peptide-MHC complex T cells
terminally differentiate into cytotoxic T lymphocytes (CTLs) and T helper cells (TH1, TH2, TH17,
TH9) respectively. It is at this point that T cells are capable of executing their effector function 33
.
A tolerogenic environment, in which the immune system does not attack its host, is
fundamental to a healthy immune system. The foreign microbes of the gastrointestinal tract do
not cause an inflammatory response in healthy individuals. The explanation for this phenomenon
stems from regulatory T cells (T regs) that promote tolerance by secreting anti-inflammatory
cytokines IL-10 and TGF-β. T regs are positive for forkhead/winged-helix transcription factor
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(FoxP3), CD25, and CD4. FoxP3+ T regs occur commonly at sites of recently cleared infection
to terminate the inflammatory response allowing the tissue to be restored to homeostasis.
In C57BL/6 mice at 30 weeks of age approximately 50% of CD4+ T cells are CD25+
FoxP3+ T reg cells. In vitro suppression assays demonstrate that T reg cell from the VAT of
mice poorly suppress CD+ T cells with no deficiency in proliferation when compared to T regs
taken from subcutaneous adipose125. These VAT T regs had increased gene transcripts for
chemokines that recruit leukocytes and promote extravasation (CCR1, CCR2, CCR9, CCL6,
integrin αV, CXCL10, and CXCL2). These cells also produce large of amounts of IL-10 and its
receptor IL-10R. Studying the function of the fat resident T reg cells has proven to be
technically difficult. Therefore the precise role that these tolerogenic cells play in the
development of obesity associated inflammation remains to be elucidated 126.
The chronic inflammation that is associated with long-term obesity is sustained by the
adaptive immune system. In support of this, CD3 gene transcripts have been shown to be
elevated in humans VAT during obesity most of which are CD8+ and CD4+ 127. The majority of
T cells in VAT in obese individuals are effector memory CD8+ CD44+ CD62L-. These CD8 T
cells, in contrast to naïve CD8+CD44-CD62L+T cells, are capable of promoting a long-term
inflammatory response by recruiting and activating macrophages into the adipose tissue 128.
Effector CD8+ T cells or CTLs release cytotoxic granules once binding with their cognate
peptide-MHC complex. Cells that are exposed to cytotoxic granules will start to undergo
program cell death called apoptosis 109.
In adipose tissue, the CD4 T cell population is mainly comprised of TH1 and TH2 T cells
128

. TH1 cells are primary producers of the pro-inflammatory cytokines INF-γ. INF-γ is a

macrophage-activating factor that also stimulates the natural killers (NK) cell population.
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However, it is the action of the macrophage that initially stimulates TH1 cells 127. The
presentation of peptide-MHC II and release of IL-1 and IL-12 from macrophages that have
encountered an extracellular pathogen stimulates TH1 cell activation. TH1 cells are notably
primary producers of INF-γ, which is a potent activator of macrophages in vivo and in vitro
129,130

.
The recruitment of additional macrophages into the adipose tissue by INF-γ produced by

TH1 cells is a potential mechanism for the role of the adaptive immune system in chronic
inflammation. In support of this, Rocha (2008) and Winer (2009) independently demonstrated
that obese mice have greater total number of CD4+ and CD8+ T cells than when compared to
lean controls131,132. In vitro stimulation of T cells from obese mice produce significantly greater
amounts of INF-γ and display a skewed TCR-Vα repertoire suggesting that expanding adipose
tissue drives T cell biased towards adipose. These mice also show increased MHC II (I-Ab)
presentation 131,132. These data support the theory that obesity elicits a specific T cells receptor
repertoire response to adipose tissue that potentially displays self-epitopes.
The TH2 cytokines, IL-4 and IL-13, serve a role to promote the activation of antiinflammatory M2 macrophages 133. As stated previously, M2 macrophages promote a
tolerogenic environment via the production of anti-inflammatory cytokines and through the
production of arginase-1101. Arginine, the primary substrate for arginase-1, is necessary to
sustain a CD4 T cell response. The arginase-1 produced by M2 macrophages depletes arginine
and is sufficient to reduce the CD4 T cell response 134. The potential protective role for a TH2 cell
response in the protection of obesity induced inflammation and insulin resistance, however, is
still up in question, as T reg cells also promote tolerance and reduce inflammation 135.
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It is important to note that many other cells of the immune system have been implicated
in the pathogenesis of chronic inflammation. Eosinophils are granulocytes that are major
producers of IL-4 and IL-13, which have been shown to promote M2 macrophages activation in
VAT. Genetic deletion of eosinophils increased adiposity and insulin resistance in mice fed a
HFD when compared to eosinophil intact mice 136. Conversely, mast cell deficient mice were
protected from DIO and insulin resistance when compared to wild type mice 137. However, the
validity of mast cell deficient mice has been the subject of some scrutiny and care should be
taken into consideration when interpreting the metabolic implications of mast cell deficient
models 138.

Anti-Inflammatory treatments to ameliorate metabolic disease:
Evidence of increased acute phase proteins and inflammatory cytokines has linked
metabolic dysfunction with the immune system response 27. The inflammation associated with
these conditions is a low-grade subclinical level. It is not yet clear if inflammation is responsible
for organ dysfunction or chronic over-nutrition and metabolic stress is the impetus for the
inflammation of the organ. Much research has been dedicated to reversing the perceived harmful
effects of inflammation on metabolically stressed organs by treating patients with antiinflammatory compounds (salsalate) and antibodies medications (infliximab, entanercept,
tocilizumab)

139-142

. The results of these trials have failed to demonstrate efficacy in improving

glucose tolerance and insulin resistance 34.
The shortcomings of anti-inflammatory therapies aimed to improve glucose homeostatsis
emphasize the critical role that inflammation plays in the body’s response to metabolic stress. It
is possible that the early response to nutritional overload and expanding adipose tissue is the
increase in inflammation that acutely works to maintain energy homeostasis. However, if the
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stimuli for inflammation (over-nutrition, glucotoxicity, and physical inactivity) are not altered,
than the inflammatory cycle promotes a negative adaptation that fundamentally alters the
function of the organ 1.
Exercise is a potent anti-inflammatory therapy that reduces chronic inflammatory
biomarkers associated with T2D and obesity 16,28-30,143. However, exercise, in particular
resistance training, promotes a transient inflammatory response that increases the circulating
levels of inflammatory cytokines (ex. IL-6). This transient spike is followed by an increase in
anti-inflammatory cytokines144. The degree of improvement in the biomarkers for chronic
inflammation (ex. CRP) are positively associated with the intensity of the exercise 17. Muscle
produced myokines present a novel a mechanistic explanation for the anti-inflammatory effects
of exercise 145. The remainder of this review will focus on the various myokines and their
relationship to exercise.

Skeletal Muscle as a Mediator of Inflammation:
IL-6 Myokine
Regular exercise has been shown to reduce levels of chronic inflammation 146. The antiinflammatory mechanisms of exercise have focused on the production of pro-and antiinflammatory cytokines. Observations by Ostrowski et al (1998) first suggested that the elevation
in IL-6 from prolonged running was a result of exercising muscle 147. Since that time extensive
research has been conducted to confirm the muscle origins of increased IL-6 during exercise.
This phenomenon of skeletal muscle production and release of myokines into circulation
suggests that skeletal muscle itself may mediate the anti-inflammatory effects of exercise 146. IL-

121

6 is the most extensively studied myokine to date. Therefore IL-6 will provide the conceptual
framework to understand how skeletal muscle can act as an anti-inflammatory endocrine organ.
Northoff and Berg (1991) were amongst the first to identify the elevation in cytokines in
response to strenuous exercise in humans148. However, observations by Ostrowski and
colleagues provided the bulk of the evidence for increased cytokines in circulation in response to
prolonged running 147,149. These early studies demonstrate that in marathon runners IL-6 levels
peak immediately post-race and remain elevated for up to 4 hours. Work from this laboratory
also demonstrates significantly increased circulating IL-6 levels at 30 minutes of treadmill
running at 75% VO2max.
Ostrowksi et al (1998) postulated that skeletal muscle is the primary producer of IL-6
measured in circulation during exercise 149. To test this hypothesis, muscle biopsies and blood
were collected before, immediately after, and two-hours post marathon. Comparative
polymerase chain reactions were conducted to detect the mRNA levels of IL-6 and other
cytokines in skeletal muscle and blood mononuclear cells (BMNC). IL-6 mRNA was only
detected immediately and 2hrs post-marathon in skeletal muscle sample and not PBMC 149.
The primary source of IL-6 in circulation, during conditions like sepsis, is leukoycytes
(monocytes). Ostrowski et al (1998) provided indirect evidence to the contrary as it applies to
increased IL-6 during strenuous exercise 149. Starkie et al (2000) utilized flow cytometry to rule
out circulating monocytes as the producer of IL-6 150. Using a similar cohort and study design
these researchers measured IL-6 and TNF-α levels and found no increase in the number of cells
producing IL-6 or TNF-α or the fluorescent intensity of each cell. This study directly excluded
PBCM as the producers of IL-6 during exercise150.
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IL-6 production and release from skeletal muscle
In order to determine that skeletal muscle was in fact the source of IL-6 during exercise
Steensberg et al (2000) measured IL-6 concentration during single leg extension exercise 151. In
this landmark study, subjects completed 5 hrs of single leg extension exercise only against
concentric resistance while blood flow was collected from catheters placed in the femoral artery
of one leg and the femoral vein of both legs (arterio-venous difference method). IL-6
concentrations only increased in the blood from the exercising limb with no release from resting
muscle and the non-exercised leg. This is the first study to provide strong evidence for IL-6 as a
contraction mediated myokine.
The criticism of a-v difference method is that it does not indicate if other cells residing
within skeletal muscle (macrophages, fibroblast, endothelial cells, etc). To address this Jonsdottir
et al (2000) showed that in rodent models, electrical stimulation of skeletal muscle increased IL6 mRNA as measured by quantitative-PCR 152. This effect could not be recapitulated by infusion
of epinephrine at doses that reached peak exercise conditions 153,154. Together, these data indicate
that contraction is an essential component of IL-6 release from the skeletal muscle and not the
influence of circulating hormone on muscle.
Utilizing immunohistochemistry and in situ hybridization IL-6 protein and mRNA
respectively was detected in biopsies taken from male subjects before and after 120-minutes of
continuous cycling at significantly higher levels post exercise compared to pre-exercise sections
155

. More recently, Lauritzen et al (2013) identified IL-6 containing vesicles in a mouse

quadriceps muscle that was transfected with enhanced green fluorescent protein (EGFP), which
was reduced upon muscle contractions 156.
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Initial observations from Brauusgaard (1997) indicate the IL-6 released from the skeletal
muscle was due to damage that occurs during eccentric muscle contractions 149,157. This
hypothesis was based from studies that compared the concentration of IL-6 in men after
completing two separate exercise trials. In the first bout, 9 male subjects completed 30 minutes
of concentric cycling at 65% of VO2 max. After two weeks the same group of men completed a
bout of eccentric cycling that matched the workload achieved by the concentric cycling bout. As
expected, the results of this study demonstrate that eccentric exercise significantly increases
markers for muscle damage (ex. creatine kinase) when compared to concentric exercise157.
These levels persist even up to 7 days after the exercise bout. IL-6 is significantly increased only
after the eccentric training bout. The authors of this study concluded that IL-6 was likely
increased due to exercise as a result of muscle damage and was linked the inflammatory
response. However, there was no significant difference in the concentration of blood monocytes
or the composition of leukocytes between exercise bouts. Taking this response into account, the
authors suggest that the source of IL-6 was still completely unknown as it pertains to exercise 157.
Further work to demonstrate that muscle damage was a primary component for elevated
IL-6 circulation during exercise does not support this hypothesis 158-160. Coisier et al (1999)
provides compelling evidence that muscle damage is not a necessary component for IL-6
production during exercise 161. In this trial IL-6 and myoglobin were measured immediately after
2 bouts of eccentric exercise, thereafter subjects completed 5 training sessions during a threeweek period. Subjects were then tested again to measure IL-6 and myoglobin. The second
testing bout at the end of the study was at the same workload as the pretest. Therefore the
markers for muscle damage were reduced in the post-test. However, IL-6 levels from the pre-and
post-test were similar.
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IL-6 and glycogen
The highest measurements of circulating IL-6 during exercise have been recorded during
prolonged running with elevations as high as 128-fold 144. These data shifted the focus from
muscle damaging exercise to glycogen depletion as the mechanism for skeletal muscle IL-6
production. Nehlsen-Cannrella et al (1997) made the observation that carbohydrate intake (6%)
attenuated the IL-6 response to 2.5 hrs of running (~75% VO2max) when compared to placebo
162

. Previously mentioned work by Starkie et al (2000) demonstrated that carbohydrate intake

influenced IL-6 release and that circulating monocytes were not the source of secretion 150.
Bishop et al (2001) demonstrated that exercising in the glycogen-depleted state exacerbates the
cytokine response 163. Due to the fact that carbohydrate intake during prolonged exercise
preserves muscle glycogen 164 it is logical to speculate that IL-6 release from skeletal muscle is
in some way modulated by those levels.
To test this hypothesis, Steensberg et al (2001) conducted a study on 7 recreationally
active men to determine if pre-exercise glycogen levels influence the skeletal muscle mRNA and
circulating IL-6 levels 165. Subject performed 2 hrs of single legged extensions for 1 hr followed
by 1 hr of two-arm ergometery. The investigators stated that workload for single leg extension
was sufficient to deplete muscle glycogen from the exercised leg and that upper body exercise
prevented resynthesis in the depleted muscle from endogenous glucose production. Prior to
exercise muscle glycogen was depleted 40% compared to control leg. As measured by the a-v
difference across the exercising limbs the circulating levels of IL-6 produced by the depleted leg
were significantly greater at throughout the exercise bout and up to three hours post-exercise.
Skeletal muscle IL-6 mRNA showed a similar significant relationship165.
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In a similar study Keller et al (2001) depleted muscle glycogen levels by having 6 male
subjects undergo two identical 180-minute bouts of dynamic extension exercise 166. Subjects
were glycogen depleted the night prior and given a high-carbohydrate or low-carbohydrate meal.
When participants were given the low-carbohydrate meal muscle glycogen levels were depleted
by 40% compared to the high-carbohydrate condition plasma IL-6 levels were significantly
elevated during exercise at 120-and 180-minute time points. Measurement of isolated muscle
nuclei IL-6 mRNA transcript also revealed significantly higher IL-6 expression in the lowglycogen condition during exercise. It is important to note that in both trials by Steensberg and
Keller that pre-exercise IL-6 levels were not different between low-and normal glycogen levels.
It was not until exercise commenced that the levels of IL-6 increased at the greater level in the
glycogen-depleted condition. This indicates a clear role for muscle contraction as a primary
inducer of IL-6 transcription and protein release during exercise165,166.
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During intense or prolonged exercise hormonal factors are primary regulators of skeletal
muscle glucose metabolism. Skeletal muscle expresses a large amount of β2-adergnic receptors
to which epinephrine 167,168, norepinephrine, and cortisol 169 may bind and contribute to increased
endogenous glucose production (EGP) during exercise and increase during intense or prolonged
exercise. Interestingly, as glycogen levels decrease during exercise sympathoadrenal activity
increases, as do circulating levels of IL-6. Therefore, epinephrine induced increases in IL-6 is a
factor that may confound the relationship between IL-6 and glycogen levels.
Ex vivo studies utilizing rat skeletal muscle have demonstrated that physiological doses of
epinephrine (10-100 nmol) do not increase mRNA or protein release of IL-6 from incubated rat
skeletal muscle 153. Only supraphysiological doses were shown to increase IL-6 mRNA into
supernatant. Infusions of physiological doses (8 ngkgmin-1) of epinephrine that mimic the
levels experienced during exercise were shown to produce a 6-fold increase in plasma IL-6,
whereas during exercise treadmill running for 2.5 hrs at 70% VO2max plasma IL-6 increased 29fold 154. The authors of these studies conclude that epinephrine plays only a minor role in the
production and release of IL-6 from skeletal muscle during exercise.
IL-6 and Calcium (Ca2+)
During exercise the signal for muscle contraction is initiated by an abrupt increase in the
release of Ca2+ from the sarcoplasmic reticulum (SR) 170. Ca2+ is a second messenger that acts as
a transcription factor that controls gene expression and cellular function and for that purpose
intracellular Ca2+ levels are tightly regulated within all mammalian cells 171. The Ca2+ ionophore,
ionomycin, transports Ca2+ across the plasma membrane to raise intracellular Ca2+ concentrations
172

. Multiple studies have demonstrated that ionomycin is capable of increasing IL-6 gene

expression in rat and human skeletal muscle 153,173,174.
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The signaling pathways mediated by Ca2+ involve protein phosphatase calcineurin, which
is activated during exercise 175 and electrical stimulation 176. Calcineurin is of interest because it
dephosphorylates and therefore activates nuclear factor of activated T cells (NFAT). NFAT is
involved in the integration of mechanical stress response from exercise and remodeling that
occurs as a consequence, which may explain why NFAT levels are 10-times higher in myocytes
when compared to other cell types 177,178. Activation of NFAT induces its translocation to the
nucleus where it increases transcription of cytokines most notably IL-6 and IL-2 33. Muscle cells
cultured with ionomycin and a selective inhibitor of calcineurin, cyclosporine A (CSA),
significantly reduce IL-6 mRNA production when compared to ionomycin alone 174. The mRNA
expression of TNF-α is not reduced, but rather increased in these conditions indicating the IL-6
in skeletal muscle is linked to calcium/calcineurin signaling.
Interestingly, NFAT can be retained in the cytosol by phosphorylation via
serine/threonine kinases, such as glycogen synthase kinase 3 (GSK3) 33. This supports the theory
that skeletal muscle contraction, which increases the influx of calcium within the muscle cell,
promotes mRNA transcription immediately upon exercise and that appreciable levels of IL-6 are
detected in plasma as muscle glycogen levels are depleted. In addition to NFAT, p38 MAPK is a
stress-activated protein kinase that is activated during muscle contractions 179,180. In order to link
IL-6 to upstream transcription factors that correspond to glycogen level, Chan et al isolated
nuclear fractions of muscle samples pre-and post-exercise in subject with normal and lowglycogen levels 181. This important study demonstrates that low glycogen levels in exercising
muscle cause increased phosphorylation of nuclear p38 MAPK and that IL-6 is likely induced by
this phenomenon. L6 myotubes cultured with ionomycin phosphorylated nuclear p38 was
increased significantly along with IL-6 mRNA. P38 MAPK is significantly reduced in muscle
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cells treated with ionomycin and the p38 MAPK inhibitor (SB203580) and IL-6 mRNA is nearly
undetectable 181.
Anti-inflammatory effects of IL-6
The beneficial anti-inflammatory response to exercise is multi-factorial. Reduction in
inflammatory visceral adipose tissue, inhibition of macrophage infiltration in adipose tissue, reduced
expression of toll-like receptors, and increased catecholamine levels all in some way account for the antiinflammatory effects of exercise. However, skeletal muscle release of IL-6 plays an important biological
role in the induction of the anti-inflammatory cytokine cascade.
During an acute infection TNF-α, IL-1β, and IL 6 are initially detected in that order followed by
IL-1ra, sTNFR1 and IL-10. Exercise, of a sufficient intensity, can induce 100-fold elevations in IL-6
without increasing TNF-α levels significantly. Muscle derived IL-6 induces the production of IL-10, IL1ra, and sTNFR1. After marathon running IL-10 peaks immediately post exercise (27-fold), but unlike
IL-6 declines rapidly post exercise 144. IL-1ra and sTNFR1 are increased 1.5 to 2.5 told, but peak
approximately 1.5 hrs post exercise 145.
IL-6 functions as an anti-inflammatory myokine that not only stimulates the release of antiinflammatory cytokines, but also stimulates the release of cortisol. To demonstrate the acute
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anti-inflammatory effects of exercise Starkie et al (2003) injected LPS (0.6 ng/kg bw) into resting
controls, exercising subjects (2.5 hrs treadmill running), and rhIL-6 infusion and measure TNF-α levels
for up to 5.5 hrs 182. Exercising subjects demonstrate a blunted TNF-α response to the endotoxin injection
when compared to controls. Importantly, rhIL-6 infusion mimics the effects of exercise by reducing the
production of TNF-α in vivo 182. These results demonstrate that muscle derived IL-6 promotes an antiinflammatory environment.
IL-6 is typically designated as an inflammatory cytokines often associated with a high prevalence
of obesity and T2D. This observation has led many researchers to believe that IL-6 is associated with
negative metabolic consequences which potentially feedback to activate the immune response. However,
this belief is not support by recent studies utilizing IL-6 knock out mice that develop late onset obesity
and impaired glucose tolerance that is reversed when IL-6 is exogenously administered 183. Furthermore,
clinic trials blocking IL-6 to treat chronic inflammation increase cholesterol and plasma glucose levels.
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The positive metabolic effects of IL-6 appear to be mediated by activated-AMP kinase (AMPK).
AMPK is a metabolic energy sensing enzyme that regulates catabolic and anabolic signaling by detecting
shifts in cellular AMP:ATP ratios. IL-6 signaling through its gp130 receptor transduces signaling that
activates AMPK. The metabolic consequences of this interaction affect both glucose and FA metabolism.
IL-6 treated muscle cells have increased basal and insulin stimulated glucose uptake due to increased
GLUT4 trafficking and insertion into the plasma membrane 184. In vivo work demonstrates that IL-6
infusion increases glucose infusion rate without altering hepatic glucose responsiveness 185.
AMPK is also an important regulator of FA oxidation that may modulate IL-6 metabolic
interactions 186. In fact, within skeletal muscle FA oxidation increases when infused with IL-6 (5000
pg/ml) by 50%, whereas TNF-α infusion at the same concentration does not affect FA oxidation, but
rather increases the uptake FA and increases the accumulation of DAG by 45% 187. In vivo experiments
demonstrate that IL-6 is also a potent inducer of whole-body lipolysis and FA oxidation even at low
levels (140pg/ml) without any detectable increase in lipolytic hormones 187,188.
The relationship of IL-6 and AMPK activation is supported by research that demonstrates the
robust lipolytic effects of IL-6 is reversed when AMPK function is ablated 185. These finding demonstrate
that IL-6 has potentially synergistic effects of exercise metabolism whereby substrates can be mobilized
an oxidized at greater rates. From an inflammatory standpoint there appears to be a significant benefit
from regular exercise and regular exposure to elevated IL-6 levels. However, it is difficult to tease apart
role of exercise in reducing inflammation that leads to improved metabolic health and vise versa.

Irisin: A PGC1-α derived myokine
The transcriptional co-activator peroxisome proliferator-activated receptor (PPARΥ)
coactivator-1α (PGC1-α) is a key regulator of mitochondrial biogenesis and fatty acid and
glucose metabolism in skeletal muscle and adipose tissue 189,190. The use of transgeneic mice that
overexpress PGC-1α promotes an oxidative skeletal muscle phenoytype (type I and type IIa) and

131

increases total muscle oxidative capacity 191. These transgenic mice have also been shown to
have improved insulin-sensitivity and resist age-related fat gain and muscle loss 192.
In wild type mice, cold exposure increases mRNA content of PGC1-α and robustly
increases the transcriptional activity of PPAR-γ and the thyroid hormone receptor on the
uncoupling protein (UCP-1) promoter193. UCP-1 is involved in thermogenesis by directing
protons back through the mitochondria to generate heat rather than promote ATP synthesis via
ATP synthase 194. UCP-1 content is significantly higher in brown fat than in white fat cells.
Considering that brown fat contains significantly more mitochondria and less ATP synthase than
white fat it represents an important metabolic depot 194,195.
Many of the beneficial effects of exercise appear to be mediated by the activation of
PCG1-α in skeletal muscle 191,192. PGC1-α is increased acutely after exercise and chronically due
to regular endurance exercise training. A common adaptation to endurance exercise occurs in
skeletal muscle, whereby muscle fibers undergo an observable shift to an oxidative profile 191.
Generally, the health related benefits of exercise are associated with increased skeletal muscle
oxidative metabolism. In resting skeletal muscle, levels of PGC1-α are elevated in type I and
type IIA fibers compared to more glycolytic IIb/IIx fibers. Transgenic PGC1-α (PGC1-α +/+)
mice demonstrate an oxidative muscle phenotype shift and increased endurance exercise capacity
when compared to PGC1-α knockout mice (PGC1-α-/-), which demonstrate a more glycolytic
shift and decreased exercise capacity compared to wild type mice.
Fibronectin domain-containing protein 5 (FNDC5) is a membrane-bound protein that is
highly expressed in skeletal muscle 196,197. In an attempt to identify secreted muscle factors that
increased due to PGC1-α Boström et al (2012) demonstrate that FNDC5 undergoes proteolytic
cleavage and releases a peptide fragment named irisin 198. Irisin represents the N-terminal
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domain of FNDC5 that is released in response to exercise, into the extracellular matrix and can
be detected in plasma, serum 199, urine, and saliva 200. FNDC5/irisin is 100% biologically
identical between mice and humans 198.
The application of nanomolar concentrations of irisin on white fat cells increases UCP1
by 50-fold demonstrating a browning effect. Viral delivery of irisin stimulates a 3-fold increase
in circulating levels; however, UCP1 level increase between 10-20 fold 198. Irisin administration
was shown in this important study to improve glucose tolerance and increased energy
expenditure in mice fed a HFD. The authors of this study speculate that the levels of irisin, as
stimulated by viral administration, which improve metabolic parameters, is similar to those
measured during exercise and therefore irisin must be at least in part responsible for the
beneficial effects of exercise 198.
Irisin is considered a myokine that is secreted from the muscle by the cleavage of FNDC5
after activation of PGC1-α198. Lecker et al (2012) confirmed that FNDC5 mRNA increased in
relation to the increase of PGC1-α mRNA in skeletal muscle of subjects with a high aerobic
exercise capacity, but not in subjects considered to have a low exercise capacity 201. Human
studies demonstrate that acute exercise increases circulating irisin levels 199,200,202,203. Recent
studies of acute exercise demonstrate that plasma irisin peaks immediately post exercise and
correspond to increased exercise workloads and return to baseline 10-20 minutes post exercise
202,204

.
Irisin levels appear to be increased in response to acute exercise bouts, however, there is

currently no consensus on irisin response to chronic exercise training 205. Many studies that have
demonstrated the acute increase in irisin failed to demonstrate a positive training response.
Timmons et al (2012) demonstrated FNDC5 mRNA was not different between sedentary and

133

active subjects and that analysis of approximately 200 muscle biopsies revealed that only a high
active cohort of elderly subjects has increase muscle FNDC5 mRNA 205,206. Analysis of another
relatively large cohort did not detect an increase in FNDC5 expression or serum irisin levels in
response to chronic or acute exercise. 207
Factors not related to exercise appear to also modulate the production of irisin in the
human body. A significant positive relationship between body weight and plasma irisin has been
reported on numerous occasions 199,206,208. However, these studies do not provide direct evidence
that increased muscle mass is responsible for increased irisin levels as adipose tissue can produce
irisin as well 209.
T2D is caused, in part, by impaired skeletal muscle glucose homeostasis 21 therefore the
reported benefit on glucose tolerance of irisin on rats fed a HFD is of great interest 198. In vivo
measurement of irisin showed a significant negative correlation in relationship to 2 hr plasma
glucose measured in newly diagnosed type 2 diabetics 210. In support of this several other studies
have documented a similar relationship 211-213. However, some investigators have demonstrated a
positive relationship with irisin levels and homeostatic model of insulin resistance (HOMA-IR)
in obese humans 214. In this particular study, irisin levels were positively correlated with
metabolic syndrome. In calorie restricted rats that improved insulin sensitivity did so without
any significant increase plasma FNDC5/irisin protein levels 215.
In order to clarify the complexity that surrounds the relationship between irisin and T2D
studies Kurdiova et al (2014) recently conducted a clinical study that measured circulating irisin
levels across glycemic status 216. This study confirmed that type 2 diabetics have lower
circulating irisin levels than non-diabetics. However, FNDC5 mRNA levels were increased
significantly in prediabetic muscle compared to lean muscle, but not in T2D. When muscle cells
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from type 2 diabetics were cultured a decrease in irisin was not observed, rather FNDC5 gene
expression and secreted irisin was increased. When cells were cultured with excess palmitate and
glucose, the levels of irisin and FNDC5 were reduced. It is reasonable to speculate that factors
involved in the in vivo diabetic environment contribute to the reduced irisin secretion 216,217.
Myonectin/C1q Tumor Necrosis Factor-α Related Protein 15 (CTRP15)
Myonectin is characterized by an N-terminal peptide, a collagen repeat domain, and C
terminal C1q-like globular domain. Some confusion exists regarding the classification of
myonectin as a member of the C1q tnf-α family 218,219. Work by Park et al (2009) originally
described a protein CTRP5 discovered during a search for nuclear genes that were differentially
expressed as a result of altered mitochondrial DNA (mtDNA) content 220. Marked reductions in
mtDNA and PGC1-α have been measured in the insulin resistant offspring of T2D parents and is
also associated with obesity 221. Therefore the identification of factors that are associated with
increased or decreased mtDNA are important to understand the mechanisms of metabolic
dysfunction in T2D and obesity. CTPR5 is described in this study has having 40% sequence
homology with adiponectin, an adipokine that improves insulin sensitivity.
In cell culture (L6 myotubes) CTRP5 activates energy utilization pathways by increasing
phosphorylation of AMPK and acetyl-CoA carboxylase 220. Glucose uptake, measured by 2deoxyglucose (2-DG), uptake and FA oxidation, as measured by palmitate oxidation, is
significantly increased in myocytes treated with myonectin. The increase in GLUT4
translocation is accomplished without a measured increase in the phosphorylation of IRS-1 and
AKT. Rather, GLUT4 translocation was related to an increase in AMPK, ACC, and p38 MAPK.
AMPK phosphorylation of ACC is required for skeletal muscle FA oxidation and insulin
sensitivity 222. These results indicate that CTRP5 functions in similar manner to 5-amino-4-

135

imidazolecarboxamide ribonuleoside (AICAR) and adiponectin to increase FA oxidation and
glucose uptake. However, it is important to note that ablation of the adiponectin receptors
(AdipoR1 and AdipoR2) did not ameliorate the phosphorylation of myonectin treated cells. This
indicates that myonectin is a novel protein functioning through a novel receptor 220.
The loss of mtDNA and mitochondrial function is implicated in the etiology of insulin
resistance 223-225. The benefits derived from exercise are known to involve transcriptional factors
and co-activators such as PGC1-α and PGC1-β that stimulate mitochondrial biogenesis 191,226.
When a cell undergoes mitochondrial stress, such as reduced mtDNA, nuclear transcription
factors are induced to aid in recovery 227. It is believed that mitochondrial rescue is mediated
through PGC1-α via calcium/calmodulin signaling pathways 228. As previously mentioned Park
et al (2009) demonstrated elevated circulating levels of CTRP5 in diabetic (db/db) obese rats
(ob/ob) and mtDNA depleted rats (OLETF) rats 220. A follow-up study in humans confirmed that
circulating myonectin levels were positively correlated with HOMA-IR 229. Fifty-six women
underwent 10-weeks of moderate intensity exercise (60% VO2max) for 1 hr three times a week,
where after, significant increases in VO2max, mtDNA density, and adiponectin were observed.
These improvements coincided with significant reductions in serum CTRP5 229.
These the studies demonstrated that CTRP5 is related to insulin resistance and
mitochondrial dysfunction. Lim et al (2012) erroneously designated CTRP5 “myonectin”,
however, work by Seldin et al (2012) reported that CTRP15 is preferentially expressed in muscle
and secreted by muscle, whereas CTRP5 is produced by predominantly adipocytes, suggesting
that CTRP is a novel proprietary myokine 230. It is accepted that CTRP15 is now referred to as
myonectin 231.
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Myonectin mRNA and protein secretion increases in cultured myotubes in response to the
exercise memetics ionomycin, forskloin, and epinephrine, but not to insulin or AICAR in vitro.
In mice, two weeks of wheel running significantly increased serum myonectin and mRNA in the
plantaris and soleus muscles. Remarkably, myonectin levels are suppressed in skeletal muscle
and serum concentration during periods of fasting and drastically increase upon refeeding. This
response was not preferentially induced by either glucose of emulsified intralipid gavage.
Muscle cells were treated with glucose or palmitate also increase their expression of myonectin
mRNA and secretion into media, which indicates that myonectin production is linked to nutrient
flux though the cell230.
Injection of myonectin (sufficient to raise myonectin levels 60-70% above resting levels)
does not lower blood glucose in mice, however, it was sufficient to reduce non-esterfied fatty
acids (NEFA) by 30%. Similar levels of myonectin cultured with 3T3-L1 adipocytes and H4EII
hepatocytes increase FA uptake by 50% above non-treated cells and equal to 50nM insulin
exposure. The measurements coincided with a significant increase in FA transporters CD36,
FATP1, Cav1, and Fabp4. The level of FA uptake was in range with experiments that induce
overexpression of currently measured FA transporters 232.
Myonectin is secreted in response to exercise and nutrient flux through the muscle cell
via food intake. Recent work demonstrates that myonectin functions in an endocrine manner by
activating mammalian target of rapamycin (mTOR) and AKT pathway to suppress liver
autophagy in a similar manner to insulin 231. Myonectin peaks approximately 3 hrs. after food
intake or glucose gavage. This suggests that myonectin provides a postprandial signal that acts
long after the effects of insulin. These data provide evidence that myonectin is secreted in
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response to nutrient flux through the muscle and released into the circulation to act in an
endocrine manner by regulating autophagy in hepatocytes 231.

Literature Review Summary
Chronic inflammation is a unique phenomenon that represents a disruption in metabolic
homeostasis. Adiposity due to poor diet and exercise habits can contribute to the induction of an
immune system response. The fundamental function of the immune system is to protect the host
from pathogens and noxious stimuli. In order to fulfill this responsibility, inflammation is a
necessary component of the survival and repair of cells, tissues, and organ systems that have
been affected. Typical inducers of inflammation such as bacteria and viruses can elicit strong
inflammatory response. However, metabolic dysfunction is also a strong inducer of inflammation
Obesity and T2D represent metabolic insults to adipose tissue and skeletal muscle. These
tissues demonstrate increased infiltration of inflammatory macrophages and T cells. These
immune system cells receive signals from the cellular milieu to increase their secretion of
inflammatory cytokines. Since obesity and T2D are chronic conditions, these conditions will
likely continue unless considerable action is taken to restore the organism back to metabolic
homeostasis. If this inflammatory environment persists, the physiological function of the tissue
organ system can be damaged further.
Exercise has potent anti-inflammatory effects that are mediated through metabolic
perturbations, which regulates the expression and behavior of the cells of the immune system.
Physical inactivity is associated with numerous disease conditions such as obesity, T2D,
Alzheimer’s disease, and some cancers. Furthermore, prolonged bed rest has well characterized
effects on muscle atrophy and the loss of type IIx muscle fibers. This functional decline in
muscle mass coincides with a marked increase in insulin resistance. Inflammation has an
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underappreciated role in this process. Increased inflammatory cytokines (TNF-α, IL-6, IL-1β) as
well as acute phase proteins (CRP) are significantly elevated during prolonged physical
inactivity.
Muscle contractions are a fundamental component of exercise. Failure to adequately
engage muscle fibers has serious deleterious effects on health and longevity. Therefore, the
discovery of myokines provides reasonable speculative grounds that the beneficial effects of
exercise are mediated through factors produced by the skeletal muscle during exercise (i.e.
myokines). Skeletal muscle has a well-understood role in metabolism during rest and exercise.
However, the discovery that a classical cytokine, IL-6, is produced by and secreted from skeletal
muscle forms a bridge between the metabolic and immune system.
The focus of this review was to establish the grounds for chronic inflammation that is
induced by metabolic dysregulation and to provide a framework to understand the burgeoning
field of “immunometabolsim”. The discovery and study of myokines has recently been dealt a
considerable blow. Key researchers involved in myokine research have been convicted of fraud
and several papers have been retracted. Investigation into irisin has yielded few of the positive
results first reported by Bostöm et al (2012) casting doubt on the importance of this novel
myokine. However, several independent laboratories have reported the discovery of hundreds of
currently unidentified myokines that appear to be regulated by muscle contraction.
In conclusion, skeletal muscle represents a major target for the disposal of glucose during
insulin-stimulated conditions. Insulin resistance is considered to be the initial defect in the
pathogenesis of T2D. Insulin sensitivity and chronic inflammation are inversely correlated in
vivo whereas in vitro inflammatory cytokines have been shown to cause insulin resistance.
Exercise that improves insulin sensitivity to the greatest degree also appears to have the greatest
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impact on reducing chronic inflammation. Therefore, the study of myokines that are produced in
relation to the improvements in insulin sensitivity would be of great importance.
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1.2 Study Protocol

Title of Study: THE IMMEDIATE AND EXTENDED EFFECTS OF HIGH INTENISTY INTERVAL
EXERCISE ON METABOLIC FLEXIBILITY AND MITOCHONDRIAL FUNCTION

Overview
Metabolic flexibility is defined as the ability to switch from predominantly lipid oxidation and fatty acid
uptake in the fasted state to insulin-stimulated suppression of lipid oxidation and high rates of muscle
233
glucose uptake and glycogen synthesis that occurs in the postprandial state . The inability to “shift” (Δ
respiratory exchange ratio (RER)) metabolism from lipid to glucose oxidation, termed metabolic
234-236
inflexibility, is a characteristic of obesity and T2D
and is implicated in the development of insulin
233,237,238
resistance
. However, metabolic inflexibility is present prior to the development of insulin
238-240
resistance and fasting hyperglycemia in the offspring of T2D individuals
and remains in previously
236
obese individuals after weight loss .

235,237,241

Metabolically inflexibility is associated with impaired fasting lipid oxidation
, which suggests that
234
metabolic inflexibility is a reflection of the inability of the mitochondria to switch between fuels. Since
lipid oxidation occurs in the mitochondria, it is logical to deduce that impairments in mitochondrial function
could alter whole-body lipid oxidation. Adding clarification to this issue, Ukropcova (2007) and van de
Weijr (2013) have demonstrated that skeletal muscle mitochondrial function is reduced in metabolically
240,242
inflexible individuals
. Recent evidence also suggests that the offspring of type 2 diabetics have
239
impaired metabolic flexibility without the presence of other metabolic risk factors . Moreover,
individuals with a biological mother that has T2D are at greater risk of developing T2D, when compared
243,244
with a father with a positive history
.

Continuous moderate to high intensity exercise training (6-12 weeks) has been shown to improve insulin
sensitivity and metabolic flexibility in obese and type 2 diabetic patients, with greater improvements
245,246
demonstrated with higher intensities
. Interestingly, the time course of glucose tolerance and insulin
action in response to a single bout of exercise reveals periods of increased insulin sensitivity (immediately
247,248
post exercise to 3 days) and resistance (5 to 7 days post exercise)
. Recent research suggests that
2-6 weeks of high intensity interval training (HIIT) improves insulin sensitivity and skeletal muscle
249,250
oxidative capacity
. However, data on the immediate and extended effects of a single bout of high
intensity interval exercise area lacking. To date there are no studies investigating the time-course of
metabolic flexibility in response to a single bout of high intensity interval exercise (HIIE). Characterizing
the immediate and extended response of a single bout of HIIE could provide insight into the therapeutic
applications of this exercise approach.

Purpose and Procedures

The purpose of this research is to determine the immediate and extended (48-hr) effects of a bout of high
intensity interval exercise prior to a mixed meal on metabolic flexibility and mitochondrial function in men

173

and women with and without a family history of T2D. The offspring of type 2 diabetics without other risk
factors (obesity, hyperglycemia, sedentary lifestyle) demonstrate the signs of metabolic inflexibility.

2

Twenty apparently healthy, active, normal weight (BMI = 18 to 25 kg/m ) young (age 18 to 40 y) men and
women with (n=10) and without (n=10) a positive family history of T2D will be recruited to participate in
this study. After an initial screening visit, graded exercise test, muscle oxidative capacity (OXPHOS), and
mixed meal tolerance test (MMTT), participants will undergo 1 acute exercise session followed by a
MMTT immediately after and 48 hours post exercise. Results from the graded exercise test will be used
to determine the peak power output at VO2maxto prescribe a practical low-volume, high intensity interval
program. Dietary intake will be recorded 24 hours before the initial MMTT and replicated 24 hours prior to
the exercise session and the post-exercise MMTT. The primary outcome of the study is the change in
substrate oxidation (carbohydrate and fat) in response to the MMTT immediately and 48 hours post
exercise. Secondary outcomes include measures of insulin action (plasma glucose, insulin, and free fatty
acid responses). Skeletal muscle OXPHOS, blood flow, on oxygen consumption using near infrared
spectroscopy (NIRS) will also be measured.
Inclusion/Exclusion Criteria: The inclusion/exclusion criteria are summarized in Table 1. Active,
college-age men and women with a normal weight (BMI 18-25 kg/m2), with and without a family history of
T2D will be recruited. Participants will be frequency matched to control for race. Women that are enrolled
in the study will be tested at least 10 days after the last day of their menstrual cycle. Individuals with
known cardiovascular disease, T2D, and/or metabolic diseases will be excluded to reduce the likelihood
of confounding circumstances regarding the exercise testing, acute aerobic exercise, and MMTT.

Table 1. Summary of the Inclusion/Exclusion Criteria
Inclusion Criteria
Age
Sex
Positive Family
History of T2D
BMI
Informed Consent

18-40 years
Men and Women
Biological Mother with T2D or biological mother and father with T2D
2

18-25 kg/m
The capability and willingness to give written informed consent, to understand the exclusion
criteria, and to accept that the randomized group assignment is required

Exclusion Criteria
Significant CVD or
disorders
Physically Inactive
Diabetes
Blood pressure
Other significant
medical conditions

Including but not limited to serious arrhythmias, cardiomyopathy, congestive heart failure,
stroke or transient ischemic attacks, peripheral vascular disease with intermittent
claudication, acute, chronic or recurrent thrombophlebitis or myocardial infarction
Currently participating in aerobic exercise <20 minutes on <3 days per week and no
resistance training.
Fasting glucose >125 mg/dL or 2 hour glucose of >200 mg/dL during MMTT
Systolic blood pressure >130 and diastolic blood pressure >90.
Including but not limited to chronic or recurrent respiratory, gastrointestinal, neuromuscular,
neurological, or psychiatric conditions. Hospitalization for mental illness within the past 5
years or currently undergoing treatment for severe mental illness. Musculoskeletal problems
interfering with exercise. Autoimmune or collagen vascular diseases. Any other medical
condition or disease that is life-threatening or that can interfere or be aggravated by exercise

Primary Outcomes – Shift in Substrate Metabolism and Insulin Action: The primary outcome for this
study is metabolic flexibility determined as ΔRER during an MMTT, which suggests a shift in substrate

174

metabolism. In addition, insulin action will be
assessed by examining glucose, insulin and
free-fatty acid responses during the MMTT.
The MMTT will be conducted at baseline,
immediately post-exercise and 48-hours after
HIIE session (total of 3 MMTT; Figure 1). The
ΔRER in response to a MTTT was selected for
the following reason: the MMTT is a more costeffective and physiologically relevant stimulus
for assessing metabolic flexibility compared to
the gold-standard hyperinsulinemic-euglycemic
clamp.

Phone
Screening

Baseline
VO2max
NIRS-OXPHOS, mVO2

Exercise
MMTT, mVO2

Baseline
MMTT

48 hrs.

HIIE

________"

(-3)
"_Week"1 "

(-1)
"________"

(1)
________"

MMTT, mVO2

"_Week"2 "

(3)
"________"

Visit Schedule (Days)
Figure 1. Visit schedule. *After confirmation of study eligibility participants will undergo a baseline VO2max and
mitochondrial function test (OXPHOS). The following week participants will complete a baseline mixed meal tolerance test
(MMT) to determine metabolic flexibility. The next day participants will return to complete high intensity interval exercise
(HIIE) followed by a MMTT with measures of mVO2. 48 hrs post exercise intervention MMTT and mVO2 will be repeated.

Measurement of Metabolic Flexibility and Insulin Action: Resting metabolic rate will be measured via
indirect calorimetry while the subject is in the fasted state. An intravenous (IV) line will be placed in an
antecubital vein for blood drawing purposes and will remain there throughout the testing. During each
collection time point, 5 ml of blood (~1 teaspoon) will be drawn and stored for future analysis. A resting,
fasting blood sample will be drawn after which the mixed meal will be prepared using a powered Ensure
® and 250 ml of water measured to one-third the resting metabolic rate (RMR). Additional blood samples
will be drawn at the 5, 10, 15, 20, 30, 60, 90, 120, 150, 180 minute time points after drinking the mixed
meal. Blood samples obtained during the MMTT will be analyzed for plasma glucose, insulin, and freefatty acid concentrations using commercially available methods (Glucometer and/or Spectrophotometric
assays and ELISA).
Muscle Measurements: NIR spectroscopy will be used to measure skeletal muscle OXPHOS at
baseline. NIR spectroscopy will measure resting skeletal muscle oxygen consumption (mVO2) and blood
flow before and during the MMTT. The NIRS protocols developed and described by Kevin McCully’s
251-253
Laboratory will be implemented with slight modifications as discussed below
.
High Intensity Interval Exercise Sessions: The HIIE prescription will be based on the established
practical low volume, high-intensity technique using a cycle ergometer (Velotron, Racermate, Inc.,
249
Seattle, WA) . Prior to exercise, participants will complete a 5-minute warm-up at 50 watts. Based on
the results of the VO2max test participants will engage in work intervals at 90% of the power output at
VO2max for 60 seconds followed by rest intervals at 30 watts for 60 seconds. Participants will complete 10
total intervals (~25 minutes).
Resting Metabolic Rate during the MMTT: Indirect calorimetry will be performed prior to and during
each MMTT. Resting energy expenditure and substrate utilization will be assessed using the
ParvoMedics, TruOne 2400 metabolic cart (Sandy, UT) calibrated with standard gas mixtures. A
transparent plastic hood connected to the metabolic cart will be placed over the participant’s head and
calculations of energy expenditure and carbohydrate and fat oxidation rates will be made from expiratory
gases diluted to produce a constant fraction of expired carbon dioxide (~1.0%). Resting metabolic
measurements will be assessed before the MMTT and at 10 to 30, 40 to 60, 70 to 90, 100 to 120, 130 to
150 and 160 to180 minutes after ingestion of the mixed meal. The average of the 20minute
measurement will be used to calculate resting metabolic rate and substrate oxidation using the equations
254
of Jequier et al . Participants will remain motionless and awake during the entire protocol.

Visits and Timeline (Figure 1)
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Recruitment and informed consent: Word of mouth, Facebook ®, and strategically placed fliers on the
Louisiana State University campus will be utilized to recruit for this study. Interested individuals will meet
with study personnel and be provided a full description of study (structure of the study, study-related
procedures, risks, benefits, etc). Individuals who are still interested in participating in the study will be
offered informed consent and the opportunity to ask questions. If a participant chooses to sign the
consent, he or she will continue on to study screening for inclusion/exclusion criteria including a medical
history questionnaire, assessment of cardiovascular risk for exercise testing (PAR-Q), medication
inventory, and anthropometric measures (height, weight, and resting blood pressure).
VO2max testing: If participants meet all inclusion/exclusion criteria during the screening visit, they will
undergo a maximal cardiorespiratory test (VO2max) on a cycle ergometer (Velotron, Racermate, Inc.,
Seattle, WA). Participants will ride at an initial workload of 25 Watts for 4 minutes. The workload will be
increased by 25 Watts every 4 minutes until respiratory exchange ratio reaches 1.05 after which, the
workload will increase by 25 Watts every 2 minutes until volitional exhaustion. Throughout the test,
respiratory gases will be analyzed using a metabolic cart (ParvoMedics Inc., Sandy, UT) and fat oxidation
255
rates will be determined using stoichiometric equations ..
Mixed Meal Tolerance Test (MMTT): The baseline MMTT will occur ~1 week after the screening visit
and VO2max test. Participants will record all food and beverages ingested and physical activity levels for
the 24-hour period prior to the baseline MMTT. Participants will arrive fasted for at least 10 hours and
refrained from moderate/vigorous exercise for at least 48 hours. mVO2 and muscle blood flow will be
measured prior to and 1 and 2 hours post mixed meal (see NIRS Protocols for further details). The
baseline MMTT will also complete the exclusion criteria for high fasting glucose (> 125 mg/dL) and
abnormal 2-hour glucose (> 200 mg/dL). Additional MMTTs will be conducted immediately (1 hour) post
exercise and 48 hours after the HIIE session. Prior to the post-exercise MMTTs, participants will replicate
the 24-hour food and beverage diary recorded prior to the baseline MMTT. In addition, both MMTTs, will
be conducted in the morning hours after a 10 hour fast.
NIRS Protocols to Measure Muscle Metabolism (e.g., NIRS mVO2, blood flow, and OXPHOS): Subjects
will rest in the supine position with knees slightly flexed. The NIRS optode (Oxymon MKIII, Artinis
Medical Sytsems) will be placed on the vastus lateralis just anterior to the iliotibial band and ~1/3 the
distance between the top of the patella and the greater trochanter of the test leg. The optode will be
secured in place with adhesive tape and Velcro strap. A blood pressure cuff (Hokanson, Bellevue WA)
will be placed proximal to the optode, and connect the cuff to a rapid cuff inflation system (Hokanson E20,
Bellevue WA) that will be controlled using an external controller and Labview
Software. We measure resting muscle blood flow in triplicate using venous
Cuff Occlusions
On
Off
1-6
5
5
occlusions by inflating the blood pressure cuff to (50-60 mmHg) for 20 seconds
7-10
7
7
with at least 60 seconds between each measurement. We will make
11-14
10
15
measurements of resting muscle oxygen consumption (mVO2) in triplicate
15-20
10
20
using arterial occlusions by inflating the blood pressure cuff to (250-300
Table 1. Arterial Occlusion Protocol
mmHg) for 20 seconds with at least 60 seconds between each measurement.
For measurement of muscle oxidative capacity (NIRS-OXPHOS), subjects will
complete a 20 second isometric contraction of the vastus lateralis (by knee extension) immediately
followed by a series of 15-20 arterial occlusions (250-300 mmHg) to measure the rate of recovery of
mVO2 as depicted in Table 1. We will repeat this NIRS-OXPHOS protocol three times with ~5-10 min
between each trial. Finally, we will perform an ischemic calibration procedure and calculate mVO2
corrected for blood volume as previously described, which includes a 15-20 second isometric contraction
of the vastus lateralis (by knee extension) immediately followed by ~5-6 minute arterial occlusion (250300 mmHg). NIRS signals for oxygenated, deoxygenated, and total hemoglobin will be continuously
monitored by NIRS. Prior to testing, we will measure adipose tissue thickness by skin fold thickness
and/or B-mode ultrasound (LOGIC e, GE) at the location of the optode. Before and after the MMTT we
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will measure resting blood flow and mVO2 as described above and at the time points indicated in the
description of the MMTT.
Continuous Glucose Monitoring: Participants will be given continuous glucose monitors (Dexcom G5, San
Diego, CA). CGM use a sensor inserted under the skin by the participant to check glucose levels in the
interstitial fluid. A transmitter sends sensor glucose readings to a display device. The participant will be
required calibrate the CGM with a finger stick reading from blood glucose monitor. Participants will be
provided with two sensors (1 for the baseline visits and 1 for the week of the exercise bout and 48hr visit).
Heart Rate Monitoring: Heart rate will be monitored during the exercise bouts and oral glucose
tolerance testing with a telemetric heart rate monitor (Bioharness, Annapolis, Maryland). The monitor
captures time intervals between R-R waves and can produce valid measures of heart rate variability.
Statistical Analysis: All statistics will be performed using JMP statistical software (SAS Institute Inc.,
Cary, NC). Data analysis will generally follow CONSORT recommendations using General Linear Models
and repeated measures analysis of variance (RM-ANOVA) co-varied as needed depending on normality
distributions at baseline. An unpaired t-tests will be used to compare between group baseline
characteristics. In addition, two way RM-ANOVA (exercise session x time point) will be used to determine
differences in responses in both the primary and secondary outcome variables. A power analysis
conducted indicated that to measure a difference RER of .04 would require 20 participants (α=.05, β=.80)
Significant effects will be further evaluated using Tukey’s HSD post-hoc analyses were appropriate. Data
will be reported as mean±SD and differences declared at P<0.05.
Expected Outcomes: Based on previous work we expect that the offspring of type 2 diabetics will have
239
impaired metabolic flexibility . We hypothesize that high intensity exercise will cause a greater shift in
substrate metabolism in response to a mixed meal when compared to no prior exercise. We expect that
high intensity interval exercise will result in a greater glucose tolerance and result in higher peak insulin
levels, but lower area under the curve (AUC). Additionally, we expect that greater mitochondrial function
will be associated with greater fasting fat oxidation and lower AUC for the change in RER in response to a
mixed meal.
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1.3 LSU IRB Approval

ACTION ON PROTOCOL APPROVAL REQUEST
Institutional Review Board
Dr. Dennis Landin, Chair
130 David Boyd Hall
Baton Rouge, LA 70803
P: 225.578.8692
F: 225.578.5983
irb@lsu.edu | lsu.edu/irb

TO:

Neil Johannsen
Kinesiology

FROM:

Dennis Landin
Chair, Institutional Review Board

DATE:

March 23, 2016

RE:

IRB# 3696

TITLE:

The Immediate and Extended Effects of High Intensity Interval Exercise on Metabolic
Flexibility and Mitochondrial Function

New Protocol/Modification/Continuation: New Protocol
Review type: Full

X

Expedited

Risk Factor: Minimal
Approved

X

Review date: 2/12/2016
Uncertain

X

Greater Than Minimal_______

Disapproved __________

Approval Date: 2/12/2016

Approval Expiration Date: 2/11/2017

Re-review frequency: (annual unless otherwise stated)
Number of subjects approved: 20
LSU Proposal Number (if applicable):
Protocol Matches Scope of Work in Grant proposal: (if applicable) ______
By: Dennis Landin, Chairman
PRINCIPAL INVESTIGATOR: PLEASE READ THE FOLLOWING –
Continuing approval is CONDITIONAL on:
1. Adherence to the approved protocol, familiarity with, and adherence to the ethical standards of the Belmont Report,
and LSU's Assurance of Compliance with DHHS regulations for the protection of human subjects*
2. Prior approval of a change in protocol, including revision of the consent documents or an increase in the number of
subjects over that approved.
3. Obtaining renewed approval (or submittal of a termination report), prior to the approval expiration date, upon request
by the IRB office (irrespective of when the project actually begins); notification of project termination.
4. Retention of documentation of informed consent and study records for at least 3 years after the study ends.
5. Continuing attention to the physical and psychological well-being and informed consent of the individual participants,
including notification of new information that might affect consent.
6. A prompt report to the IRB of any adverse event affecting a participant potentially arising from the study.
7. Notification of the IRB of a serious compliance failure.
8. SPECIAL NOTE:
*All investigators and support staff have access to copies of the Belmont Report, LSU's Assurance with DHHS, DHHS
(45 CFR 46) and FDA regulations governing use of human subjects, and other relevant documents in print in this office
or on our World Wide Web site at http://www.lsu.edu/irb
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1.4 Study Consent Form

CONSENT TO PARTICIPATE IN A RESEARCH STUDY
INFORMED CONSENT
Title of Study: THE IMMEDIATE AND EXTENDED EFFECTS OF HIGH INTENISTY
INTERVAL EXERCISE ON METABOLIC FLEXIBILITY AND MITOCHONDRIAL
FUNCTION

We give you this consent form so that you may read about the purpose, risks and
benefits of this research study.
•
•
•
•
•

The main goal of a research studies is to gain knowledge that may help future
patients.
You have the right to refuse to take part, or agree to take part now and change
your mind later on.
Please review this consent form carefully and ask any questions before you
make a decision.
Your participation is voluntary.
By signing this consent form, you agree to participate in the study as it is
described.

1- Investigators:
The following investigators will be available for questions about this study:

Principal Investigator:

Neil M. Johannsen, Ph.D.
Phone: 225-578-5314
Email:njohan1@lsu.edu

Co-Investigators:

Tim Allerton, MS
Phone: 504-919-3799
Email: taller2@lsu.edu
Brian Harrell, M.D.,
Phone: 337-292-0431,
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Email: brian.harrell@brgeneral.org
Brian Irving, PhD
Phone:225-578-7179,
Email: brianirving@lsu.edu
Guillaume Spielmann, PhD
Phone: 225-578-2926 gspielmann@lsu.edu

Neil Johannsen, Ph.D. directs this study. We expect about 20 people from one site will
be enrolled in this study. The study will take place over a period of 4 visits and each
participant will be enrolled for ~2 weeks.

2- Performance Site:
This study will take place at Louisiana State University-Baton Rouge Campus.

3- Purpose of the Study:
The purpose of this research is to determine the immediate and extended (48-hr) effects
of a bout of high intensity interval exercise prior to a mixed meal on the ability to use
nutrients after consuming a meal in men and women with and without a family history of
T2D.

4- Participant Inclusion:
Study staff will discuss with you the requirements for participation in this study. It is
important that you are completely truthful with the staff about your health history. You
should not participate in this study if you do not meet all the qualifications.

You are eligible for this study if you are:
•
•
•
•
•

Capable and willing to give written informed consent, understand exclusion
criteria and accept the randomized assignment
Male or Female age 18-40 years
Have a biological mother with type 2 diabetes
Healthy (no uncontrolled disease) with a BMI between 18 and 25 kg/m2 and/or a
waist circumference < 35 inches for women and < 40 inches for men.
Currently active (greater than 30 minutes/day, 3 or more days/week of moderate
intensity, structured physical activity)
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•
•
•
•
•
•
•

Willing to record food intake and replicate for the 24 hours before each testing
period.
Willing to participate in VO2max testing on a treadmill.
Willing to participate in an intense bout of interval based exercise (~20 minutes)
Willing to participate in 3 mixed meal tolerance tests with ingestion of 250-400
calories
Willing to have blood drawn through an IV catheter and by finger stick
Willing to have a blood pressure cuff inflated (50-250 mm Hg) around your upper
thigh
Willing to wear a continuous glucose monitor

You are NOT eligible for this study if you have any of the following conditions:
•
•
•
•
•
•
•
•
•
•
•

HIV, Hepatitis B, or Hepatitis C
Uncontrolled CVD/ arrhythmia
COPD, Emphysema, Exercise Induced asthma/bronchospasm
Cerebral Palsy, Multiple Sclerosis, Amyotrophic lateral sclerosis, Cystic Fibrosis
Diabetes (Type 1 or 2); fasting glucose >125 mg/dL or 2 hour glucose >200
mg/dL during the baseline mixed meal tolerance test
Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 90 mmHg
Uncontrolled thyroid disorder (controlled = 6 months of medication)
Epilepsy
Osteo/Rheumatoid arthritis
Unresolved orthopedic injury of any kind
Any other medical, psychiatric or behavioral factors that in the judgment of the
Principle Investigator that may interfere with study participation or the ability to
follow the protocol

Medications/Non-Drug Therapies:
•
•
•
•
•
•

Blood pressure medication
Diuretics
Beta-blocker
Anti-inflammatory drug (corticosteroid/anabolic steroid/NSAID)
Antipsychotic
Other medications that may affect glucose and or fat metabolism

Lifestyle:
•
•
•

Consume > 3 drinks/day of any alcoholic beverage
Smoker (Former smokers must be smoke free for 12 months)
Donated blood within the past 6 weeks
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5-Study Procedures:
The study for which you are volunteering will take about 2 weeks to complete and will
include 4 visits

1. Screening Phase – 1 Screening Visit (Visit 1)
2. Baseline Testing Phase – 1 Baseline Visits (Visit 2)
3. Follow-up Phase – 2 Visits (3 and 4)
Summary of Visit Schedule

Procedure (Time)
Informed Consent
PARQ and Medical
History
Height
Weight
Body Composition and
skin folds
Vital Signs
Medication Inventory
NIRS-blood flow and
mVO2
NIRS-OXPHOS
Questionnaires
Food Recall
Physiological Monitors
VO2max test
Blood Samples
Mixed Meal Tolerance
Test

Screening
Baseline
OXPHOS,
VO2max

Baseline
Metabolic
Flexibility

Exercise
Interventi
on

Visit 1
Day 0
X
X

Visit 2
Day 1

Visit 3
Day 2

48
hours
PostExercis
e
Visit 4
Day 4

X

X

X

X

X

X

X
X

X
X
X

X
X

X
X

X
X

X
X

X
X
X
X
X
X
X
X
X
X
X

182

Substrate Metabolism

X

X

X

Study Timeline

Phone
Screening

Baseline
VO2max
NIRS-OXPHOS, mVO2

Exercise
MMTT, mVO2

Baseline
MMTT

48 hrs.

HIIE

________"

(-3)
"_Week"1 "

(-1)
"________"

(1)
________"

MMTT, mVO2

"_Week"2 "

(3)
"________"

Visit Schedule (Days)
Figure 1. Visit schedule. *After confirmation of study eligibility participants will undergo a baseline VO2max and
mitochondrial function test (OXPHOS). The following week participants will complete a baseline mixed meal tolerance test
(MMT) to determine metabolic flexibility. The next day participants will return to complete high intensity interval exercise
(HIIE) followed by a MMTT with measures of mVO2. 48 hrs post exercise intervention MMTT and mVO2 will be repeated.

Screening Visit –(Phone or In-person)

At this visit, the informed consent will be explained to you by our study staff and
procedures are performed. If you choose to sign the informed consent, the following
tests and procedures will be performed to determine if you qualify to participate in this
research study:

•

You will be asked questions about your:
o Demographics
o Medical history
o Medication use

•

You will be asked to perform the following medical assessments:
o Blood pressure and heart rate
o Height and weight
o Skin Folds for body composition
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Volunteers who are meet the inclusion/exclusion criteria at the screening visit will be
scheduled for baseline visits and intervention and follow-up visits.

Baseline Visits: Visit will last approximately 1 ½ hour
Baseline visit 1 (This visit may be divided into two separate days) :
(Non-Fasting visit: Please refrain from caffeine for at least 5 hours prior to visit. )

•

You will be asked to return to the Clinical Exercise Testing Laboratory at LSU for
Baseline Testing Visit 1. For 24 hours prior to Baseline Visit 2, you will be asked
to record your food and drink intake. You will be asked to replicate this record
before follow-up visit 1 and 2. The following tests will be performed:
o Blood pressure and heart rate – by a cuff placed around your arm and
monitor worn around your chest
o Weight
o Resting Muscle Oxygen Consumption and Oxidative Function
measurements (NIRS OXPHOS and NIRS mVO2)
o Graded Exercise Test (VO2max)
o Given continuous glucose monitor for self application

The time involved with the VO2max test depends on your fitness level. Your aerobic
fitness will be assessed while you pedal on a cycle ergometer. The workload of the
ergometer will increase at regular increments (every 2 to 4 minutes) until you are unable
to continue pedaling. Your tiredness will in most cases be due to your muscles
becoming too tired to perform the work required of the stage and you may feel short of
breath. Both or a combination of both are normal responses to this type of test. The
purpose of this test is to determine your fitness level in order to prescribe the exercise
intensities during the high intensity interval exercise bout (Visit 3).

During the exercise test, the volume of oxygen and carbon dioxide you are breathing
will be measured continuously using an instrument known as a metabolic cart. The test
requires that you breathe through a mouthpiece, similar to a snorkel, with a nose clip
on. The mouthpiece is attached to a long tube, which is then attached to the metabolic
cart. The breath gasses collected during the exercise test allow us to accurately
measure your energy expenditure and type of fuel (carbohydrate or fat) you are using at
each stage of the test. Your heart rate will be monitored continuously through a
wireless heart rate monitor (Bioharness 3.0). At the end of each stage, you blood
lactate levels will be measured by finger stick blood analysis.
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In order to measure glucose levels throughout the study period you may or may not be
asked to wear a continuous glucose monitor. The monitor is self-applied by inserting
the sensor under the skin by use of the sensor applicator. Instruction will be provided on
site in addition to the manufactures guidebook.

To measure muscle metabolism and blood flow, we will place a monitor on the upper
leg secured with adhesive tape and a Velcro strap. A blood pressure cuff will be placed
above the monitor and connected to a rapid inflation device. Triplicate measurements
of resting muscle blood flow will be taken by inflating the blood pressure cuff to 50-60
mm Hg (venous occlusion) for 20 seconds and releasing the pressure with at least 60
seconds between each measurement. Triplicate measurements of resting muscle
oxygen consumption (mVO2) will be taken by inflating the blood pressure cuff for ~20
seconds to ~250-300 mm Hg (arterial occlusion) and releasing the pressure with at least
60 seconds between each measurement. For muscle recovery measurements, you will
complete ~20 second of maximum isometric knee extension exercise followed by 15-20
arterial occlusions. You will complete this muscle recovery protocol three times with ~510 min between each trial. You will also complete a 15-20 second maximum isometric
knee extension exercise immediately followed by a ~5-6 minute arterial occlusion to
calibrate the measurements. Prior to testing, we will measure the fat tissue thickness
under the monitor by skin fold thickness and/or ultrasound.

Baseline Visit 2: Visit will last approximately 3 ½- 4 hours

(Fasting Visit- Please arrive at 10 hours fasting and refrain from caffeine at least 5
hours and refrain from vigorous exercise 48 hours prior to study visit)

•

You will be asked to return to the Clinical Exercise Testing Laboratory at LSU
and the following tests will be performed:
o Mixed meal tolerance test – ingestion of 250-400 calorie Ensure drink.
o Blood samples – An IV catheter will be placed in your arm vein for blood
draw purposes and will remain there throughout the testing period. Blood
will be drawn at specific times. About 5 teaspoons of blood will be
collected each trial and measured for glucose, insulin, and free fatty-acids.
The remaining blood will be stored for this study and for future research if
you consent.
o Respiratory measures - a plastic, transparent hood will be placed over
your head before and periodically during the oral glucose tolerance test to
measure resting energy expenditure and the type of fuel you are using
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(carbohydrate or fat). The hood will be attached to the metabolic cart
similar to the exercise test.
o Resting muscle oxygen consumption and blood flow measurements as
described during testing visit 1 will be performed before and 1 and 2 hours
after starting he mixed meal tolerance test.

Exercise Intervention: Visit will last approximately 4 hours
(Fasting visit – please refrain from eating 10 hours alcohol and exercise for 48
hours and caffeine for 5 hours before this visit.)

•

You will be asked to return to the Clinical Exercise Testing Laboratory at LSU
and the following tests will be performed:
o Heart rate – by a cuff placed around your arm and monitor worn around
your chest
o Perform repeated bout of cycling lasting 1 minute followed by one minute
of recovery for 20 minutes total.
o Mixed meal tolerance test will be initiated 1 hour after the acute bout of
exercise.
o Resting muscle oxygen consumption and blood flow measurements as
described during testing visit 1 will be performed before and 1 and 2 hours
after starting he mixed meal tolerance test.

Follow-up 48 hour Recovery Visit: Visit will last approximately 3.5- 4 hours

(Fasting visit – please refrain from eating 10 hours alcohol and exercise for 48
hours and caffeine for 5 hours before this visit.)

•

You will be asked to return to the Clinical Exercise Testing Laboratory at LSU
and the following tests will be performed:
o Mixed meal tolerance test – ingestion of 250-400 calorie Ensure drink.
o Blood samples – An IV catheter will be placed in your arm vein for blood
draw purposes and will remain there throughout the testing period. Blood
will be drawn at specific times. About 5 teaspoons of blood will be
collected each trial and measured for glucose, insulin, and free fatty-acids.
The remaining blood will be stored for this study and for future research if
you consent.
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o Respiratory measures - a plastic, transparent hood will be placed over
your head before and periodically during the oral glucose tolerance test to
measure resting energy expenditure and the type of fuel you are using
(carbohydrate or fat). The hood will be attached to the metabolic cart
similar to the exercise test.
o Resting muscle oxygen consumption and blood flow measurements as
described during testing visit 1 will be performed before and 1 and 2 hours
after starting he mixed meal tolerance test.

6- Risks/Discomforts:

VO2max and exercise testing: All exercise testing is completed in accordance with the
American College of Sports Medicine’s Guidelines for Exercise Testing and Prescription
as well as the American Heart Association. There is minimal risk of injury or a
cardiovascular event during testing. We believe the use of a highly trained staff, a
pretest review of participant associated risk factors including the Physical Activity
Readiness Questionnaire (PAR-Q) and medical screening by your doctor, and welldefined emergency procedures minimize the risk of an event during testing. During
testing you may experience temporary discomfort during blood pressure recordings due
to the pressure of the blood pressure cuff on the arm. You may also experience muscle
fatigue, weakness, soreness and/or muscle pulls or tears. All tests are conducted in the
presence of trained staff. In addition, all staff are trained in BLS (basic life supportCPR) and/or ACLS (advanced cardiac life support). In the event of an emergency, you
would be treated appropriately and transported to the nearest acute care medicalsurgical facility via Emergency Medical Services.

IV procedure and blood draws: There may be minimal discomfort and bruising and/or
bleeding where the needle is inserted for finger prick blood sampling. There is a
possibility of pain, bruising, and/or infection at the site of the needle insertion for the IV
line for mixed meal tolerance test. Aseptic (sterile) technique and trained personnel
minimize this risk.

Body composition: The measurement of skinfold thickness using skinfold calipers
requires a firm squeezing and subsequent measurement of the skin. This measurement
may cause slight discomfort and possible bruising of the measured site. However, if
undue bruising, soreness, or if more than slight swelling occurs, please notify the
Principal Investigator.
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Metabolic testing: It may be uncomfortable to have the plastic hood over your upper
body during resting measurements if you are claustrophobic. The hood is easily
removed if you experience this symptom.

Loss of Confidentiality: Completing questionnaires may result in a breach in
confidentiality of personal data. Participants will be assigned ID numbers and
information that could identify a participant will not appear in publications.

Muscle Blood Flow and Metabolism Measurements: Inflation of the blood pressure cuff
around the leg may cause some discomfort and pain during the test. The temporary
numbness and tingling are similar to the sensation of having your foot “fall asleep”. If
the discomfort is too severe, you may stop the test by notifying the technician to stop
and the test will be immediately terminated. There is no known risk from the use of skin
folds and/or ultrasound to measure your adipose tissue thickness.

CGM Sensor Insertion: Inserting the sensor and wearing the adhesive patch might
cause infection, skin irritation, bleeding, or pain. Sensors can be easily removed without
discomfort.

Unknown risks: In addition to the risk listed above, you may experience a previously
unknown risk or side effect.

7- Benefits:
We cannot promise any benefits from your being in the study. However, possible
benefits include:
•
•
•

Information about your general health
Knowledge of your cardiovascular fitness
An understanding of your exercise performance and physical activity

8-Alternatives to Participation:
There are no alternatives to the study described in this consent. You have the choice at
any time not to participate in this research study. If you choose not to participate, any
benefits to which you are entitled will not be affected in any way.

9- Injury/Illness or Questions:
188

If you have any questions about your rights as a research volunteer, you should call
Dennis Landin, Ph.D., Institutional Review Board Office at 225-578-8692. If you have
any questions about the research study or think you have a research-related injury or
medical illness, contact Neil Johannsen, Ph.D. at 225-578-5314 during regular working
hours.

10-Privacy:
Every effort will be made to maintain the confidentiality of your study records. Results
of the study may be published; however, we will keep your name and other identifying
information private. Other than as set forth above, your identity will remain confidential
unless disclosure is required by law.

11-Early Study Withdrawal:
Neil Johannsen, Ph.D. can withdraw you from the study for any reason or for no reason.
You may withdraw from the study at any time without penalty. Possible reasons for
withdrawal include injury, the presence of an old or existing injury that may be deemed
risky, sufficient medical history deemed too risky for testing.

12-Additional Information:
During the course of this study there may be new findings from this or other research
that may affect your willingness to continue participation. Information concerning any
such new findings will be provided to you.

13-Charges for Participation:
None

14-Payments for Participation:
Participants will receive $100.00 for completion of the study.

15- Compensation for study-related injury or medical illness:
No form of compensation for medical treatment or for other damages (i.e., lost wages,
time lost from work, etc.) is available from Louisiana State University. In the event of
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injury or medical illness resulting from the research procedures in which you participate,
you will be referred to a treatment facility. Medical treatment may be provided at your
own expense or at the expense of your health care insurer (e.g., Medicare, Medicaid,
Blue Cross-Blue Shield, Dental Insurer, etc.) which may or may not provide coverage.

16- Signatures:
The study has been discussed with me and all my questions have been answered. I
understand that additional questions regarding the study should be directed to the study
investigators. I agree with the terms above and acknowledge that I have been given a
copy of the consent form.

Printed Name of Volunteer

__________________________________

_____________

Signature of Volunteer

Date

__________________________________
Date of Birth of Volunteer

__________________________________________

_____________

Signature of Person Administering Informed Consent

Date

Neil M. Johannsen, Ph.D.
Principal Investigator

190

18- Tissue/Specimen Storage for Future Research or Use
Biospecimens for future research:
You are being asked to allow some of your blood to be stored and used for research at
a later time. These bodily materials are called biospecimens. The donation of
biospecimens in this study is optional. No matter what you decide to do, it will not affect
your study participation. You will still be allowed to take part in the study even if you
don't want your specimens to be collected and used for future research. Some
biospecimen samples will be stored and used for the study and other biospecimen
samples will be stored for future studies. The collection of samples may give scientists
valuable research material that can help them to develop new diagnostic tests, new
treatments, and new ways to prevent diseases. If you agree to have your samples
stored, you can change your mind up until the end of the study.

The samples will be stored indefinitely. If you agree to donate your samples, they may
be given to other investigators for future research as well. The future research may take
place at Louisiana State University and may involve Louisiana State University
Researchers in this study. The future research may not take place at Louisiana State
University and may not be reviewed by Louisiana State University's Institutional Review
Board. For privacy and confidentiality, your biospecimens will be labeled with a unique
series of letters and numbers. Louisiana State University will store your biospecimens
with this unique identifier and the minimum number of personal identifiers to meet
laboratory standards. The research done with your specimens may help to develop new
products in the future, or may be used to establish a cell line or test that could be
patented or licensed. You will not receive any financial compensation for any patents,
inventions or licenses developed from this research.

Making your choice about future research:
Please read about each biospecimen below. It is your choice which samples will be
collected, stored and used for future research for this study or future studies. After
reading about each I below, initial next to "Yes" or "No" to show your choice about the
collections for this research study and for future research studies.

Blood
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If you give permission, approximately 1 tablespoon of blood will be stored by this study.
Your stored samples may be tested at Louisiana State University or other locations
used in future research.

Do you give permission for your blood to be collected and used in future research by
this study?

Yes, I give permission
SIGNATURE

No, I do not give permission
SIGNATURE
If you decide you would like to withdraw your consent to use your samples, you will be
able to do so until the study ends. After the study ends, you will not be able to withdraw
your consent to use your samples because investigators will not know which one is
yours. You must provide a written request to have your samples destroyed.

For destruction of your samples, you can contact the Principal Investigator at:

Neil Johannsen, PhD
Louisiana State University
112 Huey P. Long Fieldhouse
Baton Rouge, LA 70803
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VITA

Timothy Allerton was born in New Orleans, LA to William and Constance Allerton. Timothy
received his bachelor’s degree in Kinesiology in May of 2005 from Louisiana State University.
In December of 2007 Timothy received his master’s degree in Clinical Exercise Physiology from
Northeastern University in Boston, MA. Upon graduation, Timothy will receive the Doctor of
Philosophy in Kinesiology from the Graduate School at Louisiana State University and become a
postdoctoral fellow in the T32 “Training in Botanical Approaches to Combat Metabolic
Syndrome” at Pennington Biomedical Research Center. Timothy currently resides in New
Orleans with his wife, Kelly, and two sons, Harry and Finn.
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